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General Introduction 
Aim and Outline of 
this Thesis 
 
Recent advances in biotechnology research have led to a boost of targets in a variety of 
diseases that can be treated by gene therapy approaches. Different types of nucleic acids, such as 
DNA, messenger RNA (mRNA) and short interfering RNA (siRNA), have shown potential to treat viral 
infections and inherited or acquired genetic disorders like cancer. To be effective, these nucleic acids 
should be delivered to a well defined compartment of the target cells. However, they encounter 
several major barriers before the target site is reached. Therefore, advanced delivery systems, either 
viral or non-viral carriers, are needed. Although recombinant viruses are the most efficient vehicles 
to deliver therapeutic nucleic acids into the cells, the genetic material they can carry is limited, they 
can induce insertional oncogenesis and severe immunogenic responses. As a consequence, several 
non-viral gene delivery systems have been developed for safe delivery of therapeutic nucleic acids 
into target cells. Unfortunately, in general these non-viral systems exhibit a low delivery efficiency 
due to their limited ability to cross the encountered cellular barriers before reaching their 
intracellular target site. 
In brief, as clinical applications of gene therapy are largely dependent on the development of 
non-toxic and efficient delivery systems, the primary aim of this thesis was to improve the 
intracellular delivery of functional nucleic acids by addressing several cellular hurdles encountered by 
non-viral delivery vehicles. 
Chapter 1 gives an overview of the main gene therapy strategies, the different available 
nucleic acid delivery systems and the intracellular barriers that have detrimental effects on the 
nucleic acid delivery efficiency of non-viral delivery systems. Although the endocytosis-mediated 
uptake of non-viral nucleic acid containing nanoparticles is a very efficient cellular uptake pathway, 
internalized molecules
 
suffer from poor availability at the target sites such as the cytoplasm or 
nucleus. Therefore, it would be advantageous to bypass
 
the endocytic pathway and somehow 
achieve cytosolic delivery
 
of nucleic acids by other pathways, e.g. through coupling of the cell 
penetrating peptide HIV-1 Tat to the vehicle surface (Chapter 2) or through ultrasound combined 
with microbubbles (Chapter 3). As several problems were encountered studying the endocytic 
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pathways of non-viral delivery vectors, we had a closer look at the use of endocytosis inhibitors to 
study the endocytic uptake of gene complexes in Chapter 4. Since most non-viraI delivery vectors are 
taken up by endocytosis, strategies to escape from the endosomes have been developed. In 
Chapter 5, we studied the use of biodegradable polymers for siRNA delivery and their ability to 
induce endosomal release of the siRNA into the cytoplasm. Once in the cytoplasm, siRNA has 
reached its intracellular target region. In contrast, pDNA still needs to cross a final and major barrier: 
the nuclear envelope (NE). In Chapter 6 we tried to overcome this barrier by using a nuclear 
localization signal (NLS) containing peptide and in Chapter 7 by using a small amphiphilic molecule 
called trans-cyclohexane-1,2-diol (TCHD). 
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ABSTRACT 
 
While safer than viral strategies, the clinical applicability of non-viral nucleic acid delivery 
systems is still limited due to their poor in vivo efficacy. Indeed, upon administration, e.g. by 
intravenous injection, several extra- and intracellular barriers need to be overcome before the 
nucleic acids reach their intracellular target region, i.e. the cytoplasm for siRNA and the nucleus for 
pDNA. This chapter gives a short introduction to gene therapy and the delivery systems for nucleic 
acids and focuses mainly on the intracellular barriers encountered by non-viral nucleic acid 
containing nanoparticles. 
It is well known that serum proteins can adsorb onto the nucleic acid vehicle surface resulting 
in the subsequent uptake of opsonized particles by macrophages and other immune cells. To avoid 
rapid clearance from the blood and thus prolong the circulation time of the vehicles, covering their 
surface with inert polymers such as PEG can be beneficial. 
Once the target cell is reached, most particles are taken up through endocytic mechanisms, 
such as clathrin-dependent or -independent endocytosis or macropinocytosis. Upon endocytosis, 
these particles end-up in vesicles that are processed from early to late endosomes with lysosomes as 
their final destination. The harsh environment of the lysosomes, with low pH and destructive 
enzymes, will cause degradation and inactivation of most particles together with their cargo. 
Therefore, several strategies aimed to either avoid endosomal uptake, e.g. by using cell penetrating 
peptides or ultrasound, or to escape from endosomes, e.g. by using fusogenic peptides or pH-
responsive polymers, have been developed. 
When released in the cytoplasm and once dissociated from its carrier, siRNA molecules have 
reached their intracellular target region, but pDNA needs to be transported into the cell’s nucleus to 
exert its function. When cells undergo mitosis, the nuclear envelope (NE) transiently breaks down 
and the permeability barrier to the nucleus is lost, opening the opportunity for the pDNA to enter the 
nucleus. Unfortunately, many target cells in gene therapy do not divide or divide very slowly, which 
makes the entry of plasmids into the nucleus a major limiting step in non-viral gene transfer. As it 
was shown that plasmids can be transported into the nuclei of non-dividing cells via the nuclear pore 
complex (NPC), non-viral pDNA delivery research has focused mainly on the enhancement of the 
pDNA NPC transport. 
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Chapter 1 
Introduction 
 
INTRODUCTION 
 
Gene therapy is a promising approach to correct many genetic-based human diseases. 
Several strategies are followed to correct faulty genes: (i) addition of the normal gene, either 
transient or by inserting it into a non-specific place in the genome, to correct for the non-functional 
gene, (ii) replacement of the non-functional gene by the corresponding normal gene through 
homologous recombination, (iii) correction of the abnormal gene through selective reverse mutation, 
which returns the gene to its normal function and (iv) alteration of the gene regulation or gene 
expression level of a deregulated gene 
1
. 
 
Figure 1. Genetic-based diseases, caused by a genomic mutation/deletion resulting in either an absent or a 
disease causing protein, can be treated by adding DNA encoding a therapeutic protein or by using the RNAi 
mechanism to knock down the disease causing protein, respectively. 
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In general, two types of genetic-based diseases can be distinguished (Fig. 1). A gene mutation 
or deletion can result on the one hand in the absence of a specific protein and on the other hand in 
the presence of a disease causing protein, e.g. by mutated activity or altered expression levels. The 
first type can be treated by adding the DNA that encodes the absent protein. The latter by using the 
RNA interference (RNAi) mechanism, resulting in specific protein expression knock down of 
unwanted or deregulated proteins (Fig. 2). 
DNA can be introduced by viral expression cassettes (in case of viral vectors) or recombinant 
plasmids (in case of non-viral vectors), engineered to encode specific proteins. Plasmid DNA (pDNA) 
and viral vectors can be considered as pro-drugs that upon cellular internalization make use of the 
cellular transcription and translation apparatus to synthesize the protein of interest. 
 
 
Figure 2. Overview of the RNAi mechanism (adapted from Raemdonck et al., submitted). 
 
RNAi (Fig. 2) is a naturally occurring gene silencing mechanism initiated by double stranded 
RNA (dsRNA) that triggers sequence-specific cleavage of mRNA transcripts. In succession of 
pioneering research in plants 
2
 and nematodes 
3
, RNAi was evidenced in mammalian cells in 2001 by 
Tuschl and colleagues 
4
. When long dsRNA enters the cell, it is immediately recognized and processed 
by Dicer, an RNase III type enzyme, resulting in short interfering RNAs (siRNAs), i.e. RNA duplexes 
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about ~21 to 25 nucleotides in length 
5
. These siRNA molecules are subsequently incorporated into a 
protein complex called RNA induced silencing complex (RISC) that contains the Argonaute 2 (Ago2) 
endonuclease. Only one strand of the RNA duplex is retained inside the RISC, called the antisense or 
guide strand. It is suggested that the sense or passenger strand is initially cleaved by Ago2, thereby 
triggering its dissociation from the complex 
6-8
. Finally, the activated RISC (RISC*) scans the 
messenger mRNA (mRNA) and binds to its complementary region, followed by Ago2 directed 
transcript cleavage between bases 10 and 11 with respect to the 5’ end of the guide strand, leading 
to mRNA degradation 
9
. As long dsRNA can induce severe interferon (IFN) responses in mammalian 
cells 
10
, inducing RNAi is mostly accomplished by the addition of chemically synthesized 21mer 
siRNAs, mimicking Dicer cleavage products, or by the intracellular production of siRNAs from short 
hairpin RNA (shRNA) precursors that can be continuously expressed from RNA polymerase III driven 
expression cassettes. 
 
DELIVERY SYSTEMS FOR THERAPEUTIC NUCLEIC ACIDS 
 
The use of nucleic acids as a drug faces major challenges. For instance, nucleic acids are 
prone to degradation by nucleases that are widely distributed in the body. Additionally, their size and 
high negative charge prevents them to cross the negatively charged cellular membrane. 
Subsequently, several delivery systems that protect the nucleic acids and/or facilitate their cellular 
uptake have been developed. Ideally, a nucleic acid delivery method needs to meet three major 
criteria: (1) it should protect the nucleic acids against degradation by nucleases, (2) it should bring 
the nucleic acids across the plasma membrane to the desired intracellular region of the target cells, 
and (3) it should have no detrimental effects on the cell 
11
. In general, two types of delivery vehicles 
can be distinguished, i.e. viral and non-viral. 
 
VIRAL DELIVERY SYSTEMS 
 
Beyond any doubt, viruses such as retroviruses, adenoviruses, adeno-associated viruses and 
herpes simplex viruses, are currently the most efficient vehicles to deliver therapeutic DNA into the 
cell nucleus, as viruses hijack a variety of cellular mechanisms to bypass all cellular barriers and ferry 
their genomic material into the nucleus 
12,13
. 
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Retroviruses 
 
Retroviruses are RNA containing infectious particles surrounded by a protein capsid and a 
lipid bilayer. They are variable in shape and size, but their average diameter is ~100 nm. After reverse 
transcription, the newly synthesized DNA is integrated into the genome of the host cell at which 
point the retroviral DNA is referred to as a provirus. They can carry up to 8 kb of foreign DNA and 
transduce dividing cells only 
14
. The life cycle of retroviruses, involving integration of proviral DNA 
into the host cell genome and stable transmission to subsequent cell generations, offers the 
potential for long-term cure of inherited monogenic diseases. Lentiviruses, e.g. HIV-1, are a subclass 
of the retroviruses and are able to transduce both dividing and non-dividing cells. 
 
Adenoviruses 
 
Adenoviruses (AdV) were first isolated and cultured from tonsils and adenoid tissue 
15
 and 
now already 51 human AdV serotypes have been identified, grouped in six species (A–F), which 
mostly cause mild infection of the upper respiratory tract, gastrointestinal tract, and the eye 
16
. AdV 
are icosahedral, non-enveloped, dsDNA viruses of ~70 nm diameter that transduce both diving and 
non-dividing cells 
17
. The capsid is built up from 252 capsomers of which 240 are hexavalent and 12 
(situated at the apices) are pentavalent. Wild type (wt) AdV is a lytic virus, killing infected cells and 
not integrating into chromosomes of permissive cells. However, wt AdV occasionally integrates into 
chromosomes of non-permissive cells 
18
. They can carry about 8 kb foreign DNA and, as they mostly 
do not integrate into the host genome, the gene expression is rather limited in time (reviewed by 
19
). 
 
Adeno-associated viruses 
 
Adeno-associated viruses (AAV) are non-enveloped single stranded DNA (ssDNA) viruses that 
belong to the parvoviruses. They are icosahedral, ~20-25 nm diameter, contain a capsid protein and 
transduce both dividing and non-dividing cells. AAV have the ability to stably integrate into the host 
cell genome at a specific site (designated AAV integration site-1 or AAVS1) in human 
chromosome 19 
20
. The cloning capacity of the vector is relatively limited and most therapeutic genes 
require the complete replacement of the viral 4,8 kb genome. 
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Herpes simplex viruses 
 
Herpes simplex virus (HSV) is a dsDNA virus that can infect both dividing and non-dividing 
cells. Amplicons are defective, helper-dependent HSV type 1 (HSV-1) based vectors with a large 
transgenic capacity, allowing the delivery of up to 100 kb of foreign DNA. Both features make these 
vectors one of the most powerful, interesting and versatile gene delivery platforms (reviewed by 
21
), 
although their utility in gene therapy has been
 
impeded to some degree by their inability to achieve 
stable
 
transgene expression. Introduction of
 
the integrating elements of AAV into HSV-1 amplicon 
vectors
 
has shown to significantly improve stable gene
 
transduction by conferring the AAV-like 
capability of site-specific
 
genomic integration 
22
. 
 
NON-VIRAL GENE DELIVERY SYSTEMS 
 
The above described viral gene delivery systems have important disadvantages, such as risk 
of insertional mutagenesis, immunogenicity and cytotoxicity 
23,24
. Besides these clinically dangerous 
virus-mediated gene delivery systems, several non-viral gene delivery systems have been proposed 
for safe delivery of therapeutic nucleic acids into target cells. Basically, non-viral gene delivery 
methods are either physical, i.e. carrier-free, or chemical, i.e. carrier-based. Physical methods, 
including electroporation, hydrodynamic injection, sonoporation, laser assisted delivery, 
magnetofection and ballistic delivery employ a physical force that permeates the cell membrane and 
facilitates intracellular nucleic acid transfer. The chemical approaches use synthetic or naturally 
occurring compounds as carriers to deliver the nucleic acids into the target cells. 
 
Physical methods 
 
ELECTROPORATION. Electroporation, also referred to as electropermeabilization or 
electrotransfer, consists of the local application of electric pulses and has proven to be the most 
simple and efficient non-viral delivery method (reviewed by 
25-27
). Until now, the exact mechanism by 
which electroporation enhances nucleic acid delivery into cells is not clear, though it is known that 
membranes become effectively permeable once a critical electrical potential has been achieved. 
Beside permeabilization, the appliance of electrical pulses was shown to facilitate the electrophoretic 
movement of pDNA into the nucleus and to exert some protection against cytosolic degradation 
28-30
. 
A wide range of target tissues have been studied including skin, kidney, lung, liver, skeletal and 
cardiac muscles, joints, spinal cord, brain, retina, cornea, the vasculature and a variety of 
tumours 
31-40
. Nevertheless, in vivo clinical applications are still limited due to the small effective 
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range of ~1 cm between the electrodes, the necessity of surgical procedure and the high voltage 
applied to tissues possibly resulting in irreversible tissue damage 
41
 or even affecting the stability of 
the gDNA. 
 
HYDRODYNAMIC DELIVERY. Hydrodynamic delivery (reviewed by 
42
), the first systemic delivery 
method for naked nucleic acids, is performed by a rapid injection of a large volume of naked nucleic 
acids solution via the tail vein of mice, inducing potent gene transfer predominantly in the liver 
43,44
. 
Alternatively, rapid injection of naked DNA via the inferior vena cava resulted in gene expression 
mainly localized in the proximal tubular epithelial cells of the corticomedullary region of the 
kidney 
45
. Of course, translating this simple and effective procedure to one that is applicable in 
humans is quite challenging. 
 
SONOPORATION. Sonoporation is a technique that makes use of ultrasound for the intracellular 
delivery of nucleic acids. In contrast to e.g. electroporation and pressure-mediated delivery, 
ultrasound is a non-invasive and locally applicable technique. High-intensity focused ultrasound is 
already clinically used for therapeutic purposes (e.g. thermal destruction of tumours and treatment 
of kidney stones) and low level ultrasound is used for diagnostic purposes, making it an attractive 
technique for in vivo gene delivery. The application of ultrasound results in acoustic cavitation and is 
believed to produce transient membrane permeabilization, thus enhancing the delivery of nucleic 
acids to the cytoplasm. Addition of nucleation agents (reviewed by 
46
), such as ultrasound contrast 
agents (also called gas-filled bubbles or (micro)bubbles), has shown to enhance cavitation and/or 
transfection efficiency 
47-50
 and to induce transient pores in the cell membrane immediately following 
treatment, as evidenced by electron microscopy images 
51
. In contrast, other researchers suggest 
that ultrasound combined with microbubbles facilitate the uptake of macromolecules through 
endocytosis and macropinocytosis 
52
. Both hypotheses are displayed in Fig. 3. Combining both 
electroporation and ultrasound (electro-sonoporation) has shown to be superior to either 
electroporation or ultrasound alone 
53
. 
 
Figure 3. Principle of sonoporation in the presence of microbubbles and nucleic acids. 
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LASER BEAM GENE TRANSDUCTION, MAGNETOFECTION AND BALLISTIC DELIVERY. The use of a focused 
laser to enhance gene delivery, called laser beam gene transduction (LBGT), provides an energy 
source, possibly resulting in a local disruption of the cell membrane 
54
. It remains to be seen if LBGT 
can be significantly scaled up in studies of larger muscles or other tissues, although Zeira et al. 
recently showed that by using femtosecond laser pulses (SG-LBGT) long term intradermal gene 
expression and genetic immunization could be obtained 
55
. Also magnetofection, i.e. the use of 
strong magnetic fields providing an energy source to assist transfer of nucleic acids coupled to 
paramagnetic nanoparticles, can be used to enhance nucleic acid delivery (reviewed by 
56-58
). Finally, 
particle bombardment through a gene gun is an ideal method for gene transfer to skin, mucosa, or 
surgically exposed tissues within a confined area 
59-61
. 
 
Chemical methods 
 
LIPOSOMES. Cationic liposomes are spherical, nano-sized artificial vesicles, composed of 
cationic and other (helper) lipids that form one or more (phospho)lipid bilayers enclosing aqueous 
compartments. Based on the strong negative charge of the nucleic acids, cationic liposomes (LPSs) 
were shown to be very efficient in binding nucleic acids, forming lipoplexes (LPXs) and transferring 
them into cells 
62
. They are widely used because of their advantages over viral gene transfer: they are 
non-immunogenic, easy to produce and non-oncogenic (reviewed by 
63,64
). The cationic LPX structure 
is still under discussion and depends on the composition of the LPS: an ‘external’ model, in which the 
nucleic acids are adsorbed onto the surface of cationic liposomes, or an ‘internal’ model, in which the 
nucleic acids are surrounded or ‘coated’ by a lipid envelope 
65
. The commonly used cationic lipid N-
(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammoniumchloride (DOTAP; Fig. 4A) and the neutral lipid 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE; Fig. 4B) are depicted in Fig. 4, together with 
the general structure of LPXs (Fig. 4C). 
 
 
Figure 4. Representation of (A) DOTAP and (B) DOPE (C) LPXs 
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POLYMERS. Like cationic lipids, cationic polymers (reviewed by 
66-72
) self-assemble with the 
negatively charged nucleic acids into so-called polyplexes due to electrostatic interactions. Different 
types of non-degradable and degradable polymers have been evaluated as nucleic acid delivery 
vehicles, e.g. poly(ethyleneimine) (PEI), poly(2-dimethylaminoethyl methacrylate) (pDMAEMA), poly-
(L-lysine) (pLL), poly(ester)s and poly(urethane)s (Fig. 5). 
 
 
Figure 5. Structure of some commonly used cationic polymers: (A) linear PEI, (B) pLL and (C) poly(β-amino 
ester) 
 
NON-VIRAL DELIVERY BARRIERS 
 
Until now, the use of non-viral delivery systems for clinical gene therapy applications is 
limited by overall poor transfection efficiency 
73,74
. Several extra- and intracellular barriers have been 
shown to dramatically affect the success of non-viral gene therapy (Fig. 6). Upon administration (e.g. 
by intravenous injection) the extracellular barriers include limited stability in the blood, adhesion to 
non-target tissues such as the endothelial cells lining the blood vessels, phagocytosis by 
macrophages, degradation of the nucleic acids, etc. Furthermore, once the target cell is reached, an 
additional series of barriers need to be crossed before the nucleic acids reach their intracellular 
target ‘region’: the cellular and/or endosomal membrane, the cytoplasm and in case of pDNA also 
the nuclear envelope (NE). 
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Figure 6. Overview of non-viral gene delivery barriers (adapted from Raemdonck et al., submitted). 
 
EXTRACELLULAR BARRIERS 
 
Naked nucleic acids, as well as nucleic acids complexed with polycations or LPSs, undergo 
major first-pass clearance by the liver upon intravenous administration 
75-77
. Additionally, the 
presence of plasma nucleases reduces the half-life of DNA, and results in urinary excretion of 
degraded DNA 
77
. Systemic administration of polybasic carriers, with or without simultaneous 
addition of nucleic acids, has been shown to activate the complement system, and the continued 
presence of administered carriers is likely to evoke an immune response 
78
. Furthermore, these 
carriers accumulate in organs with very fine capillary structures such as the skin, lung, and the 
intestine, possibly due to the formation of aggregates with serum proteins, as suggested by Pouton 
and Seymour 
79
. LPXs commonly exceed 100 nm in diameter, and are also expected to self-aggregate 
in the blood stream, resulting in limited passage through the wall of the blood vessel 
79
. Accordingly, 
cells in areas with supernormal vessel permeability are easily transfected using LPXs 
80-82
 and 
techniques to enhance transfection efficiency in vivo, such as hydrodynamic injection, are based on 
the mechanical disruption of the structural integrity of the blood vessel wall barrier 
83
. 
To avoid the adsorption of serum proteins onto the nanoparticle surface and the subsequent 
aggregation and uptake of opsonized particles by macrophages and other immune cells, various 
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strategies have been considered. For example, covering the surface with inert polymers could, in 
principle, reduce protein adsorption and their affinity to immune cells thereby minimizing the toxic 
responses. Toward this end, poly(ethylene glycol) lipid (PEG-lipid) conjugates have been incorporated 
into the LPXs to minimize the non-specific interactions with blood components 
84-87
. It is believed that 
PEG, being hydrophilic and unable to interact with either nucleic acids or cationic lipids, results in 
longer circulation times of LPXs in the blood by minimizing the binding between LPXs and blood 
components. 
 
CELLULAR UPTAKE 
 
Once the target cell is reached, the cellular microenvironment may play a critical role in 
mediating the cellular response to the presented nucleic acids, especially as many diseases disrupt 
normal extracellular matrix (ECM) architecture, cell adhesion to the ECM and subsequent cellular 
activity (reviewed by 
88
). After passage through the ECM, the nucleic acids must be taken up by the 
target cell. As the cell membrane is naturally impermeable to molecules larger than 1 kDa, cells 
posses a variety of active internalization mechanisms to accommodate cellular entry of larger 
molecules or complexes. It has been shown that several forms of endocytosis are involved in the 
cellular uptake of nucleic acid containing nanoparticles 
89,90
. The internalization mechanism varies 
widely according to cell type 
91
, type of nanoparticle 
92
, presence of targeting ligand and particle 
size 
93,94
. The majority of the reports suggests that endocytosis is the preferred route of cell entry for 
non-viral carriers 
95
. Additionally, some reports deal with the involvement of endocytosis-
independent uptake mechanisms active in some specific cases 
96
. 
In general, endocytosis can be classified in two broad categories: phagocytosis and 
pinocytosis 
97
 (Fig. 7). Phagocytosis is typically restricted to specialized cells whereas pinocytosis 
occurs in all cell types. The different pinocytotic pathways can primarily be divided in 
macropinocytosis, clathrin-dependent (CDE) and clathrin-independent (CIE) endocytosis. 
Additionally, under CIE, one can make the discrepancy between dynamin-dependent and -
independent endocytosis 
91
. 
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Figure 7. Endocytic internalization pathways (adapted from 
91
). 
 
Clathrin-dependent endocytosis (CDE) 
 
CDE is the most important and best characterized endocytic pathway and is claimed to be the 
preferred pathway for particles ~200 nm in size 
94
. During CDE, a local, clathrin-associated 
invagination of the plasmamembrane (PM), a coated pit, pinches off to form a membrane-derived 
coated vesicle. This is followed by GTPase dynamin-dependent fission of the mature vesicle 
98
 and 
the immediate release of the clathrin coat, resulting in 60-200 nm sized vesicles 
99
. By fusion with the 
sorting (early) endosomes, CDE typically ends up in the acidifying and degrading endolysosomal 
pathway resulting in hydrolytic and enzymatic destruction of the endocytosed molecules. 
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Clathrin-independent endocytosis (CIE) 
 
The current CIE classification is based on the role of dynamin and several small GTPases 
91
. 
Dynamin-independent CIE is subdivided in ADP-ribosylation factor 6 (ARF6) and cell division cycle 42 
(CDC42) regulated endocytosis. Dynamin-dependent CIE is subdivided in caveolae-mediated and 
RhoA-regulated endocytosis. All CIE endocytic pathways are related by the fact that the endocytic 
vesicles bud from a liquid, ordered membrane environment, called lipid rafts, enriched in 
unsaturated phospholipids, cholesterol, glycosphingolipids and certain proteins 
100
. Additionally, all 
CIE processes strongly depend on the integrity of actin microfilaments 
91
. Caveolae-mediated 
endocytosis is probably the best characterized CIE pathway. Caveolae are small (50-80 nm), smooth, 
flask-shaped invaginations of the PM that are characterized by the presence of caveolin 
101
. The post-
endocytic trafficking of CIE is quite diverse and mostly dependent on the cargo: from ending up in the 
early endosomes 
91
 to fusing with caveosomes 
102
. Caveosomes are neutral endosomes which do not 
acidify 
103
 nor do they fuse with lysosomes 
104
. Additionally, they have a longer life time compared to 
other endosomes 
102
. 
 
Macropinocytosis (MP) 
 
MP is a non-selective endocytic mechanism of suspended macromolecules that gives rise to 
vesicles with sizes up to 5 µm 
105
. MP is based on the formation of membrane protrusions, often 
called ruffles, which can subsequently fuse with each other or with the PM to enclose large 
volumes 
106
. Once taken up, the intracellular itinerary differs from cell to cell. In macrophages, the 
formed macropinosomes shrink, acidify and fuse with lysosomes. In contrast, in epithelial cell lines 
these vesicles do only partially acidify, do not fuse with lysosomes and are finally mostly 
exocytosed 
107
. 
 
Phagocytosis 
 
Phagocytosis shares many features with MP, but instead of membrane ruffles that form a 
macropinosome, the fagosome is formed by actin-driven pseudopodia that ingest micron-sized 
particles. This is no fluid-phase but adsorptive endocytosis and is exclusive for specialized cells such 
as macrophages and dendritic cells that engulf large structures, i.e. > 500 nm, such as bacteria, dead 
cells or yeast 
108
. 
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Endocytosis-independent uptake mechanisms 
 
CELL PENETRATING PEPTIDES (CPPS). So called CPPs, e.g. the HIV-1 Tat peptide, have been 
reported to accomplish direct cytosolic delivery when attached to various cargoes, such as 
fluorochromes 
109
, proteins 
110,111
, oligonucleotides 
112
 and even magnetic nanoparticles 
113
 and 
liposomes 
114,115
. Initially, analysis of fixed samples after incubation at low temperature and in the 
presence of metabolic inhibitors suggested that the uptake mechanism was energy-independent, 
excluding the involvement of endocytosis. The proposed uptake mechanism was called translocation 
or transduction and seemed to be non-saturable, very fast (i.e. within minutes), and independent of 
cell type. However, based on different observations, such as the redistribution of CPPs after cell 
fixation and the fact that endocytosis inhibitors such as cytochalasin D (cytoD) and low temperature 
did abolish the CPP uptake in living cells, serious issues were raised concerning the general nature of 
the translocation mechanism 
116-118
. Subsequently, re-evaluation
 
of the uptake of these peptides and 
their cargoes lead to the conclusion that endocytosis is the major uptake pathway
 119,120
. The 
possibility
 
of the energy-independent uptake of these peptides and their
 
cargoes, however, cannot 
be excluded 
121
, and
 
it may be possible that certain factors, which may affect the
 
uptake mechanism, 
should be optimized to achieve a successful
 
endocytosis-independent delivery. 
 
MICROINJECTION, PERMEABILIZATION, ELECTRO- & SONOPORATION. Microinjection is a technique
 
that 
permits the rapid delivery of nucleic acids into the cytosol or nucleus 
122,123
 In the case of 
permeabilization,
 
pore-forming agents such as streptolysin O or anionic peptides
 
similar to the N-
terminal segment of the Hemagglutinin 2 (HA2) subunit of the
 
influenza virus hemagglutinin that 
have the ability to fuse
 
with the plasmamembrane, are used to induce transmembrane channels
 
or 
large apertures in the cell membrane, which then allow the
 
entry of large molecules 
124,125
. However, 
both techniques are highly
 
invasive and cannot be used for in vivo gene delivery. Finally, also electro- 
and sonoporation are alternative approaches to avoid endosomal uptake and are described above. 
 
ENDOSOMAL ESCAPE 
 
When the nanoparticle is taken up by endocytosis, it mostly ends up being degraded inside 
the lysosomes, unless it succeeds in escaping from the endosome before acidification takes place. A 
number of mechanisms have been proposed to facilitate the escape of particles from the 
endosomes. 
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Membrane-destabilizing and fusogenic lipids 
 
The use of membrane-destabilizing lipids is widely studied and a variety of lipids have been 
used for this purpose. Several researchers have shown that lipid contact occurs between cationic 
lipids from the LPX and anionic lipids from the inner face of the endosomal membrane, resulting in 
flip-flop of anionic lipids from the cytoplasmic face of the endosomal membrane 
126-128
 (Fig. 8). These 
anionic lipids laterally diffuse into the LPX and form a charge neutralized ion-pair with the cationic 
lipids from the LPXs, resulting in destabilization of the LPXs, displacement of the negatively charged 
nucleic acids and their subsequent release into the cytoplasm of the cells.  
 
Figure 8. Schematic representation of the cationic lipid mechanism of endosomal release: (1) internalization, 
(2) initiation of endosomal membrane destabilization resulting in a flip-flop of anionic lipids, (3) lateral diffusion 
of the anionic lipids and formation of a charged neutralized ion-pair with the cationic lipid and (4) displacement 
of nucleic acids and diffusion into the cytoplasm (adapted from 
127
). 
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Additionally, liposomes often contain lipids with pH-dependent fusogenic properties, i.e. 
lipids that undergo a phase transition in the low pH environment of the endo-/lysosomes, thereby 
promoting fusion with and/or destabilization of the endosomal membrane (reviewed by 
129
). Cone-
like lipids, such as the neutral lipid DOPE, can change at low pH from the lamellar phase into the 
inverted hexagonal phase, disturbing the endosomal membrane thereby provoking endosomal 
escape. 
 
Osmotic pressure and swelling 
 
Another strategy to obtain endosomal release is to use a carrier that can create an osmotic 
pressure inside the endosomes. Highly cationic polymers such as PEI and poly(amidoamine) (PAA) 
dendrimers contain several secondary amines that are easily protonated in the acidic environment of 
the late endosome and lysosome. These polymers are efficient transfection agents that are thought 
to act by a proton sponge effect. The high buffering capacity of these polymers prevents acidification 
of the endosomal compartment, and induces ion influx in endosomes, causing osmotic swelling, 
vesicle destabilization and finally endosomal rupture 
130-132
. Additional work on these polymers has 
demonstrated that chain flexibility is a key feature for this effect, since polymer expansion appears to 
be an important parameter leading to endosomal swelling and subsequent disruption 
130,133
. 
Increasing osmotic concentration within the endosome can also be obtained by using a 
biodegradable polymer, resulting in an increase of the osmotic pressure in the endosome, as 
proposed by Koping-Hoggard 
134
. This increase in osmotic pressure after degradation was also 
proposed for poly(β-amino ester)s (PbAEs) by our group (Vandenbroucke et al., in revision). Alternatively, 
polymers can also have a `hydrogel effect´, i.e. ‘swelling’ polymer, resulting in endosomal rupture 
135
. 
 
Endosomolytic peptides and polymers 
 
The acidic environment of the endosome has led to the design of several gene delivery 
peptides that become endosomolytic at lower pH. Once inside the endosome, these peptides can 
either buffer against the pH drop and hence build up an osmotic pressure in the endosomes or fuse 
with the endosomal membrane leading to pore formation (reviewed by 
136
). In an effort to translate 
the above described proton sponge activity to peptide based nucleic acid carriers, histidine has been 
added. Histidine-rich peptides contain an imidazole group with a pK of ~6.0, thereby allowing it to 
become protonated in the acidic environment of the endosome, with similar effects as e.g. PEI. On 
the other hand, fusogenic peptides have been used to promote endosomal escape and delivery of 
nucleic acids to the cytosol and/or nucleus. These peptides adopt an α-helical structure at endosomal 
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pH leading to hydrophobic and hydrophilic faces that can interact with the endosomal membrane to 
cause disruption and/or pore formation 
137,138
. In an effort to mimic viral mechanisms of endosomal 
escape, Wagner et al. designed short peptides derived from the N terminus of the influenza virus 
hemagglutinin HA-2 
139,140
. Additionally the conjugation of melittin, a strong amphipathic, 26 amino 
acid peptide whose sequence is derived from the venom Apis mellifera (honey bee), to polycations 
resulted in a strong increase in gene expression in a variety of cell lines 
141,142
.  
Similarly, pH-sensitive synthetic polymers, consisting of anionic carboxylated polymers such 
as acrylic and methacrylic acid (MAA) copolymers, were shown to permeabilize cell membranes at 
acidic pH and low concentrations. These characteristics are due to the neutralization of carboxyl 
groups, which gives the polymer a higher hydrophobicity and affinity for lipid membranes. When 
used at high concentrations, these polymers can even completely solubilize phospholipid 
bilayers 
130,143
. 
 
Photochemical internalization 
 
Photochemical internalization (PCI) was first presented in 1999 as a novel technology for the 
delivery of a variety of therapeutic molecules into the cytosol 
130
. PCI technology employs specific, 
preferably amphiphilic 
144
, photosensitizing compounds, called photosensitizers (PS), which 
accumulate in the membranes of the endocytic vesicles. Examples of PS are 
mesotatraphenylporphine containing two sulfonate groups on adjacent phenyl rings (TPPS2a) and 
aluminium phtalocyanine with two sulphonate groups on adjacent phthalate rings (AlPcS2a). Upon 
illumination, PS become excited and induce the formation of reactive oxygen species, primarily 
singlet oxygen. This highly reactive intermediate can damage cellular components, but the short 
range of action and short life-time confine the damaging effect to the production site. This localized 
effect induces the disruption of the endocytic vesicles, thereby releasing the entrapped therapeutic 
molecules into the cytosol. Since its discovery, several studies have been published (reviewed by 
145
), 
demonstrating that this technique can be used to enhance drug delivery, both in vitro and in 
vivo 
146-148
 for site-specific delivery of proteins 
130
, peptides 
130
, peptide nucleic acids 
149,150
, and pDNA 
carried by non-viral 
130,151-153
 and viral carrier systems 
154
. 
 
NUCLEAR IMPORT 
 
One of the crucial steps in non-viral pDNA delivery is the nuclear import, as the DNA must 
enter the nucleus to be transcribed, replicated, and/or integrated. The NE encloses the 
chromosomes as a selective barrier not allowing the passage of molecules larger than 40 kDa 
155
. 
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Therefore, the NE needs to be degraded during mitosis to assure that the chromosomes gain access 
to the microtubules of the cytoplasmic mitotic spindle 
156
. This occurs by disassembly of the major 
structural elements of the NE during the mitotic prophase. In late anaphase, the dispersed NE 
components are reused in the assembly of two new NEs around the segregated chromatids 
157
 with 
help of several proteins such as POM121 
158
 and MEL-28 
159,160
. During reassembly of the NE, nucleic 
acids present in the cytoplasm can reach the nucleus ‘by accident’. In contrast, postmitotic and 
quiescent cells have no breakdown of the NE. In addition, the transport channels in quiescent cells 
show a lower rate of nuclear uptake and smaller functional size compared to proliferating cells 
161,162
. 
Therefore, as many cells that are targeted in gene therapy do not divide or divide very slowly, the 
entry of therapeutic genes into the nucleus is a major limiting step in non-viral gene transfer 
(reviewed by 
163-165
). 
 
Obstacles encountered during pDNA nucleocytoplasmic trafficking 
 
It is estimated that at least 10
5
–10
6
 plasmids per cell are required in the extracellular 
compartment to ensure nuclear uptake and transcription in non-mitotic cells 
166
. Additionally, 
determination of the nucleocytoplasmic pDNA transport efficiency revealed that only 0.1-0.001 % of 
the cytoplasmic DNA was eventually transcribed in the nucleus in the absence of cell division 
167-171
. 
The limited nuclear localization after cytosolic pDNA delivery can be attributed to three aspects 
during nucleocytoplasmic transport: (1) restricted diffusional mobility, (2) metabolic instability and 
(3) limited nuclear transport. 
The size-dependent restricted mobility of DNA inside the cytoplasm 
172
 is mainly caused by 
the mesh-like structure of the cytoskeleton, as disrupting or reorganizating the actin cytoskeleton 
significantly increases the diffusion rate 
173,174
. Subsequently, this restricted diffusion leads to an 
increased residence time of the pDNA inside the cytoplasm, favoring metabolic degradation by 
nucleases that transiently appear in the cytoplasm before nuclear translocation 
175
. Finally, once the 
pDNA reaches the NE, the nucleocytoplasmic trafficking is controlled by the nuclear pore complex 
(NPC) that forms a channel across the NE 
176
. 
 
Nuclear pore complex (NPC) 
 
The NE forms the boundary between the nucleus and the cytoplasm, and consists of an inner 
nuclear membrane (INM) and an outer nuclear membrane (ONM). Both membranes are separated 
by a lumen, called the periplasmic space, which is contiguous with the endoplasmatic reticulum (ER) 
lumen. Increasing evidence shows that the NE also links the inside of the nucleus to the cytoskeleton 
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through complexes of lamins on the inner aspect of the INM, through transmembrane proteins of the 
INM called SUNs and through large nesprin isoforms localized specifically to the ONM 
177
. 
The presence of the nuclear barrier requires a system to efficiently transport diverse sets of 
macromolecules across the double-membraned NE. The mediators of this exchange are large 
assemblies termed NPCs that span pores in the NE connecting the nuclear and cytoplasmic 
compartments 
178
. The general architecture of NPCs is shared in all eukaryotes, and many of the NPC 
proteins are conserved across phyla. The vertebrate NPC (Fig 8) has a mass of ~125 megadalton 
(MDa) 
179
, containing 30-50 proteins 
180
 known as nucleoporins or Nups 
178,181
. The NPC exhibits an 
8-fold rotational symmetry core structure, the so-called spoke complex, that forms a 
~40 nm-diameter translocation channel, and contains ring structures at both the cytoplasmic and the 
nuclear sides of the NE 
182-185
. In addition, eight fibrils of distinctive shape are attached to both ring 
structures. The cytoplasmic fibrils have free distal ends, while the thin fibrils emanating from the 
nuclear ring are laterally interconnected at their ends, called the terminal ring. The nuclear fibrils and 
terminal ring are believed to represent a structural and functional entity, called the nuclear 
basket 
186,187
. Additionally, three-dimensional reconstructions of electron microscopic data indicate 
the existence of eight small, peripheral channels that are supposed to penetrate the individual NPC 
subunits around the large central channel 
188
. The peripheral channels in the NPC rim structures most 
probably function like ion channels with small electrical conductivity and specific gating 
characteristics 
189
, while the central channel functions like a nanomachine that transports 
macromolecules of different sizes and thus undergoes dramatic changes in conformation 
190-192
. 
 
Figure 8. General structure of the NPC. 
 
Water, ions, small macromolecules (< 20-40 kDa) 
193
 and small neutral particles (< 5 nm ∅) 
can diffuse freely across the NPC 
194
, while larger macromolecules generally need a particular 
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transport signal sequence, such as a nuclear localization signal (NLS) or nuclear export signal (NES) to 
be transported efficiently. NPCs can pass cargoes up to 30 nm diameter, at rates as high as several 
100 macromolecules per sec; each transport factor-cargo complex dwelling in the NPC for a time at 
the order of 10 msec 
195,196
. 
 
Nucleocytoplasmic transport components 
 
NUCLEAR TRANSPORT RECEPTORS. Proteins that contain a NLS or NES are recognized by nuclear 
transport receptors (NTRs) that mediate their translocation through the nuclear envelope. The 
majority of NTRs belong to the family of karyopherin β proteins, also called importin β-like proteins 
(reviewed by 
197,198
). According to their transport direction two subtypes can be distinguished, i.e. 
importins and exportins. As shown in Fig. 9, importins associate with their macromolecular cargo in 
the cytoplasm, either directly or indirectly via adaptor proteins. Subsequently, they dock to the Nups 
of the NPC, translocate through the central channel of the NPC and release their cargo. Most of the 
transport receptors use the GTPase Ran to control cargo association. The asymmetric distribution of 
RanGDP (mainly present in the cytoplasm) and RanGTP (mainly in the nucleus) ensures the 
directionality of nuclear transport 
199,200
. Indeed, importins bind their cargoes in the cytoplasm in the 
absence of RanGTP and unload them upon binding to RanGTP in the nucleus. The export process, 
mediated by exportins, is essentially the reciprocal process, also regulated by the GTPase Ran. 
 
 
Figure 9. Overview of the active, NLS-dependent nuclear import mechanism. 
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CLASSICAL AND NON-CLASSICAL NLSS. Obtaining active protein transport into the nucleus requires 
the presence of NLSs which can interact with the NTRs. In general, NLSs can be subdivided into 
classical and non-classical sequences 
201
. The classical NLS sequences are characterized by a stretch of 
basic, charged amino acids and interact with the importin α/importin β heterodimer 
202
 or are 
recognized by importin β alone 
203
 to facilitate nuclear import of their protein cargo. In contrast, non-
classical NLS sequences lack this basic amino acid stretch and bind to transportin instead of 
importin 
204
. 
 
NLS INDEPENDENT NUCLEAR TRANSPORT. In recent decades, the function of sugar molecules as 
nuclear transport signals has been clarified 
205-207
. According to these reports, sugar-dependent 
nuclear transport is mediated by its receptor (i.e. lectin) and occurs in an energy-dependent manner 
via the NPCs. Moreover, since this pathway is not inhibited by an excess of NLS peptides, this sugar-
mediated pathway appears to be quite different from the NLS-mediated pathway. The same reports 
also revealed sugar-specificity in nuclear delivery. Nuclear delivery of bovine serum albumin (BSA) 
modified with glucose, mannose, N-acetylglucosamine (GlcNAc), and fucose was clearly observed; in 
contrast, modification with galactose, lactose, and 6-phospomannose did not enhance nuclear 
delivery. Additionally, the sugar-dependent transport of BSA into the nucleus was shown to be cell 
cycle dependent as it was more efficient during the G1/S transition and S phases, in contrast to NLS-
mediated transport that did not sustain any difference during any stage cycle except a slight 
decrease for the G2 phase 
208
. Alternatively, proteins without NLS may be co-transported with 
another protein that do contain an NLS 
209
. This ‘piggy back mechanism’ has been described in 
particular for some protein kinases 
210
.  
 
Gateway models 
 
The exact mechanism of the nucleocytoplasmic transport through the NPCs is still not 
completely elucidated. Different models have been proposed to explain how the nuclear 
permeability barrier is created, such as the ‘Brownian affinity gate’ 
211,212
, the ‘oily spaghetti’ 
213
, the 
‘affinity gradient’ 
214
, the ‘dimensionality reduction’ 
215
, the ‘polymer brush’ 
216
, a ‘two-gate’ 
217
 and 
the ‘selective phase’ model 
218-221
. Most models consider the NPC as a ‘virtual gate’ 
222,223
 (Fig. 9A), 
where the phenylalanine-glycine (FG) repeats of the Nups create a barrier for entrance into the NPC 
and transport through the NPC involves facilitated diffusion controlled by association and 
disassociation of transport receptors with FG Nups. They differ only in specific assumptions, such as 
the conformation and spatial deployment of the FG Nups, their physicochemical state, or the 
distribution of affinities of binding sites (reviewed by 
224
). In contrast, an alternative model to the 
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‘virtual gate’ was proposed by Ribbeck and Görlich, called the ‘selective phase’ model (Fig. 9B), in 
which FG domains within the central channel of the NPC interact with each other to form a protein 
meshwork, forming a separate hydrophobic phase. Subsequently, the ‘selective phase’ model 
assumes that the central channel of the NPC has a sieve-like structure. NTR and NTR-cargo complexes 
can partition into this phase because of their capacity to bind to the FG repeats, thereby locally 
perturbing FG domain interactions. The capacity of Nups to form a three-dimensional meshwork with 
hydrogel-like properties was confirmed by Frey et al. who demonstrated that recombinant 
nucleoporins (Nsp1p) could form a free-standing hydrogel in vitro with an elasticity comparable to 
0.4 % agarose (Fig. 9C) 
225
. Additionally, mutation of the 55 phenylalanines (F) within the FG context 
of the essential yeast Nup Nsp1p to serines (S), resulted in the absence of gel formation and the 
mutated protein failed to bind to NTRs.  
 
 
Figure 9. Two main models of the NPC permeability barrier. (A) The ‘virtual-gate’ model proposes that FG 
domains are non-cohesive, entropic bristles that repel the entry of non-karyophilic proteins into the NPC 
through Brownian motion. (B) The ‘selective phase’ model proposes that FG domains interact with each other 
via hydrophobic attraction between FG motifs to create a filamentous meshwork that sieves particles by size 
exclusion (adapted from 
226
). (C) Formation of a hydrogel by the wt FG repeat domain from Nsp1p. Insert 
illustrates how interactions between the hydrophobic clusters (shown in red) crosslink the repeat domains. (D) 
Nsp1p with F→S mutated repeat domain was unable to form a hydrogel (adapted from 
227
). 
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Opening the gateway 
 
The molecular mass of pDNA can be estimated between 2 and 10 MDa. Subsequently, it is 
unlikely that pDNA can enter the nucleus via passive diffusion. Additionally, there are several reports 
indicating that the transport mechanisms for pDNA and molecules larger than 60 kDa share some 
characteristics, such as wheat germ agglutinin (WGA) sensitivity and temperature- and energy-
dependent translocation 
228
, supporting the hypothesis that plasmid molecule accumulation 
proceeds by active transport via the NPC 
229
. 
To promote the nuclear import of pDNA, different strategies are currently used: (i) hijacking 
the nuclear import machinery by attaching NLS peptides, NLS containing proteins or even importin β 
to the pDNA, (ii) compacting the pDNA in small nanosized particles to fit the NPC as a complex, (iii) 
mimicking the sophisticated viral mechanisms, and (iv) physical or chemical disruption of the nuclear 
barrier. 
 
HIJACKING THE NUCLEAR IMPORT MACHINERY. Recruiting components from the nuclear import 
machinery to augment pDNA transport into the nucleus, requires the direct or indirect attachment of 
e.g. NLSs to pDNA, which can be achieved by different approaches (reviewed by 
230-233
): (i) 
electrostatic interaction 
234-243
, (ii) covalent binding 
244-250
, (iii) via protein-DNA interaction 
251,252
, (iv) 
via peptide nucleic acid (PNA) clamps 
253-256
, (v) coupling to polymers 
257-259
, (vi) coupling to 
lipids 
260-266
 and (vii) coupling to recombinant lambda phage 
267
. As an alternative to NLSs or NLS 
containing proteins, also importin and histones were used to enhance the nuclear pDNA 
delivery 
268,269
. Although all these results support the fact that recruiting the nuclear import 
machinery can have some benefits for non-viral gene delivery, all these attempts have achieved only 
limited success compared to viral gene delivery. Probably, when condensing pDNA with NLSs or NLS-
modified polycations, controlling the NLS surface display and density is difficult. Indeed, NLSs contain 
cationic amino acids which can interact with pDNA via strong electrostatic forces probably masking 
the NLS and hence preventing nuclear import enhancement. 
 
COMPACTING THE PDNA. Although it was previously believed that complex dissociation 
precedes the nuclear uptake of pDNA 
270
, several researchers recently questioned this and showed 
that dissociation may not be a prerequisite for nuclear translocation. Furthermore, considering (1) 
the problems related to cytoplasmic mobility, (2) the limited pDNA stability and (3) the 25-30 nm 
cutoff of the NPC 
271-273
, it is reasonable to assume that compacting pDNA into cytoplasmic released 
nanoparticles can enhance transfection efficiency compared to naked cytoplasmic DNA release, 
particularly in slowly dividing and non-dividing cells 
274
. Additionally, in case of LPXs, pDNA could be 
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detected in the nucleus in time intervals as low as 1 hr after LPX-mediated transfection, implying the 
involvement of dissociation independent mechanisms in this early nuclear delivery 
275
, such as LPX 
fusion with the nuclear membrane and subsequent pDNA release into the nucleus 
276
. Furthermore, 
several nanoparticles were shown to end up inside the nucleus as a complex, i.e. without dissociation 
between DNA and carrier, e.g. DNA–PEI complexes 
277,278
 and multifunctional envelope-type nano 
device (MEND) nanoparticles 
279
. 
 
MIMICKING VIRAL MECHANISMS. In general, sugars have been used as a tool in gene delivery to 
enhance the efficiency of cellular uptake. For example, galactose and mannose are specifically 
recognized by lectins expressed on the cell membrane surface, i.e. the asialoglycoprotein receptor 
and mannose receptor, respectively 
280-282
. But in contrast to the influence on cellular uptake, 
different types of sugars, such as β-GlcNAc, α-mannose, and β-galactose, can also be used as nuclear 
targeting ligands, as already discussed above 
283-285
. Nuclear lectin-mediated gene delivery by means 
of glycosylated polymers such as lactosylated pLL and lactosylated PEI, has been recently 
reported 
286-291
. Additionally, Masuda et al. 
292
 developed a nuclear gene delivery system based on the 
novel concept of a ‘degradable lipid envelope on the NPC’, mimicking the mechanism of adenoviral 
nuclear entry. Once in the cytoplasm, the AdV capsid targets the NPC, allowing binding between 
capsid protein hexon and histone H1. Subsequently this leads to hexon–histone H1 complex 
transport into the nucleus by histone H1 import factors (i.e. importin 7 and importin β), triggering 
nuclear transfer of AdV gDNA in conjunction with disruption of the viral capsid 
293
. In the study of 
Masuda et al. an octaarginine modified MEND (R8-MEND) was used, i.e. polycation-condensed pDNA 
followed by encapsulation with a stearylated R8 modified lipid envelope 
279,294
. The presence of the 
R8 induces cellular uptake via macropinocytosis and uptake via this pathway is advantageous as it 
avoids a lysosomal degradation and releases its cargo into the cytoplasm 
295,296
. Additionally, nuclear 
targeting was achieved through the addition of sugars on the MEND surface via anchorage of the 
cholesterol moiety of a sugar–cholesterol conjugate in the lipid envelope. 
 
DISRUPTING THE BARRIER. Several studies showed that permeability is not ‘fixed’ but, in contrast, 
seems to be highly variable. Apparently, NPCs can undergo dramatic conformational changes, which 
subsequently strongly affect the electrical conductivity and macromolecule permeability of the 
central channel 
297
. Different data stress the importance of combining both atomic force microscopy 
(AFM) and functional data, as it is not clear if the AFM derived terms ‘NPC contraction, dilation or 
collapse’ can be correlated to NPC ion and macromolecule permeability, although it is hypothesized 
that contracted NPCs are active pores while collapsed NPCs are inactive 
298
. AFM images have shown 
that NPCs are calcium sensitive supramolecular structures that contract when the calcium 
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concentration is high 
298
, indicated by a sharp increase in NPC height and a narrowed NPC lumen. 
Additionally, after depletion of nuclear store calcium by inositol 1,4,5-trisphosphate or calcium 
chelators, fluorescent molecules conjugated to 10 kDa dextran were unable to enter the nucleus, 
while diffusion of molecules < 500 Da and ions was not affected 
299,300
. In the presence of ATP, 
nucleoplasmic NPC rings were clearly contracted. Also CO2 was shown to have an effect: cytosolic 
acidification by exposing the nuclear envelope to CO2 induced NPC collapsing 
301
. More recently, Enss 
et al. (2003) examined the effect of Ca
2+
, pH and addition of an antibody against gp62, a glycoprotein 
located at the central channel entrance, on the NPC permeability for 10 kDa dextran, which is too 
large to penetrate the small peripheral channels but freely diffuses through open NPC central 
channels 
302
. Neither Ca
2+
 nor pH influenced the NE permeability for 10 kDa, while the gp62 antibody 
reduced macromolecule diffusion. As it was previously shown that the peripheral channels could be 
activated by Ca
2+
 and ATP 
303
, these observations indicate that there are separate routes for 
macromolecules and ions to cross the NE, regulated by different mechanisms. Also different steroid 
hormones were tested on their functional and structural effect on nuclear pores of Xenopus laevis 
oocytes 
304-306
. E.g. aldosteron was shown to influence the nuclear barrier integrity: ten minutes after 
aldosterone exposure a sharp increase in both electrical conductivity 
305
 and dextran permeability 
307
 
was observed. These effects are possibly caused by the opening (or unplugging) of the central 
channels of a small ‘aldosteronesensitive’ population of NPCs, allowing both inorganic ions and 
macromolecules to travel through the central channel pathway. Shulga and Goldfarb demonstrated 
that aliphatic alcohols, such as methanol, ethanol, isopropanol, n-butanol, cyclohexanol, and 1,6-
hexanediol, could increase the NPC permeability in wild-type yeast cells at high alcohol 
concentrations (1 to 5 %) 
308
. In conjunction with increases in permeability, aliphatic alcohols, 
deoxyglucose, and chilling triggered the reversible dissociation of several Nups from the NPCs, 
consistent with the hypothesis that NPC gating occurs when molecular latches composed of FG 
repeats and structural nucleoporins dissociate. In contrast, it was also found that exposure of cell 
nuclei isolated from Xenopus oocytes to clinically relevant ethanol concentrations, i.e. concentrations 
between 0.05 and 0.2 %, decreased NE permeability within hours together with nucleus swelling and 
clustering of the nuclear pores in the NE 
309
. In contrast to the above described aliphatic alcohol 
effects, this effect was not attributed to disruption of the hydrophobic interactions inside the central 
NPC channel, but to transcriptional processes, as blocking the transcriptional activity also prevented 
the permeability changes. The effect of the amphiphilic alcohol trans-cyclohexane-1,2-diol (TCHD) 
was studied more in detail by Ribbeck and Görlich to verify their NPC gateway model. They 
demonstrated that TCHD enhanced the rate of nuclear entry of the 40 kDa maltose binding 
protein 
310
. Subsequently, our group studied whether non-selective gating of nuclear pores by an 
amphipathic alcohol like TCHD could also be used as an alternative method to facilitate nuclear entry 
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of plasmid DNA 
311
. Indeed, addition of TCHD to the cellular medium resulted in reversible and 
enhanced nuclear membrane permeability for both high molecular weight dextrans and pDNA at 
non-toxic concentrations. Furthermore, TCHD enhanced the transfection efficiency of both naked 
pDNA and DOTAP:DOPE-based LPXs. 
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ABSTRACT 
 
Several reports have shown a fast and efficient translocation of Tat-modified lipoplexes (LPXs) and 
particles into the cell cytoplasm. However, neither the uptake mechanism nor the biological effect of 
Tat-modified LPXs has been studied in detail. In this report we show that the increase in gene 
transfer of Tat-modified LPXs depends on the amount of cationic lipid in the LPXs and on the way Tat 
was coupled to the LPXs. We demonstrate that the cellular uptake of both Tat-modified and 
unmodified LPXs is very fast and, in contrast to previous publications, temperature-dependent. 
Additionally, after internalization Tat-modified as well as unmodified LPXs end up in lysosomal 
vesicles, indicating the involvement of clathrin-mediated endocytosis. Furthermore, chlorpromazine, 
a specific inhibitor of clathrin-dependent endocytosis, strongly inhibits the cellular uptake and 
biological activity of both the Tat-modified and unmodified LPXs. We also found that the uptake and 
biological activity of these LPXs are diminished when cholesterol in the cell membrane was bound by 
filipin, an inhibitor of the lipid-raft mediated pathway. Considering these data, we conclude that Tat-
modified and unmodified LPXs are mainly internalized via a cholesterol-dependent clathrin-mediated 
pathway. 
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Chapter 2 
Cellular Entry Pathway and Gene Transfer 
Capacity of Tat-modified Lipoplexes 
 
INTRODUCTION 
 
Gene therapy may become an important strategy in the treatment of various diseases. 
However, the clinical applications of gene therapy depend largely on the development of suitable 
gene transfer vehicles. Although generally not as efficient as viral vectors, non-viral systems, such as 
lipids, have the advantages of being less toxic, safer, non restrictive in DNA size, potentially 
targetable, and easy to produce in relatively large amounts. However, poor transfection efficiencies 
presently limit their usefulness for gene therapy applications, caused by critical steps such as 
endosomal release and nuclear uptake 
1
. 
Viruses, such as influenza viruses and adenoviruses, have developed peptides that warrant 
their escape from endosomes by membrane fusion or disruption upon the acidification of the 
endosomes. Such viral peptides and also synthetic polymers capable to disrupt endosomes upon 
acidification have been applied to enhance non-viral gene delivery (reviewed by 
1-4
). However, it has 
been shown that an excessive disruption of endosomes by endosomolytic agents may be harmful to 
the cell 
5
. Alternatively, to circumvent the endosomal escape barrier, it has been proposed to bypass 
the endosomal pathway by using cell penetrating peptides (CPPs) that rapidly translocate cargoes 
across the cell membrane 
6-8
. Peptides derived from the HIV-1 transactivator of transcription protein 
or ‘Tat’, have been shown to facilitate both in vitro and in vivo the intracellular delivery of cargoes of 
various sizes and physicochemical properties (recently reviewed by 
8-10
). These Tat peptides, typically 
having a positive charge at physiological pH, consist of a short stretch of basic amino acids 
(GRKKRRQRRR), which is responsible for the translocation across
 
cellular membranes and is called the 
protein transduction domain (PTD) sequence 
11
. Additionally, this sequence also functions as a 
nuclear localization signal 
12
. 
Initially it was believed that the uptake of Tat peptide or Tat peptide conjugated cargoes 
occurs in a receptor-independent 
13,14
 and temperature-independent manner 
11,15-17
. However, this is 
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currently questioned by the increasing evidence that the original data might originate from artefacts 
in the experimental procedure for fixation and removal of membrane-bound material 
18
. Until now, 
the precise entry mechanism of Tat peptides and Tat peptide conjugated cargoes is still controversial 
(reviewed by 
19
). Both clathrin-mediated endocytosis 
20-23
, caveolae-mediated endocytosis 
24-27
 and 
macropinocytosis 
14,28
 have been suggested. Possibly the mechanism of cellular entry depends on the 
cell type, the Tat sequence, physicochemical properties of the cargo, the amount of Tat peptides on 
the surface of the cargo, and the way Tat peptides are bound to the cargo 
9
.  
The ability of Tat peptides to translocate cargoes across cell membranes is an attractive 
feature that could bring significant advantages to the cellular delivery of proteins, therapeutic DNA 
or small interfering RNA (siRNA) molecules 
24,29,30
. However, in contrast to Tat peptides conjugated to 
proteins, the biological effect and the cellular entry mechanism of Tat/plasmid DNA (Tat/pDNA) 
conjugates and in particular Tat-modified lipoplexes (LPXs) 
30-33
 have not been studied in detail. 
Therefore, in this work we aimed to determine (1) whether the attachment of Tat peptides to LPXs 
could enhance their transfection efficiency, (2) whether the uptake of the Tat-modified LPXs is 
energy dependent, and (3) the cellular entry mechanism and intracellular routing of the Tat-modified 
LPXs. 
 
MATERIALS & METHODS 
 
Materials 
 
Dulbecco's modified Eagle's medium (DMEM), L-glutamine (L-Gln), heat-inactivated fetal 
bovine serum (FBS), and penicilline-streptomycine (P/S) were supplied by GibcoBRL (Merelbeke, 
Belgium). The Tat peptide AA 37-72 (CFITKALGISYGRKKRRQRRRAPQGSQ-THQVSLSKQ) was obtained 
from the Centralised Facility for AIDS Reagents, EU Programme EVA (European Vaccine Against AIDS). 
The secreted alkaline phosphatase (SEAP) expression plasmid (pMet7 hβc SEAP) was a kind gift from 
Prof. Tavernier (Ghent University, Belgium). 1,2-Dioleolyl-3-trimethylammonium-propane (chloride 
salt) (DOTAP), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and 1,2-distearoyl-sn-glycero-
3-phosphatidylethanolamine-N-[maleimide(polyethylene glycol)2000] (DSPE-PEG2000-MAL) were 
purchased from Avanti Polar Lipids (AL, USA). 
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Cell culture 
 
Cos-7 cells (African green monkey kidney cells; ATCC number CRL-1651) were cultured in 
Dulbecco's modified Eagle's medium (DMEM) containing 2 mM L-Gln, 10 % heat inactivated FBS, 
100 U/ml P/S and grown at 37°C in a humidified atmosphere containing 5% CO2. 
 
Preparation of cationic liposomes 
 
Cationic liposomes composed of DOTAP:DOPE:DSPE-PEG2000-MAL with molar ratios of 
5:5:0.2, 3:7:0.2, and 1:9:0.2 (containing 50 mol%, 30 mol% and 10 mol% DOTAP, respectively) were 
prepared as described previously 
34
. Briefly, appropriate amounts of lipids were dissolved in 
chloroform and mixed. To obtain FITC labeled liposomes 0.01 mol% FITC-DOPE was added to the 
mixture. The chloroform was subsequently removed by rotary evaporation at 37°C followed by 
flushing the obtained lipid film with nitrogen during 30 min at room temperature. The dried lipids 
were then hydrated by adding Hepes buffer (20 mM, pH 7.4) till a final lipid concentration of 
10.2 mM. After mixing in the presence of glass beads, liposome formation was allowed overnight at 
4°C. Thereafter, the formed liposomes were extruded 11 times through two stacked 100 nm 
polycarbonate membrane filters (Whatman, Brentfort, UK) at room temperature using an Avanti 
Mini-Extruder (Avanti Polar Lipids). 
 
Preparation of Tat-modified and unmodified LPXs 
 
To prepare 'post Tat-LPXs’, the liposomes, with or without FITC-DOPE, were mixed with the 
appropriate amount of pDNA, in a +/- charge ratio of 4:1 and incubated at room temperature for 
30 min. The final concentration of pDNA in the LPX dispersion was 0.126 µg/µl. Subsequently, Tat 
peptides were coupled to the MAL-group, present at the end of the PEG chains in DSPE-PEG2000-MAL. 
Therefore, the Tat AA 37-72 peptide was first incubated under a nitrogen flow for 2 hrs with a 10-fold 
molar excess of TCEP (tris-2(carboxyethyl)phosphine) to reduce the disulfide bonds. Again under a 
nitrogen flow, the 'activated' Tat AA 37-72 peptide was added to the LPXs in a 4-fold molar excess 
compared to the DSPE-PEG2000-MAL and incubated overnight at 4°C on a shaker.  
To prepare 'pre Tat-LPXs’, the same protocol was used, except that the Tat peptide was 
coupled to the liposomes before they were complexed with the pDNA.  
The unmodified LPXs (i.e. LPXs without Tat) were prepared as the ‘pre or post Tat-LPXs’, but 
without the addition of Tat AA 37-72 peptide. 
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Size and zeta potential measurements 
 
The average particle size and the zeta potential (ζ) of the liposomes and LPXs were measured 
by photon correlation spectroscopy (PCS) (Autosizer 4700, Malvern, Worcestershire, UK) and by 
particle electrophoresis (Zetasizer 2000, Malvern, Worcestershire, UK), respectively. The liposome 
and LPX dispersions were diluted 40-fold in 20 mM Hepes buffer pH 7.4 before the particle size and 
zeta potential were measured. 
 
Agarose gel electrophoresis 
 
To determine the extent of pDNA association to the liposomes and the release of the pDNA 
from the liposomes after incubation with SDS, agarose gel electrophoresis was used. 18 µl of the Tat-
modified and unmodified LPXs, prepared as described above, were mixed with 2 µl 20 µg/µl SDS or 
2 µl dH2O and loaded together with 5 µl 5 x loading solution (30 % glycerol, 0.02 % bromophenol 
blue) on a 1 % agarose gel prepared in TBE buffer (10.8 g/l Tris base, 5.5 g/l boric acid and 0.58 g/l 
EDTA). The samples were subjected to electrophoresis at 80 V during 45 min and the DNA was 
visualized by UV transillumination using EtBr (0.5 µl/ml) staining prior to photography. 
 
Cytotoxicity assay 
 
The cytotoxicity of the LPXs was determined using the tetrazolium salt based colorimetric 
MTT assay (EZ4U, Biomedica, Vienna, Austria) according to the manufacturer’s instructions. Briefly, 
2.5 x 10
4
 cells/cm
2
 were seeded in a 96-well plate and allowed to adhere. After 24 hrs, cells were 
washed twice with serum free medium and incubated with LPXs, containing 0.18 µg pDNA per cm
2
 in 
serum free medium. After 2 hrs, the complexes were removed and cells were washed with culture 
medium. Finally, to each well, 20 μl substrate was added together with 180 μl culture medium and 
after 4 hrs incubation at 37°C the concentration of reduced formazan was measured at 450 nm and 
630 nm on a Wallac Victor
2
 absorbance plate reader (Perkin Elmer-Cetus Life Sciences,
 
Boston, MA). 
 
Transfection experiments 
 
Cells were seeded into 24-well plates (2.5 x 10
4
 cells/cm
2
) and allowed to attach overnight. 
The culture medium was removed from the cells and they were washed twice with serum free 
medium. Subsequently, the LPXs (with and without bound Tat peptide) were diluted in serum free 
medium and the diluted LPXs, containing 0.18 µg pDNA per cm
2
, were added to the 24-well plates. 
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Cells were incubated at 37°C for 2 hr and, after a washing step with culture medium, the medium 
was replaced by 1 ml culture medium, and further incubated at 37°C. 
For the transfection experiments at 4°C the cells, grown overnight as described above, were 
cooled down to 4°C during 30 min. Subsequently, pre-cooled solutions for washing and for the 
transfection were used. After addition of the complexes, the cells were incubated at 4°C and after 
2 hrs, cells were washed with culture medium. 
For treatment with uptake inhibitors, cells were pre-incubated for 1 hr at 37°C in DMEM 
with chlorpromazine (10 µg/ml) 
35
, filipin III (10 µg/ml) 
36
 before the complexes were added. In a 
recent study we have demonstrated that these inhibitors, at their respective concentrations, 
predominately block clathrin or raft mediated pathways without causing drastic cytotoxic effects 
37
. 
After removal of the LPXs and addition of culture medium, cells were further incubated in an 
incubator. After 48 hrs the SEAP activity in the culture medium and the total protein concentration in 
the cells was measured. 
 
Gene expression analysis 
 
To determine the SEAP activity in the medium, 100 µl of the culture medium above the cells 
was taken and incubated at 65°C for 30 mins. Subsequently 100 µl dilution buffer (0.1 M glycine, 
1 mM MgCl2, 0.1 mM ZnCl2, pH 10.4) and 15 µl 4-methylumbelliferyl phosphate (4-MUP, 5.1 µg/µl in 
distilled water) was added to the culture medium in a 96-well plate. The obtained mixtures were 
then incubated at 37°C and the fluorescence (λex/λem = 360/449 nm) was followed during 45 min on a 
Wallac Victor
2 
fluorescence plate reader (Perkin Elmer-Cetus Life Sciences,
 
Boston, MA). The 
fluorescence obtained after 30 min was used for comparing the gene transfer capacity of the 
different LPXs. 
Finally, after removing the culture medium, the cells were washed twice with PBS to remove 
dead cells and serum proteins. Thereafter, cells were lysed with lysis buffer (10 % glycerol, 2.3 % w/v 
SDS, 0.125 M Tris-HCl, pH 6.8), sonicated for 30 min and the protein concentration was determined 
by BioRad DC protein assay. 
 
Cell binding and cellular uptake experiments 
 
2.5 x 10
4
 cells/cm
2
 were seeded onto sterile glass bottom culture dishes (MatTek 
Corporation, MA, USA) and allowed to adhere for 1 day. For lysosome staining, the cells were 
incubated during 30 min at 37°C with 50 pM of the lysosomal marker LysoTracker

 Red (Molecular 
Probes, Eugene, OR, U.S.A.). For 4°C experiments, cells were cooled in the refrigerator during 30 min, 
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washed with pre-cooled DMEM and incubated with the LPXs at 4°C. At different time points samples 
were analyzed.  
In the experiments with cellular uptake inhibitors, the cells were pre-incubated for 1 hr at 
37°C in DMEM with chlorpromazine (10 µg/ml) 
35
, filipin III (10 µg/ml) 
36
. Subsequently, the cells were 
washed twice with DMEM before the appropriate amount of fluorescent Tat-modified or unmodified 
LPXs and inhibitor-containing serum free medium was added. Immediately after adding LPXs, the 
cells were visualized on different time points by confocal laser scanning microscopy (CLSM) (BioRad 
MRC 1024; Hemel Hempstadt, UK). After capturing the image with a 60 x water immersion objective 
and a krypton/argon laser (488 nm and 547 nm) for the excitation of the FITC label and the 
LysoTracker

 Red, pseudocoloring was performed by using the digital imaging system Confocal 
Assistant (CAS; BioRad; Hemel Hempstadt, UK). 
 
Statistical analysis data 
 
The experimental data in this report (zeta potential, DLS, cytotoxicity and transfection) are 
expressed as mean ± standard deviation (SD). One way ANOVA was used to determine whether data 
groups differed significantly from each other. A p-value lower than 0.05 was considered statistically 
significant. 
 
RESULTS & DISCUSSION 
 
Preparation and physicochemical characterization of unmodified and Tat-modified LPXs 
 
PEGylated DOTAP:DOPE:DSPE-PEG2000-MAL LPXs bearing covalently bound Tat peptides at 
the end of their PEG chains and containing increasing amounts of DOTAP (10, 30 and 50 mol%) were 
obtained via two strategies: Tat peptides were either coupled to the PEG chains of the PEGylated 
liposomes before complexing them with pDNA (‘pre Tat-LPXs’) or after complexing them with pDNA 
(‘post Tat-LPXs’). The latter approach ensured that the Tat peptides were presented on the surface 
of the LPXs, a prerequisite for Tat peptides to promote the internalization of cargoes 
38
. Moreover, to 
prevent that steric hindrance could abolish the interaction of Tat with the cell membrane 
30
, we 
attached the Tat peptides via a 2 kDa PEG spacer to the LPXs by the aid of DSPE-PEG2000-MAL 
moieties. The maleimide (MAL) groups on these PEG chains are known to react specifically with 
sulfhydryl groups at neutral pH creating a stable thioether bond with the N-terminal cysteine of the 
Tat peptide. A schematic representation of the Tat-modified LPXs is shown in Fig. 1. 
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Figure 1. Schematic representation of the Tat-modified DOTAP:DOPE:DSPE-PEG2000-MAL LPXs. 
 
To assess the DNA binding capacity of the cationic liposomes and the ability of SDS to release 
the pDNA from the LPXs agarose gel electrophoresis experiments were performed (Fig. 2). 
 
 
Figure 2. Agarose gelelectrophoresis of unmodified, pre and post Tat-LPX containing 10, 30 and 50 mol% 
DOTAP before and after addition of SDS. 
 
LPXs containing 30 and 50 mol% DOTAP showed, both in the presence and absence of Tat, a 
complete complexation of the pDNA. 10 mol% DOTAP LPXs lacking the Tat peptide failed to bind all 
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the pDNA. Coupling of Tat peptides to these 10 mol% DOTAP LPXs retarded the pDNA on the agarose 
gel, but did not result in a full complexation. Finally, the release properties in the presence of SDS of 
the different types of LPXs were not altered by Tat peptides. 
 
Figure 3. Zeta potential (A) and size (B) measurement of the unmodified and Tat-modified LPXs containing 
30 mol% (dark grey) and 50 mol% (light grey) DOTAP. The size and zeta potential of the 10 mol% DOTAP LPXs 
could not be measured accurately due to the presence of large aggregates and/or a too high polydispersity. All 
data are shown as mean ± SD with n=4 for DLS and n=5 for zeta potential data. The asterix (*) represents data 
points that significantly differ (p<0.05; ANOVA) from the data of unmodified LPXs. 
 
The effect of the attachment of Tat peptides to the LPXs was further evaluated by comparing 
the particle size and surface charge of Tat-modified and unmodified LPXs. Fig. 3A and 3B show that 
the attachment of Tat-peptides to the LPXs causes, in the case of both the ‘pre Tat-LPXs’ (pre Tat-
LPX) and the ‘post Tat-LPXs’ (post Tat-LPX), a significant (p<0.05; ANOVA) increase in particle size and 
surface charge. The latter is an indication that cationic Tat peptides were indeed attached to the 
surface of the PEGylated LPXs. The particle size and surface charge of the 10 mol% DOTAP LPXs could 
not be determined accurately, due to large aggregates and/or a too high polydispersity. This is not 
surprising as huge amounts of free pDNA were present in the 10 mol% DOTAP LPXs (Fig. 2).  
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Cytotoxicity 
 
Several groups have reported a significant cytoxicity of free Tat peptides 
9,39,40
. Therefore, we 
characterized the cytotoxicity of our LPXs by measuring the mitochondrial activity. Linking of Tat 
peptides to the LPXs slightly increased their cytoxicity (Fig. 4). It is currently unclear via which 
mechanism Tat causes cell toxicity, however, it has been shown in HeLa cells that the α-helix 
structure, present in the Tat AA 37-72 peptide, plays an important role 
11
. 
 
 
Figure 4. Cytotoxicity of unmodified and Tat-modified LPXs containing 10, 30 or 50 mol% DOTAP relatively to 
untreated cells. Data are shown as mean ± SD with n=3. The asterix (*) represents data points that significantly 
differ (p<0.05; ANOVA) from the data of unmodified LPXs. 
 
Furthermore, except for the pre Tat-LPX containing 10 and 30 mol% DOTAP, the cytotoxicity 
of the LPXs slightly increased when they contain lower amounts of DOTAP and thus higher amounts 
of DOPE. DOPE is a fusogenic lipid that disrupts endosomal membranes during their acidification 
41
. A 
higher DOPE content in the LPXs probably results in an increased endosomal breakdown, which, as 
previously been suggested for polyethyleneimine 
5
, may explain the increased cytotoxicity. 
 
Transfection capacity of unmodified and Tat-modified LPXs 
 
The transfection efficiency of the unmodified LPXs, the ‘pre Tat-LPX’ and the ‘post Tat-LPX’ 
were subsequently compared. To correct for the above observed cytotoxicity of the LPXs, the results 
of the transfection experiments were expressed relatively to the total cell protein content. 
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Figure 5. Transfection efficiency of the unmodified, pre and post Tat-LPX containing 10 (black), 30 (dark grey) or 
50 mol% (light grey) DOTAP. Data are shown as mean ± SD and n=3. The asterix (*) represents data points that 
significantly differ (p<0.05; ANOVA) from the data of unmodified LPXs. 
 
Fig. 5 reveals the following trends. First, the transfection capacity of the LPXs increased with 
increasing DOTAP content: the gene expression of the 50 mol% DOTAP LPXs without Tat peptide was 
3.3-fold and with Tat peptide 1.4-fold higher than the gene expression of the corresponding 30 mol% 
DOTAP LPXs. Second, Tat peptide enhanced the gene expression of the 30 mol% DOTAP LPXs. ‘Post 
Tat’ modification of these LPXs gave the best results and led to a doubling of the transfection 
efficacy. This effect of Tat is slightly smaller than the effect of Tat seen on the gene expression of the 
LPXs used in the work of Torchilin et al. 
42
. This may be explained by the lower initial gene expression 
of the LPXs in the latter work, which made it more likely that Tat could increase their gene 
expression. Additionally, the fact that in Torchilin’s work a shorter Tat peptide was used may also 
explain the slight difference in gene expression. Third, Fig. 5 shows that the Tat peptide could not 
further enhance the gene transfer capacity of the (well transfecting) 50 mol% DOTAP LPXs. The ‘post 
modification’ of the 30 mol% DOTAP LPXs with Tat gave also slightly higher transfection efficiencies 
compared to the ‘pre modification’. This may indicate that the preceding attachment of Tat to the 
liposomes complicated an efficient complexation of the pDNA. Finally, the unmodified 10 mol% 
DOTAP LPXs did not transfect the cells, which is explained by their poor DNA binding capacity (see 
Fig. 2). Also Tat-modified 10 mol% LPXs showed low transfection efficiency despite the reduced 
amount of free DNA caused by electrostatic binding of the Tat peptides to the free pDNA. However, 
we (unpublished data) and others have shown 
43,44
 that such Tat/pDNA complexes do not posses 
significant gene transfer capacities. Consequently, this explains why addition of Tat peptides to the 
10 mol% DOTAP LPXs did not enhance their gene expression. Considering the low gene expression of 
the 10 mol% LPXs we decided to exclude them in our further work. 
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Tat peptide modified LPXs enter Cos-7 cells in an energy dependent manner and turn up in acidic 
vesicles 
 
The ability of Tat peptides to enhance the uptake of liposomes and other types of 
nanoparticles was demonstrated by several groups at the beginning of this millennium 
29,30,43,45
. Later 
on, Torchilin et al. 
42
 showed that the cellular uptake and gene expression of LPXs was also enhanced 
when Tat peptides were coupled to their surface. In all these reports it was proposed that the Tat-
modified particles penetrate the cell membrane in an energy independent manner. In contrast, Fretz 
et al. 
31
 showed that OVCAR cells internalize Tat peptide modified liposomes by energy dependent 
endocytosis. To determine whether the Tat-modified LPXs under investigation in this study follow an 
energy dependent or independent pathway, we focused on the cellular uptake of FITC-labelled LPXs 
at 4°C and 37°C by confocal scanning fluorescence microscope (Fig. 6). To elucidate whether the LPXs 
end-up in acidic vesicles, the cells were pre-incubated with LysoTracker
®
 Red, a compound known to 
localize primarily in the acidic compartments of cells 
46
. The experiments were performed using living 
cells, as previous reports have shown that cell fixation may lead to an artificial uptake of Tat-
modified proteins 
18
. 
 
Figure 6. Confocal laser scanning microscopy images of FITC-labeled unmodified and Tat-modified LPXs 
(containing 30 mol% DOTAP) incubated with the cells at 37°C (A, B, E and F) and at 4°C (C, D, G and H). The red 
fluorescence in the cells originates from LysoTracker
®
 Red. Yellow indicates co-localization of the green 
fluorescent from the LPXs with the red fluorescence from the Lysotracker
®
 Red. Scale bar represents 10 μm. 
Similar results were obtained with the 50 mol% DOTAP LPXs. 
 
Fig. 6A, 6B, 6E and 6F show that after incubation at 37°C, both the unmodified and Tat 
peptide modified LPXs were rapidly (even within 5 min) taken up by the cells. However, at 4°C the 
uptake was negligible for both types of LPXs (Fig. 6C, 6D, 6G and 6H). In contrast to previous reports 
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this clearly demonstrates that the uptake of the Tat-modified LPXs occurs, like for unmodified LPXs, 
via an energy-dependent process. To further confirm the energy dependency of the cellular uptake 
of the LPXs, we performed transfection experiments at 4°C. As expected from the data above, gene 
expression of both the Tat-modified and unmodified LPXs was reduced to about 3 % of the gene 
expression measured at 37°C (data not shown). 
Both the Tat-modified and the unmodified LPXs appeared in the cells in a punctuated pattern 
and strongly co-localized with LysoTracker
®
, a marker of acidic organelles (Fig. 6A, 6B, 6E and 6F). This 
implies that the LPXs were most likely internalized via a clathrin-mediated pathway as lysosomes are 
the end point of a clathrin-mediated rather than a lipid raft-mediated internalization pathway. 
Additionally, the very fast internalization observed for the LPXs, is also typical for a clathrin-mediated 
uptake mechanism 
47-49
. To further strengthen this conclusion we subsequently studied the effect of 
specific inhibitors of clathrin- and lipid raft-mediated endocytosis on the cellular uptake and gene 
expression of the LPXs. The fact that at least a portion of our LPXs turns up in lysosomes may be 
surprising as they contain DOPE, a helper lipid that is known to promote the endosomal escape of 
DNA and hence to avoid degradation of the pDNA by lysosomal enzymes 
50-52
. 
 
Cholesterol-dependent clathrin-mediated endocytosis is the productive route for gene expression of 
Tat-modified and unmodified LPXs 
 
Cells can internalize extracellular material via several mechanisms. The best characterized is 
the clathrin-coated pits pathway, which leads to intracellular vesicles that can either recycle back to 
the cell membrane or move, while they undergo a gradual acidification, along the microtubili to the 
perinuclear region 
53
. Less defined are the lipid raft-mediated internalization mechanisms, among 
which the caveolae-mediated pathway is the best described (reviewed by 
54
). Lipid rafts are dynamic 
regions of the plasma membrane which are enriched in cholesterol, sphingomyelin, glycolipids, GPI-
anchored proteins and other membrane proteins. For caveolae-mediated uptake it is known that this 
pathway leads to neutral vesicles which stay after their formation near the cell surface before they 
are transported via the golgi apparatus to the endoplasmatic reticulum. It is obvious that the 
distinctive intracellular routing profile and properties of the vesicles occurring from the different 
pathways may either favour or disfavour non-viral gene expression. Nevertheless, the cellular 
pathways by which non-viral gene complexes enter mammalian cells have gained the attention of 
only a few groups 
48,49,55
. Therefore, elucidating the entry mechanism is of interest for both the Tat-
modified and unmodified LPXs. 
To study the role of the clathrin- and lipid raft-mediated endocytosis in the uptake and gene 
expression of Tat-modified and unmodified LPXs, we performed transfection experiments in the 
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presence of a specific inhibitor of respectively clathrin-mediated (i.e. chlorpromazine) 
35
 and lipid 
raft-mediated endocytosis (i.e. filipin) 
36
. Chlorpromazine is an amphiphilic drug that prevents the 
recycling of clathrin proteins from formed endosomes back to the cell membrane and inhibits in this 
manner the formation of new clathrin-coated pits. On the other hand, filipin binds strongly to 
cholesterol which is especially present in the lipid raft domains of the cell membrane, which will 
prevent lipid raft-mediated endocytosis. However, also other entry pathways may be inhibited as 
cholesterol is present all over the cell membrane. 
 
Figure 7. Transfection efficiency of the unmodified, pre Tat- and post Tat-LPX containing 30 mol% (A) or 
50 mol% (B) DOTAP in the absence or presence of uptake inhibitors chlorpromazine and filipin. Data are shown 
as mean ± SD and n=3. 
 
The gene expression of the Tat-modified and unmodified LPXs in the presence of 
chlorpromazine and filipin is shown in Fig. 7. Chlorpromazine significantly (p <0.05; ANOVA) inhibits 
the gene expression of the 30 mol% (>86 % inhibition) and the 50 mol% (>92 % inhibition) DOTAP 
LPXs. Surprisingly, also filipin lowered the gene expression of both the Tat-modified and unmodified 
CHAPTER 2 –  CELLULAR ENTRY PATHWAY AND GENE TRANSFER CAPACITY OF TAT-MODIFIED LIPOPLEXES 
 
 80 
LPXs significantly (p<0.05; ANOVA): the inhibition ranged between 46 % (for the unmodified LPXs) 
and 66 % (for the Tat-modified LPXs). The effect of filipin on the gene expression was significant 
lower (p<0.05; ANOVA) than the effect of chlorpromazine. In the light of the clear indications for a 
clathrin-mediated uptake mechanism of our LPXs (i.e. fast internalization and co-localization with 
acidic organelles), we suspect that the effect of filipin is due to its limited selectivity. Indeed, as 
cholesterol is required for the formation of curved coated pits 
56,57
 the binding of filipin to cholesterol 
might consequently also inhibit clathrin-mediated endocytosis. This hypothesis is in agreement with 
the work of Zuhorn et al. 
49
 who showed that depletion of cell membrane cholesterol by methyl-β-
cyclodextrin, a compound previously proposed to selectively inhibit caveolae-mediated 
endocytosis 
58,59
, strongly inhibited cholesterol-dependent clathrin-mediated endocytosis of LPXs by 
Cos-7 cells. Therefore, we speculate here that our LPXs are internalized via cholesterol-dependent 
clathrin-mediated endocytosis and that this entry mechanism is also sensitive to filipin. However, we 
have to remark that we cannot totally exclude from our data that a small portion of the LPXs are also 
taken up via caveolae-mediated endocytosis.  
It has been shown that the entry mechanism may depend on the size of the nanoparticles. 
Indeed, polystyrene nanoparticles with a diameter less than 200 nm were exclusively internalized via 
clathrin-coated pits, whereas those of 500 nm entered the cells via caveolae 
47
. The average diameter 
of our LPXs, as determined by DLS, was around 300 nm. However, the size distribution of these LPXs 
typically ranged between 100 and 350 nm, with more than 70 % of the LPXs having a diameter 
smaller than 200 nm. Therefore, from the size of the LPXs a clathrin-mediated endocytosis pathway 
and to a lesser extend a caveolae-mediated pathway could be expected. 
Finally, fluorescence confocal microscopy experiments showed a nice correlation between 
the decrease in gene expression caused by chlorpromazine or filipin and the amount of internalized 
LPXs in the presence of the respective uptake inhibitors (Fig. 8). In normal conditions (Fig. 8A and 8B), 
the 30 mol% LPXs clearly co-localize with the lysosomes, while the presence of chlorpromazine 
(Fig. 8C and 8D) almost completely blocks the co-localization. In contrast, filipin (Fig. 8E and 8F) 
partially inhibits the uptake of the complexes. Similar results were obtained with the 50 mol% LPXs. 
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Figure 8. Confocal laser scanning microscopy images of Cos-7 cells incubated with FITC-labeled unmodified and 
Tat-modified 30 mol% DOTAP LPXs in normal conditions (A and B), in the presence of chlorpromazine (C and D) 
and in the presence of filipin (E and F). As marker of acidic organelles, LysoRed

 tracker was used. The left 
panel (A, C and E) shows the merged images with the complexes represented as green and the lysosomes as 
red and the right panel (B, D, F) shows in white the co-localization of red and green signals. Scale bar represents 
50 μm. The inserts show, at a higher magnification, the co-localization of LysoRed

 tracker and LPXs in one cell. 
 
CONCLUSION 
 
In conclusion, our study shows that the gene transfer of LPXs containing 30 mol% DOTAP can 
be enhanced by coupling Tat peptides to their surface. Post modification of pre-formed LPXs with Tat 
gives the best results. In contrast, addition of Tat to LPXs containing 50 mol% DOTAP does not 
improve their gene transfer. In contrast to previous reports 
30
 we clearly demonstrate that the 
uptake of both Tat-modified and unmodified LPXs is energy dependent. Furthermore, by using 
cellular uptake inhibitors we suppose that the Tat-modified and unmodified LPXs enter the 
cytoplasm mainly via cholesterol-dependent clathrin-mediated endocytosis, a pathway previously 
postulated by Zuhorn et al. 
49
 for the cellular uptake of cationic LPXs. 
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ABSTRACT 
 
Short interfering RNA (siRNA) attracts much attention for the treatment of various diseases. 
However, its delivery, especially via systemic routes, remains a challenge. Indeed, naked siRNAs are 
rapidly degraded, while complexed siRNAs massively aggregate in the blood or are captured by 
macrophages. Although this can be circumvented by PEGylation, we found that PEGylation had a 
strong negative effect on the gene silencing efficiency of siRNA-liposome complexes (siPlexes). 
Recently, ultrasound combined with microbubbles has been used to deliver naked siRNA but the 
gene silencing efficiency is rather low and very high amounts of siRNA are required. To overcome the 
negative effects of PEGylation and to enhance the efficiency of ultrasound assisted siRNA delivery, 
we coupled PEGylated siPlexes (PEG-siPlexes) to microbubbles. Ultrasound radiation of these 
microbubbles resulted in massive release of unaltered PEG-siPlexes. Interestingly, PEG-siPlexes 
loaded on microbubbles were able to enter cells after exposure to ultrasound, in contrast to free 
PEG-siPlexes, which were not able to enter cells rapidly. Furthermore, these PEG-siPlex loaded 
microbubbles induced, in the presence of ultrasound, much higher gene silencing than free PEG-
siPlexes. Additionally, the PEG-siPlex loaded microbubbles only silenced the expression of genes in 
the presence of ultrasound, which allows space and time controlled gene silencing.  
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Chapter 3 
Ultrasound Assisted siRNA Delivery using 
PEG-siPlex Loaded Microbubbles 
 
INTRODUCTION 
 
RNA interference (RNAi), a naturally occurring process of sequence-specific post-
transcriptional gene silencing, is an important biological process for modulating gene expression. The 
silencing effect of RNAi is highly potent and
 
requires only that the sequence of the target RNA is 
known. One approach to evoke RNAi in target cells is by the delivery of chemically synthesized 
siRNAs, which results in a sequence-specific, robust silencing of the targeted gene 
1
. The potential of 
siRNA molecules as therapeutic agent in the treatment of e.g. cancer, viral infections, arthritis, 
Huntington’s disease and hypercholesterolemia has been widely studied 
2
. However, cells do not 
readily take up siRNAs. Therefore, clinical applications of siRNA largely depend on the development 
of delivery systems that can bring intact siRNA into the cytoplasm of the target cells of a patient.  
Strategies that have been considered for in vivo delivery of synthetic siRNA in laboratory 
animals are hydrodynamic injection of naked siRNA 
3
 or siRNA conjugates 
4
, electroporation 
5-8
 and 
the use of cationic carriers 
9-15
. However, several aspects limit the applicability of these methods in 
humans. Indeed, hydrodynamic injection, which involves the intravascular injection of large volumes, 
generates high pressure in the vascular system and therefore often results in heart failure. 
Additionally, undesirable gene suppression may be induced in non-target organs. Electroporation 
allows targeting, but requires the insertion of electrodes into the target area, and hence invasive 
procedures that limit its range of application. Cationic siRNA delivery carriers, such as cationic lipids 
and polymers, are often cytotoxic and/or not very efficient. Furthermore, they are often not suited 
for systemic application since their positively charged surface makes them vulnerable to non-specific 
interactions with blood compounds, leading to life-threatening aggregates and a rapid clearance by 
the mononuclear phagocyte system 
10,16
. A common approach for reducing these undesired 
interactions is by masking the cationic surface of the nanoparticles with hydrophilic polymers, such 
as poly(ethylene glycol) (PEG). This prevents the aggregation of these nucleic acid containing 
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nanoparticles in blood and prolongs their circulation time 
17-20
. However, it has been observed by 
many groups that shielding the surface of non-viral gene delivery systems with polymers like PEG 
leads to a drastic reduction in gene transfer, due to a reduced cellular uptake or limited endosomal 
release 
21,22
. 
The use of ultrasound energy has intensively been studied for pDNA delivery 
23-30
. Recently, 
ultrasound in combination with microbubbles has also been used in two reports to deliver naked 
siRNA 
31,32
. However, the gene silencing efficiency in these studies was rather low and very high 
amounts of siRNA were required. Nevertheless, ultrasound assisted drug delivery is considered as 
rather safe as ultrasound, in combination with microbubbles, is routinely used in the clinic for 
diagnostic purposes. It is believed that ultrasound, especially when combined with microbubbles, 
causes small (100 to a few 100 nm large) transient pores in the cell membrane which allows large 
molecules to enter the cell cytoplasm 
33
. These perforations are caused by microjets that are 
generated by the ultrasound induced cavitation, i.e. alternate growing and shrinking of 
microbubbles, and implosion of microbubbles. The lifetime of these pores in the cell membranes is 
very short, i.e. milliseconds to seconds 
34
, making high concentrations of nucleic acids in the 
surrounding of the cells beneficial to ensure that a significant amount of nucleic acids can enter the 
cells through these short-living pores. Consequently, as recently shown by our group for pDNA, 
microbubbles that at the same time perforate cells and release massive amounts of nucleic acids 
containing nanoparticles near these perforations may drastically enhance the cellular uptake and 
hence the biological activity of nucleic acids 
26
. 
Therefore, the aim of this study was to evaluate (a) the loading and release of PEGylated 
siRNA-liposome complexes (PEG-siPlexes) on/off ultrasound responsive microbubble, and (b) the 
cellular distribution and gene silencing efficiency of the PEG-siPlex loaded microbubbles after 
ultrasound radiation. 
 
MATERIALS & METHODS 
 
Cell culture 
 
HuH-7 and HuH-7_eGFPLuc cells were cultured in Dulbecco's modified Eagle's medium 
supplemented with F12 (DMEM:F12) containing 2 mM L-glutamine (L-Gln), 10 % heat-inactivated 
fetal bovine serum (FBS) and 100 U/ml penicilline/streptomycine (P/S) at 37°C in a humidified 
atmosphere containing 5 % CO2. All cell culture products were purchased from Invitrogen 
(Merelbeke, Belgium). 
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HuH-7_eGFPLuc cells stably expressing eGFP-Luciferase were generated by transfecting 
HuH-7 cells with the vector pEGFPLuc (Clontech, Palo Alto, USA). The vector was linearized using the 
restriction enzyme DraIII and transfected using linear poly(ethyleneimine) (PEI) 22 kDa. Transfected 
cells were incubated in fresh medium for 72 hrs and then selected with 60 to 400 µg/ml G418. After 
several days, surviving cells were seeded at low densities into 6-well plates in order to generate 
separate colonies. Single cell clones were then isolated and expanded. The generated clones were 
analyzed for the percentage of GFP-positive (eGFPLuc stably transfected) cells. Clones with the 
highest number of GFP-positive cells were then further selectively grown up under the above 
described selective conditions and this procedure was repeated until all cells were positive for GFP. 
 
SiRNA 
 
Atto488-labeled and non labeled siRNA duplexes against firefly luciferase and control siRNA 
duplexes were purchased from Eurogentec (Seraing, Belgium) and dissolved in RNase free water at a 
final concentration of 20 µM. 
 
Preparation and characterization of lipid microbubbles 
 
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[biotinyl(polyethylene glycol)2000] (ammonium salt) (DSPE-PEG2000-biotin) 
were purchased from Avanti Polar Lipids (Alabaster, AL). 
Lipid microbubbles were prepared from liposomes composed of DPPC and DSPE-PEG2000-
biotin with molar ratios of 95:5. Therefore, as described previously 
35
, appropriate amounts of lipids 
were dissolved in chloroform and mixed. The chloroform was subsequently removed by rotary 
evaporation at 37°C followed by flushing the obtained lipid film with nitrogen during 30 min at room 
temperature. The dried lipids were then hydrated by adding Hepes buffer (20 mM, pH 7.4) till a final 
lipid concentration of 5 mg/ml. After mixing in the presence of glass beads, liposome formation was 
allowed overnight at 4°C. Thereafter, the DPPC:DSPE-PEG2000-biotin liposomes were extruded 
through two stacked 0.200 µm polycarbonate membrane filters (Whatman; Brentfort, UK) at 55°C 
using an Avanti Mini-Extruder (Avanti Polar Lipids). Subsequently, the liposome suspension was 
sonicated with a 20 kHz probe (Branson 250 sonifier, Branson Ultrasonics Corp.; Danbury, CT) in the 
presence of perfluorobutane gas (MW 238 g/mol; F2 chemicals; Preston, Lancashire, UK). After 
sonication, the lipid microbubbles were washed with 3 ml Hepes buffer by 5 min centrifugation at 
470 g. The amount of microbubbels per ml was determined by light microscopy and equalled 4 x 10
8
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microbubbles/ml. The size distribution of the microbubbles was determined by laser diffraction 
(Mastersizer S, Malvern; Worcestershire, UK). 
 
Preparation of avidin coated lipid microbubbles 
 
Avidinylated microbubbles were prepared by incubating them at room temperature with 
500 µl avidin (10 mg/ml). After 10 min of incubation, the microbubbbles were washed with 3 ml 
Hepes buffer by 5 min centrifugation at 470 g and finally resuspended in 10 ml. For the preparation 
of red labelled lipid microbubbles, the microbubbles were incubated with the unlabelled avidin 
supplemented with 50 µl Cy5-labelled streptavidin (1 mg/ml) (Zymed Laboratories; San Francisco, 
CA). 
 
Preparation and characterization of liposomes and PEG-siPlexes 
 
The cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) (DOTAP) and the 
helper lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were purchased from Avanti 
Polar Lipids. Cationic liposomes containing DOTAP and DOPE in a 1:1 molar ratio, supplemented with 
0 to 15 mol% DSPE-PEG2000-biotin, were prepared at a final DOTAP concentration of 5 mM. All 
liposomes were prepared as described above for the DPPC:DSPE-PEG2000-biotin liposomes, however 
extrusion occurred through two stacked 0.100 µm polycarbonate membrane filters at room 
temperature. To obtain (PEG-)siPlexes, equal volumes of siRNA solution and extruded liposomes 
were mixed in a N:P ratio of 20:1. Subsequently, the obtained mixture was vortexed for 5 sec and 
incubated at room temperature for 30 min. 
The average particle size and the zeta potential (ζ) of the (PEGylated) liposomes and siPlexes 
were measured by photon correlation spectroscopy (PCS) (Malvern zetasizer nano ZS; Malvern) and 
by particle electrophoresis (Malvern zetasizer nano ZS; Malvern), respectively. Therefore, the 
liposome and PEG-siPlex dispersions were diluted 40-fold in 20 mM Hepes buffer. The size of the 
liposomes was independent of the degree of PEGylation and averaged 120 nm. In contrast, the zeta 
potential clearly dropped with increasing degree of PEGylation, varying from ~50 mV for the 0 mol% 
and ~20 mV for the 5 mol% DSPE-PEG2000-biotin containing DOTAP:DOPE liposomes The size and zeta 
potential of the siPlexes are displayed in Fig. 5. 
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Preparation and characterization of siPlexes loaded microbubbles 
 
130 µl siPlex dispersion was mixed with 1 ml microbubbles, vortexed shortly and incubated at 
room temperature for 5 min. Subsequently, the size distribution of the siPlex loaded microbubbles 
was determined as described for the non-loaded microbubbles. The time-dependent stability of the 
(PEG-)siPLex loaded microbubbles was followed for 36 hrs at room temperature via light microscopy 
using a motorized Nikon TE2000-E inverted microscope (Nikon Benelux, Brussels, Belgium). The small 
microbubbles (< 2 µm) were stable for at least 24 hrs and the larger ones for at least 36 hrs. 
 
Gel electrophoresis 
 
(PEG-)siPlexes, before binding to the microbubbles and after ultrasound induced release 
from the microbubbles, were loaded on a native 20 % polyacrylamide gel (PAGE). All samples were 
supplemented with 10 % glycerol and subjected to electrophoresis at 100 V for 2 hrs. Finally, the 
siRNA was stained with 1:10000 diluted SYBR-green II dye (Molecular Probes; Merelbeke, Belgium) 
and visualized by UV transillumination. 
 
Confocal laser scanning microscopy 
 
The Cy5-streptavidin coated microbubbles and Atto488-siRNA containing siPlexes were 
visualized using a Nikon C1si confocal laser scanning module attached to a motorized Nikon TE2000-E 
inverted microscope (Nikon Benelux; Brussels, Belgium). Images were captured with a 60 x objective 
lens using the 488 nm line from an Ar-ion laser for the excitation of Atto488-siRNA and the 639 nm 
laser line from a diode laser for the excitation of Cy5-streptavidin. 
 
Cellular distribution of PEG-siPlexes in HuH-7 cells 
 
Atto488-siRNA containing PEG-siPlexes (with 5 mol% DSPE-PEG2000-biotin) were prepared as 
described above. HuH-7 cells were grown in OptiCells
TM
 and incubated for 20 min with the free PEG-
siPlexes or with the PEG-siPlexes loaded microbubbles, immediately followed by ultrasound 
treatment. The ultrasound settings were the same as in the transfection experiments (see below). 
After one wash step with phosphate buffered saline (PBS; Invitrogen), cells were treated for 10 min 
with Draq5 (Biostatus Limited; Leicestershire, UK), to stain the nucleus, and TRITC-concanavalin A 
(Molecular Probes), to stain the cellular membrane. Subsequently, the cellular distribution of the 
Atto488-siRNA was visualized using a Nikon EZC1-si confocal laser scanning microscope equipped 
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with a 60 x objective. The 488 nm line of the Ar-ion laser was used to excite the Atto488 label and 
the 639 nm line from a diode laser to excite Draq5 and TRITC-concanavalin A.  
 
Transfection experiments 
 
HuH-7_eGFPLuc cells were seeded in OptiCell
TM
 units (Biocrystal; Westerville, OH) at 4 x 10
4
 
cells/cm
2
, and allowed to attach overnight in a humidified incubator at 37°C and 5 % CO2. The culture 
medium was removed from the cells and after a washing step with PBS, the free siPlexes or siPlex 
loaded microbubbles, both dissolved in OptiMEM (Invitrogen) and containing 50 nM siRNA, were 
added to the OptiCell
TM
 units. Subsequently, the OptiCell
TM
 units were placed in a water bath at 37°C 
with an absorbing rubber at the bottom as shown in Fig. 1B and immediately subjected to ultrasound 
radiation for 10 sec with a sonitron 2000 (RichMar; Inola, OK) equipped with a 22 mm probe. It has 
been reported that standing waves can influence the ultrasound assisted transfection efficiency 
dramatically 
36
. In our ultrasound set up (Fig. 1B) standing waves are eliminated as much as possible 
by (1) using the ultrasound transparent OptiCell
TM
 units, (2) placing an absorbing rubber at the 
bottom of the water bath and (3) degassing the water. In all experiments the same ultrasound 
settings were applied: 1 MHz, 10 % duty cycle (DC) and an ultrasound intensity of 2 W/cm
2
 during 
10 sec. After 2 hrs incubation of the cells (at 37°C) with the free siPlexes or siPlex loaded 
microbubbles, the transfection medium was removed, cells were washed twice with PBS and culture 
medium was added. After 48 hrs incubation, discs (22 mm in diameter) were cut from the OptiCell
TM
 
membrane, transferred to a 24-well plate and lysed with 80 µl 1x CCLR buffer (Promega; Leiden, The 
Netherlands) to measure both the luciferase activity and the total protein concentration. 
Luciferase activity was determined with the Promega luciferase assay kit according to the 
manufacturer’s instructions in relative light units (RLU). Briefly, 100 µl substrate was added to 20 µl 
cell lysate and after a 2 sec delay, the luminescence was measured during 10 sec with a GloMax
TM
 96 
luminometer. To correct for the amount of cells per well, the protein concentration was determined 
with the BCA kit (Pierce; Rockford, IL). Therefore, 200 µl mastermix, containing 50 parts reagent A to 
1 part B, was mixed with 20 µl cell lysate or BSA (to make the standard curve). After 30 min 
incubation at 37°C, the absorbance at 590 nm was measured with a Wallac Victor
2
 absorbance plate 
reader (Perkin Elmer; Waltham, MA). 
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RESULTS & DISCUSSION 
 
Preparation and characterization of PEG-siPlex loaded microbubbles 
 
As schematically depicted in Fig. 1A, the first goal of this work was to attach PEGylated 
siRNA-liposome complexes (PEG-siPlexes) to gas-filled microbubbles via a biotin-avidin-biotin bridge. 
Therefore, we first prepared perfluorobutane filled lipid microbubbles by sonication of a DPPC:DSPE-
PEG2000-biotin liposome dispersion in the presence of perfluorobutane gas. The lipid coating prevents 
a rapid diffusion of the perfluorobutane gas out of the microbubbles. To assure that biotin molecules 
were present at the outer surface of the microbubbles, we incubated them with Cy5 labelled 
streptavidin. As shown by the confocal images in Fig. 2A and 2B, after removal of the unbound 
streptavidin, a thin fluorescent layer of streptavidin molecules surrounding the gas-filled 
microbubbles could be observed, which indicates the formation of biotin-avidin linkages. This 
suggests that the DSPE- PEG2000-biotin molecules in the lipid shell are oriented with their hydrophobic 
tails to the perfluorobutane gas core while their hydrophilic head groups are exposed to the 
surrounding aqueous medium, as previously suggested by Unger 
37
. 
 
 
Figure 1. (A) Schematic overview of a PEG-siPlex loaded microbubble. The white disk surrounded by lipids (95 
mol% DPPC and 5 mol% DSPE-PEG2000-biotin) represents an avidinylated lipid microbubble with its 
perfluorobutane (C4F10) gas core. PEG-siPlexes with increasing amounts of DSPE-PEG2000-biotin were attached 
to these avidinylated microbubbles via a biotin-avidin-biotin bridge. (B) Experimental setup used in the 
transfection experiments. An OptiCell
TM
 unit containing a monolayer of HuH-7 cells on one of their membranes 
was placed in a water tank with a rubber plate, designed to minimize ultrasound reflection or scattering, at the 
bottom. In all experiments the same ultrasound settings were applied: 10 sec, 1 MHz, 10 % duty cycle and an 
ultrasound intensity of 2 W/cm
2
. The ultrasound was delivered vertically to the cells which were present on the 
upper membrane of the OptiCell
TM
 unit, closest to the ultrasound probe. Different regions of the OptiCell
TM
 unit 
were sonicated separately by moving the ultrasound device. 
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Figure 2. Transmission image (A) and confocal laser scanning microscopy image (B) of avidinylated 
microbubbles coated with Cy5-streptavidin (red). The inserts display a close-up of three microbubbles. 
 
In a next step, we prepared DOTAP:DOPE based siPlexes containing increasing amounts of 
DSPE-PEG2000-biotin (0, 2, 5 and 15 mol%). In all cases, a N:P ratio of 20:1 was chosen as non-
PEGylated siPlexes showed at this ratio the highest gene silencing effect in HuH-7 cells (data not 
shown). The ability of the siPlexes to bind siRNA was analyzed by PAGE (Fig. 3A). In case of the 0, 
2 and 5 mol% DSPE-PEG2000-biotin containing siPlexes, no free siRNA could be detected. This implies 
that all the siRNA is complexed with the liposomes, which are too large to migrate into the gel 
network. In contrast, a smear of siRNA was observed in case of the 15 mol% PEG-siPlexes, indicating 
only a partial siRNA complexation in these siPlexes. 
Subsequently, the ability of the different siPlexes to bind to the surface of the biotinylated 
microbubbles was tested. Therefore, the biotinylated microbubbles were first incubated with avidin. 
An excess of avidin was used to avoid massive clustering of the microbubbles, due to avidin mediated 
bridging. After removal of the unbound avidin, siPlexes, containing Atto488 labelled siRNA, were 
added to the avidinylated microbubbles. The confocal images in Fig. 3B till 3E show that the amount 
of DSPE-PEG2000-biotin in the siPlexes clearly influences to which extent the microbubble surface 
becomes covered with siPlexes. Non-PEGylated siPlexes (Fig. 3B), thus not containing DSPE-PEG2000-
biotin, only showed some non-specific binding to the avidinylated microbubbles. In contrast, the 
PEGylated siPlexes, containing DSPE-PEG2000-biotin, clearly bound to the avidinylated surface of the 
microbubbles. The surface of the microbubbles became only partially covered with siPlexes 
containing 2 mol% DSPE-PEG2000-biotin (Fig. 3C), probably due to the limited degree of biotinylation 
of the siPlexes. In contrast, the microbubble surface was almost completely coated with siPlexes 
when they contained 5 mol% DSPE-PEG2000-biotin (Fig. 3D). The 15 mol% containing PEG-siPlexes also 
showed an efficient coating of the surface of the microbubbles. However, as these siPlexes showed 
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incomplete complexation of the siRNA, previously shown by gel electrophoresis experiments (Fig. 3A, 
lane 5), these siPlexes were further excluded from the study.  
 
 
Figure 3. (A) Polyacrylamide gel after electrophoresis of siPlexes containing 0 mol% (lane 1), 2 mol% (lane 2), 
5 mol% (lane 3) and 15 mol% DSPE-PEG2000-biotin (lane 4) before attachment to the microbubbles. As a 
reference, free siRNA was loaded in lane 5 and each lane contains 0.3 µg siRNA. (B-E) Confocal laser scanning 
microscopy images and corresponding transmission images (inserts) of avidinylated microbubbles incubated 
with siPlexes containing 0 mol% (B), 2 mol% (C), 5 mol% (D) and 15 mol% DSPE-PEG2000-biotin (E). The siPlexes 
were visualized by using Atto488-siRNA. 
 
Subsequently we studied the size distribution of the siPlex coated microbubbles by laser 
diffraction to assure that the microbubbles had the optimal size distribution for cavitation. Fig. 4 
shows the size distribution of microbubbles incubated with non-PEGylated siPlexes and microbubbles 
loaded with PEGylated siPlexes. In both cases, the diameter of the microbubbles varied between 0,5 
and 10 µm, which is an appropriate size to favour cavitation upon exposure to clinically relevant 
ultrasound energy. Fig. 4 (arrow) also shows a significant amount of sub-micron particles in case of 
the non-PEGylated siPlexes, indicating the presence of non bound siPlexes. In contrast, this sub-
micron peak was not visible in case of the microbubbles loaded with PEGylated siPlexes (Fig. 4, grey 
circles). These results are in agreement with the confocal images shown in Fig. 3B and 3D. Similar size 
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distributions were found for microbubbles that were loaded with 2 mol% DSPE-PEG2000-biotin 
containing siPlexes (data not shown).  
 
Figure 4. Size distribution measured by laser diffraction of microbubbles after addition of non-PEGylated 
siPlexes (black squares) and attachment of 5 mol% DSPE-PEG2000-biotin containing siPlexes (grey circles). The 
data are the mean of three measurements and error bars represent standard deviations. Arrow indicates a 
peak of sub-micron sized particles. 
 
Ultrasound induced release of PEG-siPlexes from microbubbles 
 
It has been shown that coupling of polystyrene beads to the surface of microbubbles via a 
biotin-avidin bridge, results in local delivery of the beads upon ultrasound radiation 
38
. However, in 
contrast to these inert beads, self-assembled siPlexes may undergo physicochemical alterations 
during the ultrasound triggered release, which may influence their biological performance. 
Therefore, we determined the size, zeta potential and siRNA complexation of the siPlexes before 
attachment to the microbubbles and after ultrasound triggered release from the microbubbles.  
The dark grey bars in Fig. 5A show that, before binding to the microbubble surface the size of 
the siPlexes was independent of the PEGylation degree and averaged 130 nm. In contrast, the 
surface charge lowered with increasing degree of PEGylation (dark grey bars in Fig. 5B) varying from 
50 mV for the non-PEGylated to 20 mV for the siPlexes containing 5 mol% DSPE-PEG2000-biotin. 
Fig. 5A also shows that binding and subsequent ultrasound assisted release of the PEG-siPlexes from 
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the microbubbles (light grey bars) had only a limited effect on the size of these PEG-siPlexes with a 
maximal increase of ~20 nm, in contrast to the clear increase in size of the non-PEGylated siPlexes. 
 
Figure 5. (A) Size and (B) zeta potential of the siPlexes containing 0 mol%, 2 mol% and 5 mol% DSPE-PEG2000-
biotin before attachment to the microbubbles (dark grey bars) and after ultrasound assisted release from the 
siPlex loaded microbubbles (light grey bars). The data are the means of three independent measurements and 
the error bars represent standard deviations. 
 
As observed for the size, the zeta potential (Fig. 5B) of the PEG-siPlexes after being released 
from the microbubbles by ultrasound was not significantly altered, while the zeta potential of the 
non-PEGylated siPlexes was significantly lower. The change in size and zeta potential of the non-
PEGylated siPlexes may be due the binding of negatively charged DSPE-PEG2000-biotin lipids from the 
imploded microbubbles to the non-PEGylated siPlexes. 
Clearly, to keep their biological performance, the siPlexes may not dissociate (i.e. release 
their siRNA) upon exposure to ultrasound, as free siRNA is prone to nuclease degradation. Gel 
electrophoresis revealed that ultrasound energy did not dissociate the siPlexes (data not shown). In 
conclusion, ultrasound mediated implosion of the PEG-siPlex loaded microbubbles and the induced 
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microjets did not drastically influence the size, zeta potential and the complexation properties of the 
released PEG-siPlexes. 
 
Cellular distribution of PEG-siPlexes 
 
Next we studied the cellular distribution of PEG-siPlexes. Fig. 6A till 6C show HuH-7 cells 
incubation with 5 mol% PEG-siPlexes. The z-scan in Fig. 6A reveals that these PEG-siPlexes, after 
20 min incubation at 37°C, were still located on top of the HuH-7 cells. This was confirmed by the 
images in Fig. 6B and 6C. In these images, the green labelled PEG-siPlexes (Fig. 6C) show exactly the 
same cellular distribution as the red labelled plasma membrane (Fig. 6B). This confirms that 
PEGylation indeed has an effect on the cellular uptake of siPlexes 
39
, as non-PEGylated siPlexes were 
clearly taken up by the cells after 20 min (data not shown). Ultrasound irradiation did not change the 
cellular distribution of these free PEG-siPlexes (data not shown). Interestingly, PEG-siPlexes released 
from siPlex loaded microbubbles by ultrasound showed a totally different cellular distribution 
(Fig. 6D till 6F). In this case, the green labelled PEG-siPlexes were localized inside the cells as shown 
by the z-scan (Fig. 6D) and the membrane colouring (Fig. 6E and 6F). These results suggest that PEG-
siPlexes enter the cells via a different mechanism when they are released from the PEG-siPLex loaded 
microbubbles by ultrasound. Although further research is needed, we suppose that they enter cells 
via the transient cell membrane perforations that arise during the exposure to ultrasound 
40
. Indeed, 
such pores, which have been reported to be a few hundreds of nanometers in size 
34,41
, are large 
enough to allow the passage of the PEG-siPlexes released from the microbubbels. This implies that 
the negative effects of PEGylation on the cellular uptake as well as on the endosomal escape of PEG-
siPlexes can be circumvented by attaching them to microbubbles and subsequently expose these 
siPlex loaded microbubbles to ultrasound. 
 
Gene silencing efficiency of PEG-siPlex loaded microbubbles 
 
Finally, we determined whether siRNA delivered by ultrasound mediated implosion of the 
PEG-siPLex loaded microbubbles could inhibit constitutive luciferase expression in HuH-7eGFPLuc 
cells (Fig. 7). The black bars in Fig. 7 show that the silencing capacity of the free siPlexes declines 
dramatically with increasing PEGylation degree. SiPlexes with a PEGylation degree of 2 mol% already 
showed a 3-fold reduced gene silencing capacity compared to the non-PEGylated siPlexes.  
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Figure 6. Cellular uptake and intracellular distribution of PEG-siPlexes (A till C) and ultrasound irradiated PEG-
siPlex loaded microbubbles (D till F). All PEG-siPlexes contain 5 mol% DSPE-PEG2000-biotin. Images A and D 
display confocal images and z-scans, at the positions indicated by the red lines, through HuH-7 cells with Draq5 
labelled nuclei (blue) and incubated for 20 minutes with Atto488-labelled siPlexes (green). Confocal image (B) 
and (E) show the localisation of TRITC-concanavalin A (red), a plasma membrane marker. Confocal image (C) 
and (F) show the localisation of Atto488-labelled siPlexes (green) in the cells shown in image (B) and (E), 
respectively. The scale bars represent 10 µm. 
CHAPTER 3 – ULTRASOUND ASSISTED SIRNA DELIVERY USING PEG-SIPLEX LOADED MICROBUBBLES 
 
 102 
Increasing the PEGylation degree to 5 mol% even completely blocked the silencing capacity 
of the siPlexes. This negative effect of PEGylation has intensively been studied for pDNA delivery and 
some groups suggest that the loss in transfection efficiency of highly PEGylated lipoplexes is due to a 
reduced cellular binding and uptake 
41,42
, while others believe that the PEG-lipids inhibit the 
endosomal release of the nucleic acids into the cytoplasm 
39,43-46
. The white bars in Fig. 7 show that 
the negative effect of PEGylation on the gene silencing efficiency of the siPlexes containing 5 mol% 
DSPE-PEG2000-biotin can be completely counteracted by loading of these PEG-siPlexes on the surface 
of microbubbles followed by exposure of these microbubbles to ultrasound. Attachment of siPlexes 
containing 2 mol% DSPE-PEG2000-biotin to the microbubbles and subsequent exposure to ultrasound 
resulted in a similar silencing as the corresponding free PEG-siPlexes. For these PEG-siPlexes the 
number of PEG-siPlexes bound to the microbubbles is probably not enough to further increase their 
gene silencing efficiency. Indeed, as shown in Fig. 3C, the 5 mol% DSPE-PEG2000-biotin containing 
siPlexes bind much more efficiently to the microbubble surface than the 2 mol% DSPE-PEG2000-biotin 
containing siPlexes (Fig. 3B). Therefore, these data may indicate that the extent of gene silencing is 
governed by the amount of PEG-siPlexes that are released near the cell perforations. Fig. 7 (dark grey 
bars) also shows that applying ultrasound energy, in the absence of microbubbles, could not enhance 
the gene silencing efficiency of the different siPlexes. Furthermore, microbubbles loaded with 
5 mol% PEG-siPlexen were not able to cause gene silencing in the absence of ultrasound (Fig. 7; light 
grey bars). This implies that the PEG-siPlex loaded microbubbles described in this work allow 
ultrasound controlled, i.e. targeted, intracellular delivery of siRNA. 
 
CONCLUSION 
 
In conclusion, we developed a novel delivery system in which PEG-siPlexes are attached to 
ultrasound responsive microbubbles via a biotin-avidin-biotin bridge. Exposure of these PEG-siPlex 
loaded microbubbles to ultrasound resulted in a massive release of unaltered PEG-siPlexes. 
Furthermore, PEG-siPlexes (containing 5 mol% DSPE-PEG2000-biotin) loaded on microbubbles were 
able to enter cells rapidly after exposure to ultrasound, while free PEG-siPlexes did not enter cells. 
Moreover, these PEG-siPlex loaded microbubbles caused, in the presence of ultrasound, a much 
higher gene silencing than free PEG-siPlexes. Interestingly, in the absence of ultrasound these PEG-
siPlex loaded microbubbles did not cause any gene silencing. Therefore, the developed siRNA 
delivery system allows both space and time controlled gene silencing. Furthermore, the PEG-siPlex 
loaded microbubbles are expected to be suitable for systematic applications as ultrasound in 
combination with microbubbles is considered as a safe and already used in the clinic for diagnostic 
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purposes. Additionally, PEG-siPlexes are known not to aggregate in serum which is important to 
avoid blockage of small blood capillaries by aggregates 
47
. The developed siRNA delivery system may 
also allow the treatment of patients with metastasized tumours. Indeed, a recently developed device 
that combines magnetic resonance imaging (MRI) and ultrasound can both track down the 
metastasized tumours and guide the ultrasound energy to these tumours 
48
. So, the siRNA delivery 
system presented in this work may open up new perspectives for ultrasound controlled in vivo 
delivery of siRNA. 
 
 
Figure 7. Silencing efficiency of free siPlexes and PEG-siPlexes in the absence and presence of ultrasound, and 
PEG-siPlex loaded microbubbles in the presence of ultrasound. The PEGylation (DSPE-PEG2000-biotin) degree of 
the siPlexes is represented in the x-axis. The black and the dark grey bars represent the gene silencing 
efficiency of free siPlexes in the absence and presence of ultrasound, respectively. The light grey and white 
bars represent the gene silencing of the siPlexes loaded on the microbubbles in the absence or presence of 
ultrasound. In all cases, the following ultrasound settings were used: 1 MHz, 10 % DC, 2 W/cm
2
, 10 sec. The 
results are expressed as percentage of luciferase expression compared to mock siRNA transfected cells. The 
asterixes (*) represent significant differences with p<0.05. (MB = microbubble; US = ultrasound) 
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ABSTRACT 
 
Several types of endocytosis have been demonstrated to be involved in the uptake of nucleic acid 
containing particles, varying according to cell type, type of carrier and particle size. As the 
intracellular processing can differ strongly depending on the precise uptake mechanism, unravelling 
this uptake mechanism of individual non-viral gene carriers in a specific cell line model can open up 
possibilities to correlate uptake to intracellular processing and subsequently to transfection 
efficiency. Consequently, several research groups have tried to quantitatively assess the contribution 
of each endocytic pathway to the uptake of non-viral gene delivery vehicles through the use of 
endocytosis inhibitors. Such chemicals are easy to apply and are presumed to inhibit specific 
endocytic pathways. However, in this work, we show that one should take extra care when using 
inhibitors to specifically perturb endocytic pathways as the inhibitory efficiency appears to be 
strongly cell type dependent, and so is the concentration threshold of cellular toxicity. Moreover, the 
inhibition is not always as efficient and specific as has been claimed in recent literature. We also 
demonstrate that the chemical compounds can exhibit side effects such as dramatic changes in 
cellular morphology. Taken together, we conclude that the use of endocytosis inhibitors is still a very 
useful approach to study the uptake mechanisms of nucleic acid containing particles, but only when 
the appropriate control experiments are performed to assure inhibitor toxicity, efficacy and 
specificity. Additionally, combining these inhibitors with other tools such as fluorescent dual colour 
colocalization studies or suppression of specific endocytic pathways through the use of dominant 
negative mutants or RNAi, will assure to draw correct and reliable conclusions. 
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INTRODUCTION 
 
Successful gene delivery relies mainly on the development of non-toxic gene carriers that can 
deliver foreign genetic material efficiently to target cells. Although more effective, the clinical use of 
viral carriers is mainly limited due to safety issues. As a safe(r) alternative, non-viral gene carriers, 
such as cationic liposomes or polymers, can be used. However, their low transfection efficiency is a 
major limiting factor. A deep mechanistic understanding of the pathways involved in the cellular 
uptake of these non-viral delivery vehicles may therefore help to design more effective gene carriers.  
The majority of the reports suggest that endocytosis is the preferred route of cell entry of 
non-viral gene carriers 1. As shown in Fig. 1, endocytosis can be classified in two broad categories: 
phagocytosis and pinocytosis 2. Phagocytosis is typically restricted to specialized cells whereas 
pinocytosis occurs in all cell types. Therefore, endocytosis and pinocytosis are mostly used in the 
same context and considered to be synonyms. The study of the different pinocytotic pathways is still 
an evolving field and no current classification system is completely satisfactory. Nowadays, one 
primarily distinguishes macropinocytosis, clathrin-dependent (CDE) and clathrin-independent (CIE) 
endocytosis. Additionally, under CIE, one can make a further distinction between dynamin-
dependent and -independent endocytosis 3.  
CDE is the major and best characterized endocytic pathway and is claimed to be the 
preferred pathway for particles up to 200 nm in size 4. A local, clathrin-associated invagination of the 
plasmamembrane (PM), a coated pit, pinches off to form a membrane-derived clathrin-coated 
vesicle. This is followed by fission of the mature vesicle which is dependent on the activity of the 
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GTPase dynamin 5 and the immediate release of the clathrin coat, resulting in vesicles of 60 to 
200 nm in size 6. The presence of cholesterol is shown to be essential for CDE 7. Actin plays an 
accessory role during CDE, but disrupting the actin filaments does not inhibit the endocytic process 8. 
By fusion with the sorting (early) endosomes, CDE typically ends up in the acidifying and degrading 
endolysosomal pathway resulting in hydrolytic and enzymatic destruction of the endocytosed 
macromolecules. The majority of the internalized receptors, such as the transferrin receptor, are 
recycled to the PM through tubulating of the sorting endosome (SE), either directly or via the 
endocytic recycling compartment (ERC) 9. In contrast, endocytosed macromolecules are retained in 
the lumen of the SE whose pH is subsequently lowered to pH 5.9 10. After 5-10 min, the SE stops 
receiving newly formed vesicles and matures into a late endosome (LE). At this point, the endosome 
exhibits intralumenal membrane structures, subsequently often referred to as multivesicular body 11, 
and is actively transported on microtubules to the periphery of the nucleus. At this stage, the pH has 
dropped to pH 4.5-5.5 10. As a final phase of the degrading endolysosomal pathway, the LE fuses with 
the prelysosomal vesicles, which contain the hydrolyzing enzymes, to form mature hybrid degrading 
endolysosomes 12. Certain macromolecules preferentially associate with this pathway and are 
specifically taken up in clathrin-coated vesicles. Examples are the Low Density Lipoprotein (LDL) 
receptor, the transferrin receptor and the Epidermal Growth Factor (EGF) receptor 7,13. 
 
 
Figure 1. Overview of the known endocytic pathways in mammalian cells (see Chapter 1 Fig. 7 for more details). 
 
Although the details of the CIE mechanism have not been completely elucidated, the current 
classification is based on the role of dynamin and several small GTPases 3 (see Fig. 1). Dynamin-
independent CIE is subdivided in ADP-ribosylation factor 6 (ARF6-) and cell division cycle 42 (CDC42-) 
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regulated endocytosis. Dynamin-dependent CIE is subdivided in caveolae-mediated and RhoA-
regulated endocytosis. All the CIE endocytic pathways are related by the fact that the endocytic 
vesicles bud from a liquid ordered membrane environment, called lipid rafts, enriched in unsaturated 
phospholipids, cholesterol, glycosphingolipids and certain proteins 14. Additionally, all CIE processes 
strongly depend on the integrity of actin microfilaments 3. Caveolae mediated endocytosis is 
probably the best characterized CIE pathway. Caveolae, not present in all cell types 15,16, are small 
(50-80 nm), smooth, flask-shaped invaginations of the PM that are characterized by the presence of 
caveolin 17. Besides the flask-shape, some flexibility in morphology has been observed 18. The post-
endocytic trafficking of CIE is quite diverse and mostly dependent on the cargo. The cargoes taken up 
by the RhoA-, ARF6- and CDC42-regulated CIE end up in the SEs from where they are further sorted 
and translocated 3. In contrast, the newly formed caveolin-containing vesicles, often named 
cavicles 19, fuse either with SEs or caveosomes 20. Caveosomes are neutral endosomes which do not 
acidify 21, nor do they fuse with lysosomes 18. Subsequently, the cargo can be translocated to the 
Golgi, the endoplasmatic reticulum (ER) or the LE 18,22. Besides this non-degrading character, 
caveosomes exist longer than other endosomes 23. For these reasons, this non-acidifying, non-
degrading environment could be an interesting target for gene-delivery. Cholera toxin subunit B 
(CTB) is often being used as marker for this pathway 24, though it is currently known that a significant 
fraction of CTB is also taken up in clathrin-coated vesicles 25. Albumin is preferentially taken up by 
CIE 26. Lactosylceramid, a glycosphingolipid, is taken up by a clathrin-independent and dynamin- and 
caveolin-dependent mechanism 27-29. Certain pathogens, like SV40 virus, use specifically this pathway 
to enter cells and to hijack the cell’s machinery 23.  
During macropinocytosis (MP), a third type of pinocytosis (see Fig. 1), membrane protrusions, 
often called ruffles, are formed which can subsequently fuse with each other or with the PM to 
enclose large volumes 30. MP is a non-selective endocytic mechanism of suspended macromolecules 
resulting in vesicles with sizes up to 5 µm 31. The process is actin-driven 32 and dependent on the 
presence of cholesterol 31. Constitutive MP has been observed in dendritic cells, but in other non-
phagocytic cells, MP is mostly a response to growth factor stimulation 30. Once taken up, the 
intracellular itinerary differs from cell to cell. In macrophages, the formed macropinosomes shrink, 
acidify and fuse with lysosomes. In contrast, in epithelial cell lines, these vesicles do only partially 
acidify, do not fuse with lysosomes and are finally mostly exocytosed 33. Ricine is a macromolecule 
which is preferentially taken up via macropinocytosis. 31. Additionally, this pinocytic pathway is the 
alternative entry pathway for adenoviruses 34, the HIV-1 Tat peptide 35 and in general for large, 
solubilised molecules such as 50 kDa dextran 36. 
Phagocytosis shares many features with MP, but instead of membrane ruffles that form a 
macropinosome, the fagosome is formed by actin-driven pseudopodia which ingest micron-sized 
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particles. This is an adsorptive type of endocytosis and is exclusive used by specialized cells such as 
macrophages and dendritic cells to engulf large structures (> 500 nm) such as bacteria, dead cells or 
yeast 37. 
Several forms of endocytosis have been demonstrated to be involved in DNA uptake 38,39 and 
varies widely according to cell type (summarized in 3), gene carrier 22 and particle size 4. This 
specificity stresses why it is imperative to study the internalization of the individual non-viral gene 
carriers in the appropriate cell line model. Therefore, a quantitative assessment of the contribution 
of each endocytic pathway to the overall cellular uptake is essential to establish the intracellular 
pharmacokinetic models in the future 40 and to evaluate if it is feasible to relate the endocytic 
pathway to intracellular processing and transfection efficiency. There are several tools available to 
study endocytosis and trafficking of gene carriers. The present paper focuses on methods of 
perturbing endocytosis through the use of endocytosis inhibitors. We show that both the inhibitory 
efficiency and the concentration-threshold of cellular toxicity is strongly cell type dependent. In 
addition, the chemical compounds exhibit cell type dependent side effects and there is redundancy 
when inhibiting one pathway. Therefore in this paper, we bring a strongly cautionary message 
concerning the use of inhibitors for studying endocytic pathways. 
 
MATERIALS & METHODS 
 
Materials 
 
Chlorpromazine, methyl-β-cyclodextrin (mBCD), nystatin, genistein, and filipin III were 
purchased from Sigma Aldrich (Bornem, Belgium) and cytochalasin D (cytoD) from Biosource 
(Nivelles, Belgium). Dulbecco's modified Eagle's medium (DMEM), OptiMEM, L-glutamine (L-Gln), 
foetal bovine serum (FBS), penicillin-streptomycin (5000 IU/ml penicillin and 5000 µg/ml 
streptomycin) (P/S) and phosphate buffered saline (PBS) were supplied by GibcoBRL (Merelbeke, 
Belgium). Human transferrin-AlexaFluor633 (hTF) and BODIPY FL C5-lactosylceramide (LacCer) were 
purchased from Molecular Probes (Merelbeke, Belgium). Other chemicals used were commercially 
available and were reagent grade products. 
 
Cell culture 
 
Cos-7 cells (African green monkey kidney fibroblast cell line; ATCC number CRL-1651) and 
Vero cells (African green monkey kidney epithelial cell line; ATCC number CCL-81) were cultured in 
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DMEM containing 10 % FBS, 2 mM L-Gln and 2 % P/S. HuH-7 cells (human hepatocellular carcinoma 
cell line; HSRRB number JCRB 0403) were cultured in DMEM:F12 supplemented with 10 % FBS, 2 mM 
L-Gln and 2 % P/S. The D407 RPE (retinal pigment epithelium) cell line 41 were a kind gift from Dr 
Richard Hunt (University of South Carolina, Medical School, Columbia, USA) and were cultured in 
DMEM with high glucose concentration (4500 mg/l), 5 % FBS, 2 mM L-Gln and 2 % P/S. All cells were 
grown at 37 °C in a humidified atmosphere containing 5 % CO2. 
 
Cytotoxicity analysis 
 
The cytotoxicity of the different inhibition protocols was evaluated using the non-radioactive 
EZ4U cell proliferation and cytotoxicity assay kit (Biomedica, Vienna, Austria). This assay is based on 
the principle of the classical MTT test where less coloured tetrazolium salts are reduced into 
intensely coloured formazan derivatives by mitochondrial enzymes which are rapidly inactivated 
within a few minutes after cell death. The assay was performed according to the manufacturer’s 
instructions. Briefly, cells were seeded at 105 cells/well in a 24-well plate for 24 hrs. Next, the cells 
were incubated in OptiMEM with various concentrations of the described inhibitors for 30 min (in 
case of cytoD) or 2 hrs (in case of all other inhibitors). In case of potassium depletion, cells were 
washed once with potassium-free buffer (140 mM NaCl, 20 mM Hepes, 1 mM CaCl2, 1 mM MgCl2, 
1 mg/ml D-glucose, pH 7.4), then with hypotonic buffer (1:1 potassium-free buffer and H2O) during 
5 min and again 3 times with potassium-free buffer. It is important to note that filipin should be 
freshly prepared. Subsequently, the cells were immediately incubated with the EZ4U substrate (40 µl 
substrate with 260 µl culture medium per well) which contains the tetrazolium salts. After 3 hrs at 
37°C, the absorbance of the coloured formazan was measured on a Wallac Victor² Plate reader 
(Perkin Elmer-Cetus Life Sciences, Boston, MA, USA) at 460 nm and corrected for the absorbance 
measured at 630 nm which represents nonspecific absorbance like fingerprints and cell debris. 
 
Inhibition and specificity studies 
 
For the inhibition and specificity studies, cells were seeded at a cell density of 2.5 x 104 cells 
per cm² on sterile MatTek coverslip (1.5)-bottom dishes (MatTek corporation, MA, USA) 24 hrs prior 
to the experiment. The cells were subsequently incubated with the appropriate concentration of 
inhibitor in OptiMEM for the appropriate time. For potassium depletion, cells were washed once 
with potassium-free buffer, then with hypotonic buffer during 5 min and again 3 times with 
potassium-free buffer. Next, cells were incubated with 25 µg/ml hTf or 1.35 µM LacCer for 10 min at 
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37°C in the presence of the appropriate inhibitor or buffer. hTF and LacCer uptake in the different 
conditions was qualitatively evaluated by the use of confocal laser scanning microscopy (CLSM). 
 
Confocal laser scanning microscopy (CLSM) 
 
The internalisation of the fluorescently tagged biomarkers hTF and LacCer was visualized and 
evaluated with a Nikon C1 confocal laser scanning module attached to a motorized Nikon TE2000-E 
inverted microscope (Nikon Benelux, Brussels, Belgium) equipped with a Plan Apo VC 60x 1.4 NA oil 
immersion objective and suitable optical elements to acquire differential interference contrast (DIC) 
transmission images. Bodipy FL (LacCer) was excited with the Argon ion 488 nm laser line and 
emission light was collected using a 500-530 nm band pass filter. AlexaFluor 633 (hTF) was excited 
with the diode 639 nm laser line and emission light was collected using a 655 nm long pass filter. 
 
RESULTS 
 
The cytotoxicity of endocytosis inhibitors is cell type dependent 
 
To establish an optimal protocol for the use of endocytosis inhibitors on different cell lines, it 
is imperative to evaluate the in vitro cellular toxicity to determine the upper limit in terms of 
concentration and incubation time that can be applied. Different concentrations of each inhibitor 
were tested on the HuH-7, Vero, Cos-7 and RPE cell lines and the cellular toxicity was subsequently 
assessed with the MTT based EZ4U test. The inhibitor was in all cases diluted in OptiMEM and 
incubated with the cells for 2 hrs, except for cytoD, where the incubation time was reduced to 
30 min. In case of K+-depletion, the cytotoxicity was determined following the treatment with the 
different buffers as described in materials and methods. As a positive control, cells were exposed for 
2 hrs to 20 mg/ml phenol solution in OptiMEM and as negative control for 2 hrs to OptiMEM. The 
cytotoxicity, expressed as a percentage of cell viability, was calculated from the measured 
absorbance values after correction for the positive control and normalization to the negative control 
and is depicted in Fig. 2. 
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Figure 2. In vitro cytotoxicity of the endocytosis inhibitors (A) chlorpromazine, (B) K
+
-depletion, (C) filipin, (D) 
nystatin, (E) genistein (F) cytoD and (G) mBCD after 2 hrs incubation with RPE, Vero, Cos-7 and HuH-7 cells. 
 
The cytotoxicity results exhibit some noteworthy effects. Cos-7 and Vero cells, both African 
green monkey kidney cells, were very sensitive to chlorpromazine (Fig. 2A). These cell lines showed a 
clear increase in cytotoxicity after 2 hrs incubation with chlorpromazine concentrations above 
2 µg/ml. In contrast, chlorpromazine concentrations up to 5 and 12 µg/ml did not affect the viability 
of HuH-7 and RPE cells, respectively (Fig. 2A). In general, while K+-depletion was not toxic to RPE 
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cells, a limited toxicity was found for the other cell lines (Fig. 2B). Filipin, up to 14 µg/ml, was not 
toxic to HuH-7, Vero and Cos-7 cells, while it was toxic for RPE cells at concentrations above 7 µg/ml 
(Fig. 2C). None of the tested nystatin, genistein and cytoD concentrations had a noticeable effect on 
the viability of the four tested cell lines (Fig. 2D till F). mBCD was slightly cytotoxic to RPE and Cos-7 
cells at a concentration of 10 mM, while Vero and especially HuH-7 cells were more sensitive to 
mBCD (Fig. 2G). Indeed, mBCD became very toxic for HuH-7 cells at concentrations above 5 mM. 
Based on these results we conclude that several of the tested endocytosis inhibitors show a cell type 
dependent cytotoxicity profile. 
 
Selecting the appropriate inhibition conditions based on cytotoxicity and efficacy experiments 
 
To determine the optimal concentration to inhibit specific endocytic pathways, we evaluated 
the (inhibition of the) uptake of biomarkers which are known to be specifically taken up either by 
CDE or CIE. hTf was used as a specific biomarker for CDE and LacCer for CIE. hTf is a plasma 
glycoprotein that binds extracellular iron. After binding with its cellular receptor hTf is taken up via 
CDE. After the first acidification step in the SEs, the transferrin-receptor complex releases the bound 
iron and the hTf-receptor complex recycles to the PM, either directly or indirectly via the ERC, 
followed by hTF-receptor dissociation 42. To study CIE specific uptake, we used LacCer as a lipid 
biomarker. LacCer is a glycosphingolipid that resides preferably in lipid rafts, i.e. a liquid ordered 
environment present in biological membranes and is taken up via a clathrin-independent and 
dynamin-dependent endocytic mechanism 27. It is stated that the lipid is preferably taken up via a 
caveolin-1 dependent mechanism 28. K+-depletion and chlorpromazine are reported to inhibit CDE, 
whilst mBCD, cytoD, nystatin, genistein and filipin have extensively been used to inhibit CIE. To test 
the specificity of these inhibitors we qualitatively evaluated, via CLSM, the uptake of the biomarkers 
hTf and LacCer. Different inhibitor concentrations and incubation times were evaluated to optimize 
the inhibition conditions. As an example, the effect of RPE cell exposure to different mBCD conditions 
on the LacCer uptake is shown in Fig. 3. Fig. 3A shows the negative control where the cells were 
incubated only with LacCer for 10 min. It can clearly be observed that the uptake of LacCer is 
increasingly inhibited with increasing concentrations of mBCD. Moreover, an increasing incubation 
time with the cyclodextrin also exhibited a stronger inhibition (Fig. 3B till H). Higher incubation times 
and concentrations are not recommended because of toxic effects which are evident from the major 
morphological changes in Fig. 3H. This is in agreement with the cytotoxicity results after mBCD 
exposure to RPE cells as was shown Fig. 2. Finally, based on the biodistribution of the biomarker in 
the various conditions, one can decide on the optimal concentration and incubation time for a 
specific inhibition protocol. In case of mBCD, this would be an incubation of 2 hrs with 5 mM mBCD in 
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OptiMEM. Similarly we have tested the efficiency of different inhibitors on the uptake of hTf and 
LacCer by different cell lines, the results of which are summarized in Table 1. This information was 
used for the inhibition and specificity studies further on. 
 
Table 1. Uptake of the hTF and LacCer biomarkers in cells in the presence of endocytosis inhibitors. 
Treatment RPE HuH-7 Cos-7 Vero 
[Conc] Compound 
Time 
(hrs) hTf LacCer hTf LacCer hTf LacCer hTf LacCer 
 K
+
-depletion  ++ + + - - - - + 
5 µg/ml  Chlorpromazine 2 ND ND ND ND + + ++ - 
10 µg/ml Chlorpromazine 2 ++ - ++ - ND ND ND ND 
5 mM mBCD 2 ++ ++ + ++ ++ ++ + + 
5 µg/ml  cytoD 0.5 - ++ - ++ - + - + 
300 U/ml Nystatin 2 - - - - - + - - 
400 µM Genistein 2 - - - ++ - ++ - - 
10 µg/ml Filipin 2 - ++ - ++ - ++ - + 
-: no inhibition; +: noticeable inhibition; ++: strong inhibition; ND: not determined 
 
 
Figure 3. Optimization of the concentration of mBCD to inhibit CIE in RPE cells. Cells were incubated with 
different mBCD concentrations for different incubation times to find the optimal inhibition conditions. The 
inhibition of CIE was evaluated based on the uptake of the LacCer biomarker (green). (A) control (B) 30 min 
2.5 mM mBCD (C) 1 hr 2.5 mM mBCD (D) 3 hrs 2.5 mM mBCD (E) 1 hr 5 mM mBCD (F) 2 hrs 5 mM mBCD (G) 
3 hrs 5 mM mBCD (H) 2 hrs 10 mM mBCD. The scalebar represents 20 µm. 
 
The inhibitor effect is clearly cell type dependent  
 
From the results in Table 1 it is clear that the inhibition efficiency of biomarker uptake is 
definitely cell type dependent. While a certain inhibitor protocol resulted in a good inhibition in one 
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cell line, it had no inhibiting effect in another one. For example, as shown in Fig. 4, 2 hrs incubation 
with 400 µM genistein inhibited the uptake of LacCer in HuH-7 and Cos-7 cells, but had no noticeable 
effect on the LacCer uptake by Vero and RPE cells. Each time, a comparison was made with the 
corresponding negative control in the absence of genistein (Fig. 4A till D). These control images show 
that after 10 min incubation, LacCer is mainly found in vesicular structures inside the cytoplasm, 
concentrated at the nuclear periphery. Fig. 4E till 4H show the uptake of LacCer after incubation with 
genistein. Numerous LacCer containing intracellular vesicles could be observed in Vero (Fig. 4F) and 
RPE cells (Fig. 4G). In contrast, almost no intracellular LacCer could be observed in HuH-7 (Fig. 4E) 
and Cos-7 (Fig. 4H) cells, indicating a cell type dependent inhibitory effect by genistein. Other 
examples of inhibitors which have a cell type dependent effect are nystatin and K+-depletion. A 2 hrs 
treatment with 300 U/ml nystatin in OptiMEM could partially inhibit LacCer uptake in Cos-7 cells 
only. K+-depletion inhibited the uptake of hTf in both RPE and HuH-7 cells, but not at all in Cos-7 and 
Vero cells.  
 
 
Figure 4. Cellular uptake of LacCer (green) by HuH-7 (A and E), Vero (B and F), RPE (C and G) and Cos-7 (D and 
H) cells. Images (A) till (D) are the control samples and (E) till (H) are the corresponding samples incubated with 
400 µM genistein for 2 hrs. The scalebar represents 20 µm. 
 
The inhibitor effect is not always as specific as claimed in literature 
 
In the end, we would like to use the endocytosis inhibition protocols to have an idea about 
the endocytic pathways that are involved in the uptake of certain non-viral gene complexes. 
Therefore, it is necessary to evaluate the specificity of the applied inhibition protocol.  This can be 
done by studying the effect of a certain inhibitor on the uptake of biomarkers which are expected not 
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to be blocked. Hence, in this research we tested the effect of the different inhibitors on the uptake of 
both hTf and LacCer biomarkers. If the inhibition protocol prevents the uptake of both hTf and 
LacCer, the inhibitor can be considered as nonspecific, limiting the application of the tested 
compound to study the internalization pathway of non-viral gene complexes. A summary of the 
specificity is represented in Table 1. 
 
 
Figure 5. Effect of K
+
-depletion on the cellular uptake of hTF (red) and LacCer (green) by Vero (A till D), RPE (E 
till H) and HuH-7 (I till L) cells. Images (A), (E) and (I) are the control samples for the LacCer uptake and (C), (G) 
and (K) for the hTF uptake. Images (B), (F), (J), (D), (H) and (L) are the corresponding samples after treatment 
with K
+
-depletion. The scalebar represents 20 µm. 
 
Despite what is often stated in literature, very few inhibitors exhibited specific inhibition of a 
single endocytic pathway in the studied cell lines. Based on our results, only the following protocols 
were shown to be specific (1) 2 hrs treatment of RPE and HuH-7 cells with 10 µg/ml chlorpromazine, 
(2) 5 µg/ml cytoD incubation during 30 min in all studied cell lines, (3) 2 hrs treatment of HuH-7 and 
Cos-7 cells with 400 µM genistein and (4) incubation with 10 µg/ml filipin during 2 hrs in all studied 
cell lines. It is for example clear that mBCD entirely lacks specificity. Although cyclodextrines have 
been used to specifically block caveolae-mediated endocytosis or lipid raft-mediated endocytosis 
(see Table 2), it is clear that incubation for 2 hrs with 5 mM mBCD blocks both CIE and CDE in the 
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four cell types which were studied (Table 1). Another example is K+-depletion. The extraction of 
cellular potassium should, according to the literature, lead to specific CDE inhibition 43 (Table 2), but 
there is no specific CDE inhibition observed in any of the examined cell lines. Moreover, when 
evaluating the effect of K+-depletion on Vero cells, the effect seems to be inversed, as CIE was clearly 
inhibited while CDE remained unaffected. Contrary to what is often claimed to be a specific CDE 
inhibitor, chlorpromazine was found to partially inhibit CIE uptake as well in Cos-7 cells (Table 1). 
 
Table 2. Overview of the chemical compounds used to inhibit membrane traffic pathways and their application 
in studies on non-viral gene therapy 
Agent Presumed effect Comments Original 
reference 
Conditions Cell type Reference 
Chlorpromazine Dissociation of 
clathrin and APs of 
PM 
Pleiotropic effects, 
e.g. receptor 
recycling is affected 
Mechanism of action 
unknown 
Interacts with 
liposomal 
membranes 
44
 10 µg/ml 
10 µg/ml, 30 min 
10.66 µg/ml, 30 min 
10 µg/ml, 30 min 
10 µg/ml, 1 hr 
7.5 µg/ml, 1 hr 
10 µg/ml, 1 hr 
10 µg/ml, 1 hr 
20 µg/ml, 1 hr 
10 µg/ml, 1 hr 
35.5 µg/ml, 30 min 
Cos-7 
HepG2 
HeLa 
A549 
HuH-7, Cos-7 
HeLa 
HUVEC 
Cos-7 
Cos-7 
Cos-7 
CHO-DP12 
45
 
46
 
47
 
48
 
49
 
49
 
50
 
50
 
51
 
52
 
22
 
Low potassium Dissociation of 
clathrin of PM 
Cell type differences 
43,53
 45 min in K
+
-free 
buffer, wash 2 x 
with K
+
-free buffer, 
1 x with hypotonic 
buffer and 3 x with 
K
+
-free buffer 
 
1 x wash in K
+
-free 
buffer, 1 x with 
hypotonic buffer, 3 
x with K
+
-free buffer 
56FHTE8o
-
 
54
 
 
 
 
 
 
 
48
 
Hypertonic 
medium 
Same effect as K
+
-
depletion 
Pleiotropic effects 
53,55
 0.45 M sucrose, 45 
min 
 
56FHTE8o
-
 
54
 
Monensin Creates 
intracellular iso-pH 
 
56
 50 µM, 30 min, 4°C HepG2 
46
 
Chloroquine Inhibits endosomal 
acidification 
Leads to decrease in 
general endocytosis 
 
Leads to swelling of 
lysosomes and 
destabilisation of 
lysosomal 
membranes 
57
 100 µM, 0 min 
200 µM, 20 min 
500 µM, 30 min 
K562 
HUVEC 
Cos-7 
58
 
50
 
50
 
 
Bafilomycin A1 V-ATPase inhibitor Show stronger 
effects than 
chloroquine 
59,60
 125 nM, 30 min 
175 nM 
200 nM, 45 min 
200 nM, 1 hr 
HeLa 
HepG2 
HUVEC 
Cos-7 
61
 
62
 
50
 
50
 
AlF4 Blocks transport 
from ERC to PM 
 
13,63,64
   - 
Jasplakinolide binds and 
stabilizes actin 
 
65
   - 
Latrunculine Actin disruption  
66
   - 
Cytochalasin B Depolymerisation 
of actin filaments 
 
67
 5 µg/ml, 45 min 56FHTE8o
-
 
54
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CytoD Depolymerisation 
of actin filaments 
 
 
 
 
 
 
 
67
 20 µM, 30 min 
20 µMl 
5 µM, 30 min 
5 µM, 30 min 
10 µM, 30 min-5 hrs 
20 µM, 1 hr 
20 µM, 1 hr 
20 µM, 1 hr 
Cos-7 
HepG2 
HeLa 
HUVEC 
Cos-7 
HepG2 
HeLa 
EA.hy 926 
45
 
46
 
47
 
50
 
50
 
68
 
68
 
68
 
Nocodazole Depolymerisation 
of microtubules 
 
69
 33 µM 
33 µM, 1 hr 
10 µM, 2 hrs 
15 µM, 2hrs 
10 µM, 60 min 
HepG2 
B16-F10 
HUVEC 
Cos-7 
Cos-7 
46
 
4
 
50
 
50
 
51
 
Nystatin Binds cholesterol 
in PM 
 
26
 25 µg/ml, 1 hr 
25 µg/ml, 30 min 
50 µg/ml, 45 min 
Hek293, CHO 
HeLa 
ΣCFTE29o
-
 
70
 
47
 
71
 
Filipin III Binds cholesterol 
in PM, inhibits 
uptake of CTB 
Filipin cannot 
interact with with 
the cholesterol in 
coated pits 
 
Specificity might be 
lost at higher 
concentrations 
26
 1 µg/ml, 1 hr 
5 µg/ml, 1 hr 
5 µg/ml, 1 hr 
 
5 µg/ml, 30 min 
5 µg/ml, 30 min 
5 µg/ml, 45 min 
1 µg/ml, 1 hr 
0.5 µg/ml, 1 hr 
10 µg/ml, 1 hr 
9 µg/ml, 1 hr 
1 µg/ml, 1 hr 
5 µg/ml, 30 min 
Cos-7 
B16-F10 
Hek293, CHO, 
EA.hy 926 
HeLa 
A549, HeLa 
ΣCFTE29o
-
 
Cos-7, HeLa 
HuH-7 
HUVEC 
Cos-7 
Cos-7 
CHO-DP12 
45
 
4
 
 
70
 
47
 
48
 
71
 
49
 
49
 
50
 
50
 
52
 
22
 
Cyclodextrin Extracts 
cholesterol out of 
PM 
Changes in cell 
morphology 
7,72
 10 mM, 1 hr 
10 mM, 30 min 
10 mM, 1 hr 
 
5 mM, 30 min 
6 mM, 15 min 
9 mM, 15 min 
164 µM, 15 min 
1 mM, 30 min 
Cos-7 
HepG2 
Hek293, CHO, 
EA.hy 926  
HeLa 
HUVEC 
Cos-7 
Cos-7 
CHO-DP12 
45
 
46
 
 
70
 
47
 
50
 
50
 
51
 
22
 
Genistein Inhibits tyrosine-
phosphorylation of 
cav-1 (inhibits cav 
and CDC42, not 
RhoA) 
 
24,73
 200 µg/ml, 30 min 
200 µM, 1 hr 
200 µM, 30 min 
200 µM, 1 hr 
200 µM, 30 min 
HepG2 
B16-F10 
A549 
Cos-7 
CHO-DP12 
46
 
4
 
48
 
51
 
22
 
Staurosporin Inhibits PKC 
(inhibits cav) 
 
74
 200 nM HeLa 
75
 
Dynasore Inhibits dynamin   
76
   - 
Clostridium 
toxin B 
Inhibits Rho 
GTPAse inhibitor, 
no effect on cav 
 
77
 
78
 
  - 
Amiloride and 
derivatives 
Inhibits Na
+
/H
+
 ion 
exchange in PM 
and so membrane 
ruffling 
More specific than PI 
3-kinase inhibitors 
 
Lowers the 
cytoplasmic pH 
79,80
 100 µM, 5 min 
10 µM, 1 hr 
5 mM, 30 min 
250 µM, 30 min 
50 µM, 1 hr 
3 mM, 30 min 
HepG2 
B16-F10 
HeLa 
HUVEC, Cos-7 
Cos-7 
CHO-DP12 
46
 
4
 
47
 
50
 
81
 
22
 
PI 3-kinase 
inhibitors: 
wortmannin, 
 
 
 
LY294002 
Inhibits fusion of 
two membrane 
protrusions  
(blocks PI 3-
kinase) 
Inhibits evenly fusion 
of endosomes, 
irreversible 
Has influence on 
membrane 
recruitment of Rab5 
 
More specific than 
82
 
 
 
 
 
 
83
 
84
 
100 nM, 30 min  
100 nM, 1 hr 
30 nM, 1 hr 
50 nM, 1 hr 
 
 
50 µM, 1 hr 
50 µM, 1 hr 
HepG2 
EA.hy 926 
HUVEC, Cos-7 
Cos-7 
 
 
HUVEC, Cos-7 
Hek293, CHO, 
46
 
68
 
50
 
51
 
 
 
50
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wortmannin, 
reversible 
 
50 µM, 1 hr 
EA.hy 926  
Cos-7 
51,68
 
Antimycin A + 
NaF + NaN3 
Restricts 
metabolic activity 
of the cell 
 
85
 1 µg/ml + 10 mM + 
0.1 %, 30 min 
HeLa 
61
 
Z-Phe-Phe-Gly Fusion inhibiting 
peptide 
 
86
 
 
100 µM, 30 min A431 
87
 
cav-1 : caveoline-1; AP: adaptor proteins; CTB: cholera toxin subunit B; PKC: protein kinase C; PI 3-kinase: 
phosphatidylinositol-3-kinase; LY294002: 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 
 
The application of inhibitors can have pronounced effects on cellular morphology 
 
Besides the risk for cytotoxic effects, nonspecific inhibition of endocytic pathways and cell 
type dependent specificity and efficiency, several other pronounced side effects have been reported 
as summarized in Table 2. Although we did not evaluate these side effects by biochemical assays in 
this work, from our DIC images we can clearly observed major effects of the inhibitors on the 
morphology of the cells, which did not always correlate with the cytotoxic effects displayed in Fig. 2.  
 
 
Figure 6. DIC images of RPE (A and D), Cos-7 (B and E) and HuH-7 (C and F) cells before (A till C) and after (D till 
F) exposure to different endocytosis inhibitors: (D) chlorpromazine (10 µg/ml), (E) cytoD (5 µg/ml) and (F) K
+
-
depletion. The scalebar represents 20 µm. 
 
Fig. 6 shows the morphological effects on the Cos-7 cells after (1) K+-depletion on the Cos-
7,cells (2) cytoD (5 µg/ml, 30 min) on the HuH-7 cells and (3) chlorpromazine (10 µg/ml, 2 hrs) on the 
RPE cells. These morphological effects seem to be very pronounced for each condition and were 
similar for all tested cell lines. 
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DISCUSSION 
 
A thorough mechanistic understanding of the intracellular pharmacokinetics, which is mainly 
determined by the endocytic pathways used by the gene carrier complexes, is of great importance 
for the design of efficient non-viral gene delivery carriers. Quantitative insight into the contribution 
of different endocytic pathways to the cellular uptake of carriers can be very helpful to achieve this 
goal since it will allow to correlate the effects of specific carrier characteristics with differences in 
intracellular processing. The internalization and post-endocytic trafficking of gene carrier complexes 
can be studied by different approaches. Besides imaging the intracellular localization at different 
time points by the use of electron microscopy, several other methods have been described. A very 
powerful strategy to define the rate-limiting steps in transfection is to quantify the fraction of 
therapeutic DNA in the different intracellular compartments. This can be achieved by subcellular 
fractionating 54, by confocal image assisted three-dimensional integrated quantification (CIDIC) 88, by 
particle tracking 89 or by modelling 90. 
To define association with a certain intracellular compartment one can also use fluorescent 
dual colour colocalization studies. In this approach, the accuracy of the achieved information relies 
on the specificity and proper use of the fluorescently tagged biological marker, which is preferably 
associated with a certain pathway. Examples are hTF for CDE 7 and LacCer for CIE 27. Although some 
of the available biomarkers can be used to specifically label a certain endocytic pathway, it must be 
stressed that the post-endocytic itinerary can show a lot of variability depending on the properties of 
the internalized macromolecule or structure. Additionally, it is known that intense interactions 
between the different pathways can occur, e.g. LacCer is specifically taken up via CIE, but after less 
than 15 min, colocalization with hTf containing vesicles can be observed, which are believed to be 
mainly the SEs 13. This is also seen in own experiments (data not shown). Furthermore, these probes 
may also themselves affect the localization and/or metabolism of the targeted compartment or 
structure that they are used as a reporter for, as reviewed in 91. However, careful application of these 
probes, especially when several ones are being combined, can lead to accurate information regarding 
intracellular trafficking of gene complexes. Finally, it must be said that the arsenal on available 
reliable biomarkers which are specifically taken up are very limited.  
Alternatively, quantification of the uptake and the intracellular trafficking of gene complexes 
can also be established by perturbing specific cellular uptake mechanisms. This can be achieved by 
using endocytosis inhibitors or by creating transient or stable knock out mutants; the latter two of 
which are often referred to as ‘biological inhibitors’. Transient knock outs can be created by using the 
RNA interference (RNAi) silencing mechanism or by introducing dominant negative proteins. In the 
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first strategy crucial genes involved in a specific uptake pathway are silenced, which can lead to the 
inhibition of a specific pathway 92-95. In the second strategy, cells are transiently transfected or 
transduced with DNA which encodes for a dominant negative protein that interferes with a specific 
uptake process, again resulting in uptake inhibition. Several examples of transient knock outs or 
biological inhibitors are summarized in Table 3. 
 
Table 3. Biological inhibitors used to study endocytosis and post-endocytic trafficking 
Strategy Presumed effect Original reference Gene therapy 
related reference 
DN-Eps15 Inhibits CDE 
96
 DN-Eps15 
DN-AP-2 (D3Δ2) Inhibits CDE 
96
 DN-AP-2 (D3Δ2) 
DN-AP180 Inhibits CDE 
97
 DN-AP180 
DN-dyn2 (K44A) Blocks dynamin-dependent 
endocytosis 
27,98-101
 DN-dyn2 (K44A) 
DN-cav-1 Inhibits caveolae-mediated CIE 
3
 DN-cav-1 
DN-clathrin HC Inhibits CDE 
102
 DN-clathrin HC 
KO-AP-2 Inhibits CDE 
93
 KO-AP-2 
KO-clathrin HC Inhibits CDE 
93
 KO-clathrin HC 
KO-epsin Inhibits CDE 
95
 KO-epsin 
KO-cav-1 Inhibits caveolae-mediated CIE 
92
 KO-cav-1 
DN-ARF6 Inhibits ARF6-regulated CIE 
3
 DN-ARF6 
DN-RhoA Inhibits RhoA-regulated CIE 
3
 DN-RhoA 
DN-CDC42 Inhibits CDC42-regulated CIE 
3
 DN-CDC42 
DN-Rab5(S34N) Inhibits trafficking from early 
endocytic vesicles to SE 
103
 DN-Rab5(S34N) 
DN: dominant negative; KO: RNAi knock out 
 
In this paper, we have focused on the use of inhibitors to selectively block different endocytic 
pathways. In the 90’s, a number of pharmacological treatments have been discovered that 
differentially affect the pinocytic pathways 104. In Table 2 a summary is given of the most important 
chemical compounds which have been used in literature to interfere with endocytic pathways, 
together with references out the research field of non-viral gene delivery with the therein used 
concentration and cell type. Although the ease of use makes these inhibitors very popular to study 
endocytic pathways, there are some serious considerations to be made before using them, as it can 
be extremely tricky to extrapolate the inhibition protocols from literature to your specific 
experimental setup. As we have shown in this paper, the treatment with endocytosis inhibitors 
exhibits extreme cell type variations, lacks in several cell lines specificity and often causes side effects 
on the cellular morphology. 
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First, we have clearly shown that almost all tested inhibitors exhibit cell type dependent 
cytotoxic effects. E.g. high chlorpromazine concentrations had no effect on the RPE cell viability, 
while all other tested cell lines, especially the Cos-7 cells, appeared to be very sensitive to it. In 
contrast, filipin was only toxic for RPE cells and also mBCD showed cell specific cytotoxicity, especially 
at high concentrations. Finally, although the effect was limited, K+-depletion decreased the cell 
viability of both HuH-7, Cos-7 and Vero cells, but not of RPE cells. Taking in account these observed 
toxicity effects, using endocytosis inhibitors to study the uptake of non-viral gene complexes will be 
even more complicated, as it is very likely that the cells will not survive the stress of both pre-
incubation with the inhibitor and a subsequent incubation with often cytotoxic cationic gene 
complexes again in the presence of inhibitor. Secondly, very few endocytic inhibitors are specific to a 
single pathway, making it necessary to implement different types of inhibition to determine the 
contribution of a specific cell entry pathway to non-viral uptake. E.g. mBCD showed (partial) 
inhibition of both CDE and CIE in all tested cell lines, while Huth et al. have reported an enhanced 
liposome uptake after mBCD treatment 50. In our experiments, some treatments did show good 
specificity, e.g. filipin and chlorpromazine, although the first treatment was shown to be slightly toxic 
in case of RPE cells and the latter one even in all tested cell lines, again limiting the reliability of the 
observed effects. Finally, we have also shown that most inhibitors exhibit pronounced effects on the 
cellular morphology. For several inhibitors it is already known that they exhibit side effects, including 
effects on post-endocytic trafficking of gene carrier complexes 45. Therefore, one must be vigilant of 
possible side effects when using endocytosis inhibitors, as this can often lead to contradictory 
results 105. It is e.g. known that amyloride lowers the cytosolic pH 106, while other examples are 
summarized in Table 2, column 3. It is clear that a detailed knowledge of the effects of inhibitors on 
cells  is an absolute prerequisite for a reliable interpretation of the obtained results. 
Regardless the approach you choose, the complete inhibition of endocytic pathway will 
rarely be achieved. It should also be realized that different pathways may be operating 
simultaneously or may be upregulated when one pathway is blocked, i.e. inhibition of one route may 
lead to an increased uptake via an alternative route 107. Finally it should be noted that the existence 
of unknown endocytic processes or even worse, the induction of non-natural pathways due to the 
cellular manipulations, cannot be excluded. Based on our results, we can state that performing the 
correct control experiments to test the efficacy of the inhibitors is of key importance to be able to 
come to reliable conclusions. In literature, however, there are only very few publications in which the 
efficiency and/or specificity of endocytosis inhibitors have been tested 47-49. 
While it is clear that endocytosis inhibitors should be used with care, we still believe they 
provide for an elegant and practical way to study the role of specific endocytic pathways, especially 
when they are combined with other approaches like biological inhibitors or colocalization studies. It 
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will be very important for new and hopefully more specific endocytosis inhibitors to become 
available, such as e.g. the recently discovered dynasore 76. Also the further development of new 
specific biomarkers will be useful and even necessary. It has for instance been shown that cholera 
toxin, which was thought to be a specific biomarker for caveolae-mediated endocytosis, is not 
exclusively taken up via caveolae 25, this is in contrast to others who claim that the cholera toxin 
uptake is not inhibited by chlorpromazine in Cos-7 50. We expect that new suitable biomarkers will 
become available when recombinant proteins will be found which are specifically taken up through 
macropinocytosis, CIE or caveolae-mediated uptake. 
 
CONCLUSION 
 
In this work we have given experimental evidence in combination with information from 
literature that care should be taken when using chemical inhibitors to study endocytic processes. The 
inhibitory effect is extremely cell type dependent and so is the concentration threshold of cellular 
toxicity. Moreover, the chemical compounds can exhibit severe side effects on cellular morphology 
and the inhibition is not always as specific for a certain endocytic pathway as is sometimes stated in 
literature. In any case it is clear that the specificity is cell type dependent. Therefore, treatments with 
endocytosis inhibitors which have been applied successfully on one cell line should not be blindly 
transferred to other cell lines without performing the necessary control experiments. On the other 
hand we would like to point out that the use of chemical inhibitors for studying intracellular 
trafficking of gene carrier complexes does not have to be banned completely as long as proper care is 
taken. For different cell types the inhibitor efficacy and specificity can be tested by using suitable 
biomarkers. To conclude, we plead for an approach where several complementary methods are 
combined, such as the combination of inhibition experiments with biomarker colocalization studies. 
We believe this is the only way to avoid erroneous conclusions and to come to reliable information 
regarding intracellular trafficking of gene carriers. 
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ABSTRACT 
 
SiRNA mediated inhibition of oncogenes or viral genes may offer great opportunities for the 
treatment of several diseases such as hepatocellular carcinoma and viral hepatitis. However, the 
development of siRNAs as therapeutic agents strongly depends on the availability of safe and 
effective intracellular delivery systems. Poly(β-amino esters) (PbAEs) are, in contrast to many other 
cationic polymers evaluated in siRNA delivery, biodegradable into smaller, non-toxic molecules. We 
show for the first time that PbAE:siRNA complexes, containing 1,4-butanediol (PbAE1) or 1,6-
hexanediol (PbAE2) diacrylate-based polymers, induced efficient gene silencing in both hepatoma 
cells and primary hepatocytes without causing significant cytotoxicity. Furthermore, carriers that 
slowly release the siRNA into the cytoplasm and hence induce a prolonged gene silencing are of 
major clinical interest, especially in fast dividing tumour cells. Therefore, we also studied the duration 
of gene silencing in the hepatoma cells and found that it was maintained for at least 5 days after 
siRNA delivery with PbAE2, the polymer with the slowest degradation kinetics. From the time-
dependent cellular distribution of these PbAE:siRNA complexes we suggest that the slowly degrading 
PbAE2 causes a sustained endosomal release of siRNA during a much longer period than PbAE1. This 
may support the hypothesis that the endosomal release mechanism of PbAE:siRNA complexes is 
based on an increase of osmotic pressure in the endosomal vesicles after polymer hydrolysis. In 
conclusion, our results show that both PbAEs, and especially PbAE2, open up new perspectives for 
the development of efficient biodegradable siRNA carriers suitable for clinical applications. 
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Prolonged Gene Silencing in Hepatoma 
Cells & Primary Hepatocytes after siRNA 
Delivery with Biodegradable PbAEs 
 
INTRODUCTION 
 
Hepatocellular carcinoma (HCC) is worldwide one of the most prevalent human cancers, with 
~600 000 new cases diagnosed annually and almost as many deaths 1. For the vast majority of HCC 
cases no effective therapy is available. Hence, new treatment approaches for HCC are urgently 
needed 2. The major cause of HCC is chronic hepatitis B (HBV) and hepatitis C virus (HCV) infection. 
The former can be prevented by vaccination and also different treatments are currently available, 
e.g. with nucleo(s)(t)ide analogues 3. In contrast, there is no vaccine available against HCV infection 
and all HCV treatments so far rely on the antiviral activity of pegylated interferon alfa (IFN-α) that is 
administered alone or in combination with ribavirin 4. Unfortunately, only a part of the HCV patients 
clear the virus during therapy and for the non-responders currently no alternative treatment exists 5. 
Clearly, more effective treatments are needed against HCV and HCC. Therefore, the selective 
inhibition of highly active genes involved in liver oncogenesis 6 or HCV genes involved in viral 
replication 7-14 via RNA interference (RNAi) may offer great improvement in the treatment of HCC and 
HCV infections. 
RNAi is a naturally occurring post-transcriptional sequence-specific gene silencing mechanism 
that is initiated by double-stranded RNAs (dsRNAs) that are homologous in sequence to the target 
mRNA 15. These dsRNAs are enzymatically processed into 21-22 nucleotide small interfering RNAs 
(siRNAs) by the RNase III-like cellular enzyme Dicer 16. The generated siRNAs are subsequently 
incorporated into a silencing complex called RNA-induced silencing complex (RISC) that scans and 
cleaves mRNA in a sequence-specific manner 17. 
Therapeutic RNAi applications mainly depend on the availability of safe delivery systems that 
cause a sufficient cellular delivery of siRNA. DNA molecules encoding short hairpin RNAs (shRNAs) 
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that are subsequently processed by Dicer into siRNAs, are often used to demonstrate the therapeutic 
potential of RNAi. Both viral and non-viral carriers have been used to deliver these DNAs. However, 
viral delivery of DNA encoding shRNA is, due to safety and production concerns, not feasible for 
therapeutic applications. Non-viral carriers are no suitable alternative as they lack the ability to 
efficiently deliver DNA into the nucleus 18. Additionally, it was suggested that HCV has evolved 
mechanisms to inhibit Dicer-dependent cleavage of longer dsRNAs like shRNAs 19,20. Therefore, to 
avoid the necessity of nuclear uptake involved with DNA delivery and safety concerns involved with 
viral carriers, the most desirable approach seems to be the cytoplasmic delivery of synthetic siRNAs 
by means of non-viral carriers. So far, non-viral carriers for delivering synthetic siRNA are mostly 
based on transfection with cationic lipids 21-25. Cationic polymers, such as polyethylenimine (PEI) and 
chitosan, have also been tested as delivery agents 26-29 but they are often less efficient 30 and more 
cytotoxic 31. 
Poly(β-amino esters) (PbAEs) are polyamines that are synthesized by Michael addition of 
either primary amines or bis (secondary amines) to diacrylate esters (Fig. 1A) 32. PbAEs are fully 
biodegradable via hydrolysis of their backbone esters to yield small molecular weight bis(β-amino 
acid) and diol products, which along with the parent polymer are significantly less toxic than many 
other polycations, such as PEI and poly(L-lysine) 33. Anderson et al. identified a library of PbAEs that 
transfect pDNA in Cos-7 cells as good as or even better than PEI 34. Additionally, several of the 
synthesized PbAEs were shown to be effective for in vivo pDNA delivery 35-37. Therefore, in this work, 
different PbAEs were synthesized and for the first time their capacity to deliver siRNA and to evoke a 
biological siRNA effect was tested. Two PbAEs that successfully delivered the siRNA in the cells were 
identified: PbAE1 (polymer 1; Fig. 1B) and PbAE2 (polymer 2; Fig. 1C). These were obtained by 
conjugation of respectively 1,4-butanediol diacrylate (PbAE1) and 1,6-hexanediol diacrylate (PbAE2) 
to 4,4’-trimethylenedipiperidine. Both polymers showed a strong gene silencing effect in both human 
hepatoma cells and primary rat hepatocytes. Furthermore, in contrast to PbAE1, PbAE2 was able to 
induce a prolonged gene silencing effect in the hepatoma cells. 
 
MATERIALS & METHODS 
 
Materials 
 
4,4’-Trimethylenedipiperidine, anhydrous dichloromethane (CH2Cl2), tetrahydrofurane (THF), 
triethylamine, insulin, glucagon, kanamycin monosulfate, streptomycin sulfate and ampicillin sodium 
salt were purchased from Sigma-Aldrich (Bornem, Belgium). Hydrocortisone hemisuccinate came 
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from Upjohn (Windsor, United Kingdom). 1,4-Butanediol diacrylate and 1,6-hexanediol diacrylate 
were purchased from Alfa Aesar Organics (Karlsruhe, Germany). SiRNA against firefly (Photinus 
pyralis) luciferase (pGL3), Alexa488-labelled pGL3 siRNA, negative control siRNA and jetSITM-ENDO 
were purchased from Eurogentec (Seraing, Belgium). All siRNAs were purchased in their annealed 
form, dissolved in RNase free water at a concentration of 20 µM, aliquoted and stored at -80°C. 
Dulbecco's modified Eagle medium (DMEM), OptiMEM, L-glutamine (L-Gln), heat-inactivated fetal 
bovine serum (FBS), G418 (geneticine) and penicillin/streptomycin (P/S) were obtained from 
Invitrogen (Merelbeke, Belgium). 
 
Synthesis of PbAE1 and PbAE2 
 
All glassware was flame-dried under vacuum before use. 37.8 mmol 1,4-butanediol diacrylate 
(in case of PbAE1) or 1,6-hexanediol diacrylate (in case of PbAE2) and 37.8 mmol 4,4’-
trimethylenedipiperidine were separately dissolved in 50 ml CH2Cl2. The 4,4’-
trimethylenedipiperidine solution was added dropwise to the 1,4-butanediol diacrylate (or 1,6-
hexanediol diacrylate) solution under vigorous stirring. The reaction mixture was placed in an oil bath 
at 50°C and the polymerisation was allowed to proceed during 48 hrs under a nitrogen atmosphere. 
After cooling to room temperature, the reaction product was precipitated in diethyl ether saturated 
with HCl. The precipitate was filtered and thoroughly washed with diethyl ether. A white powder was 
obtained after overnight drying under vacuum. The molecular weight of the polymers was 
determined by size exclusion chromatography using a Waters GPC system equipped with two PLgel 5 
micron MIXED-D, 300 x 7.5 mm columns (Polymer Laboratories, St.-Katelijne-Waver, Belgium). 
THF / 0.1 M triethylamine was used as mobile phase at a flow rate of 1 ml/min. The molecular weight 
of the polymers was calculated relative to polystyrene standards. 1H-NMR (300 mHz) spectra were 
recorded on a Varian Mercury 300 spectrometer in CDCl3 as solvent. The obtained chemical shifts δ 
were 4.12 (4H), 2.87 (4H), 2.52 (4H), 1.97 (4H), 2.63 (8H), 1.16 (12H) and 4.06 (4H), 2.91 (4H), 2.71 
(4H), 2.55 (4H), 2.01 (4H), 1.65 (8H), 1.37 (4H), 1.22 (12H) for PbAE1 and PbAE2, respectively. 
 
Preparation of siRNA complexes 
 
The synthesized PbAEs were dissolved in acetate buffer (100 mM, pH 5.4) at different 
concentrations depending on the desired nitrogen to phosphate (N:P) ratio (10:1, 20:1 and 30:1) of 
the PbAE:siRNA complexes and prior use filtered through a 0.22 µm membrane syringe filter. The 
PbAE:siRNA complexes were formed by adding an equal volume of PbAE solution to 0.5 µM siRNA, 
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followed by vigorously mixing. The resulting PbAE:siRNA complexes were incubated at room 
temperature for at least 30 min before addition to the cells. 
JetSITM-ENDO:siRNA complexes were prepared as described by the manufacturer. Briefly, the 
jetSITM-ENDO solution was diluted into OptiMEM and vigorously vortexed. After incubation at room 
temperature for 10 min, the jetSITM-ENDO mixture was added all at once to an equal volume of a 
0.5 µM siRNA solution, immediately vortexed for 10 sec and incubated at room temperature for 
15 min before addition to the cells. 
 
Characterization of siRNA complexes 
 
The average particle size and the zeta potential of the different siRNA complexes were 
measured by photon correlation spectroscopy (PCS) (Autosizer 4700, Malvern, Worcestershire, UK) 
and particle electrophoresis (Zetasizer 2000, Malvern), respectively. Before measurement, the 
jetSITM-ENDO:siRNA and PbAE:siRNA complexes were diluted 2-fold in 20 mM Hepes buffer pH 7.4 
and 0.1 M acetate buffer pH 5.4, respectively. The control JetSITM-ENDO:siRNA complexes had a size 
of 221 ± 5 nm and a zeta potential of 23 ± 4 mV. The results for the PbAE:siRNA complexes are 
summarized in Table 1. 
Native polyacrylamide gelelectrophoresis (PAGE) was used to study the complexation state 
of siRNA in the jetSITM-ENDO:siRNA and PbAE:siRNA complexes. Loading buffer containing 10 % 
glycerol was added to the siRNA complexes, containing 0.3 µg siRNA, and these samples were 
consequently loaded on a gel that contained 20 % polyacrylamide in TBE buffer (89 mM Tris·borate 
pH 8.3 and 2 mM EDTA). The PAGE gel was subjected to electrophoresis at 100 V for 2 hrs and the 
siRNA was visualized by UV transillumination using 1:10 000 diluted SYBR Green II RNA stain 
(Molecular Probes, Merelbeke, Belgium) prior to photography. 
 
Production of recombinant adenoviruses 
 
For the generation of recombinant adenovirus the AdEasyTM Adenoviral Vector system 
(Stratagene, La Jolla, CA) was employed. The firefly luciferase open reading frame (ORF) was cloned 
in the pShuttle-CMV vector and was constitutively expressed under control of the CMV promoter. 
Subsequently, recombinant, replication-deficient adenoviruses expressing luciferase (Adluc) were 
generated following the standard protocol as described by He et al. 38. 
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Gene silencing in primary hepatocytes  
 
As human primary hepatocytes are difficult to obtain because of their increasing use in 
transplantation, rat primary hepatocytes were used in this study. These hepatocytes were isolated 
from outbred adult male Sprague-Dawley rats (200–250 g; Iffa Credo), with free access to food and 
water, as described previously 39. Cell integrity was tested by trypan blue exclusion.  
For gene silencing experiments, rat hepatocytes were cultured (37°C, 5 % CO2, 100 % 
humidity) as a monolayer in 24-well plates at a density of 6 x 104 cells per cm² in DMEM containing 
0.5 U/ml insulin, 7 ng/ml glucagon, 10 % FBS and 1 % antibiotic mix (sodium ampicillin (10 μg/ml), 
kanamycin monosulfate (50 μg/ml), benzyl penicillin (7.3 IU/ml) and streptomycin sulfate 
(50 μg/ml) 40. After 4 hrs, the medium was renewed with the same medium as described above but 
supplemented with 7.5 μg/ml hydrocortisone hemisuccinate and incubated overnight. Prior to 
transfection with the siRNA complexes, the hepatocytes were transduced with replication-deficient 
adenoviruses expressing firefly luciferase at a multiplicity of infection (MOI) of 50. Subsequently, 
30 min after addition of the adenoviral vectors, the PbAE:siRNA or jetSITM-ENDO:siRNA complexes, 
containing 25 pmol siRNA, were added to the cells and incubated for 4 hrs at a final concentration of 
50 nM. The remaining viruses and siRNA complexes were removed and replaced by 1 ml culture 
medium. Thirty hours later, cells were lysed with 80 µl passive lysis buffer (PLB; Promega, Leiden, The 
Netherlands) under vigorous shaking. Luciferase activity was determined with the Promega luciferase 
assay kit according to the manufacturer’s instructions and expressed in relative light units (RLU). 
Briefly, 100 µl substrate was added to 20 µl sample and after a 2 sec delay, the luminescence was 
measured during 10 sec with the GloMaxTM 96 luminometer with injector. To correct for the amount 
of cells per well, the protein concentration was determined with the BCA kit (Pierce, Rockford, IL). 
Two hundred microliter mastermix, containing 50 parts reagent A to 1 part B, was mixed with 20 µl 
cell lysate, incubated at 37°C for 30 min and measured on a Wallac Victor2 absorbance plate reader 
(PerkinElmer Life Sciences, Boston, MA) at 590 nm. For each carrier, the RLU value per mg protein of 
the anti-luciferase siRNA transfected cells was compared to the RLU value per mg protein of the 
mock siRNA transfected cells and expressed as luciferase expression level (%). 
 
Gene silencing in human hepatoma cells  
 
The human hepatoma cell lines HuH-7 and HuH-7_eGFPLuc, stably expressing firefly 
luciferase, were cultured (37°C and 5 % CO2) in DMEM:F12 supplemented with 2 mM L-Gln, 10 % 
heat-inactivated FBS and 100 U/ml P/S. 
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HuH-7_eGFPLuc cells stably expressing eGFP-Luciferase were generated by transfecting 
HuH-7 cells with the vector pEGFPLuc (Clontech, Palo Alto, USA) as previously described 41. 
For gene silencing experiments, HuH-7_eGFPLuc cells were seeded into 24-well plates at a 
density of 5 x 104 cells per cm2 and allowed to attach overnight. Cells were washed with PBS and to 
each well the siRNA complexes, containing 25 pmol siRNA, were added at a final concentration of 
50 nM. After 4 hrs, the remaining complexes were removed and replaced by 1 ml culture medium. 
Thirty hours later, cells were lysed with 80 µl CCLR buffer (Promega), and luciferase activity and 
protein concentration were determined as described above. 
For the long term gene silencing experiments, cells were seeded in 24-wells at a density of 
5 x 104 cells per cm2 and allowed to attach overnight. All transfection experiments were performed 
as described above, but in duplex. Twenty four hours later, one sample was lysed (day 1) while the 
parallel sample was trypsinized and 1:5 diluted into four 24-wells. These were incubated at 37°C and 
cells were lysed at day 2, 3, 4 or 5. After collection of all samples, luciferase activity and protein 
concentration were determined as described above. To correct for the dilution of the cells after 
trypsinization, the RLU value per mg protein of the anti-luciferase transfected cells was compared to 
similarly treated cells, transfected with mock siRNA and expressed as luciferase expression level (%). 
 
Cytotoxicity assay 
 
The influence of the siRNA complexes on the cell viability was determined using the CellTiter-
Glo Assay (Promega) and the tetrazolium salt-based colorimetric MTT assay (EZ4U; Biomedica, 
Vienna, Austria). 5 x 104 cells per cm2 were seeded into 96-well plates and allowed to adhere. After 
24 hrs, cells were washed with PBS and incubated either with the PbAE:siRNA complexes, the jetSITM-
ENDO:siRNA complexes or free carrier. After 4 hrs, the remaining siRNA complexes or carriers were 
removed from the cells and replaced by culture medium. For the CellTiter-Glo Assay, the 96-well 
plate was incubated at 37°C for 24 hrs, subsequently incubated at room temperature for 30 min and 
100 µl CellTiter-Glo reagent was added to each well. After shaking the plate for 2 min and 10 min 
incubation at room temperature, the luminescence was measured on a GloMaxTM 96 luminometer 
with 1 sec integration time. In case of the EZ4U assay, medium was removed after 24 hrs and 20 μl 
EZ4U substrate, along with 180 μl culture medium, was added to each well. After 4 hrs incubation at 
37°C reduced formazan was measured at 450 nm and 630 nm on a Wallac Victor2 absorbance plate 
reader. 
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Confocal microscopy 
 
Primary hepatocytes or HuH-7 cells were seeded on sterile glass bottom culture dishes 
(MatTek Corporation, Ashland, MA) at a density of 5 x 104 cells per cm2 and allowed to attach 
overnight. PbAE:siRNA and jetSITM-ENDO:siRNA complexes, containing Alexa488-labelled siRNA, were 
prepared and added to the cells as described above. The distribution of the fluorescence in the cells 
was visualized using a Nikon C1si confocal laser scanning module attached to a motorized Nikon 
TE2000-E inverted microscope (Nikon Benelux, Brussels, Belgium). A non-confocal diascopic DIC 
(differential interference contrast) image was collected simultaneously with the confocal images. For 
lysosome staining, cells were incubated for 60 min with 1:15 000 diluted Lysotracker Red (Molecular 
Probes) prior to image recording. Images were captured with a Nikon Plan Apochromat 60 x oil 
immersion objective lens (numerical aperture of 1.4) using the 488 nm and 639 nm line from an Ar-
ion and a diode laser for the excitation of the Alexa488-siRNA and Lysotracker Red, respectively. 
 
RESULTS & DISCUSSION 
 
Synthesis and characterization of PbAEs 
 
Different PbAEs were synthesized (Fig. 1A) and the structures of the most efficient PbAEs for 
siRNA delivery are shown in Fig. 1B and 1C. Polymer 1 (PbAE1; Fig. 1B) and polymer 2 (PbAE2; Fig. 1C) 
were obtained by reaction between 4,4’-trimethylenedipiperidine and respectively 1,4-butanediol 
diacrylate and 1,6-hexanediol diacrylate. The structure of PbAE1 and PbAE2 was verified by 1H NMR 
spectroscopy and the integration of the peaks yielded values as expected for the proposed chemical 
structures (see Materials and Methods). As these PbAEs were not soluble at a neutral or basic pH, 
they were dissolved in acetate buffer with pH 5.4. The average molecular weight of the polymers was 
determined by size exclusion chromatography and found to be 18 kDa for PbAE1 and 22 kDa for 
PbAE2. 
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Figure 1. The synthesis of PbAEs by Michael addition between a bis (secondary amine) (1) or a primary amine 
(2) and a diacrylate is schematically represented in (A). PbAE1 (B) and PbAE2 (C) were synthesized by a Michael 
addition between 4,4’-trimethylenedipiperidine and 1,4-butanediol diacrylate, and between 4,4’-
trimethylenedipiperidine and 1,6-hexanediol diacrylate, respectively. 
 
Characterization and cytotoxicity of the PbAE:siRNA complexes 
 
The ability of PbAEs to complex siRNA was tested via polyacrylamide gel electrophoresis 
(PAGE) (Fig. 2). 
 
Figure 2. Native 20 % PAGE of free (i.e. non-complexed) siRNA, PbAE1:siRNA and PbAE2:siRNA complexes with 
N:P ratios 10:1, 20:1 and 30:1. In all lanes 0.3 µg siRNA was loaded after addition of 10 % glycerol and the 
samples were subsequently subjected to electrophoresis at 100 V for 2 hrs. The siRNA was visualized after 
staining the gel with SYBR

 Green via UV illumination. 
 
As no bands were present at the position of free siRNA, both PbAE1 and PbAE2 were able to 
bind siRNA. In case of PbAE2 N:P ratio 20:1 and 30:1 no fluorescence signal was visible in the lanes, 
which indicates that no free siRNA is present in these complexes. However, the lanes containing the 
PbAE1:siRNA complexes showed, independent of the N:P ratio, a siRNA band just beneath the slots. 
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Similarly, PbAE2:siRNA complexes with a N:P ratio 10:1 also displayed some traces of siRNA at this 
position. This may indicate the presence of partially complexed siRNA that is able to enter the gel, 
but that migrates slower than the free siRNA. Alternatively, the electric field may have caused a 
dissociation of these PbAE:siRNA complexes, generating free siRNA that entered the gel at a later 
time point than the free siRNA present in the first lane. Nevertheless, these observations indicate 
that PbAE2 forms tighter complexes with siRNA than PbAE1. 
Besides the ability to bind siRNA, we also determined the size and zeta potential of the 
PbAE:siRNA complexes (Table 1). PbAE1:siRNA complexes were, except at N:P ratio 30:1, smaller 
than PbAE2:siRNA complexes and their zeta potential clearly increased as a function of the N:P ratio. 
In contrast, the zeta potential of PbAE2:siRNA complexes was more or less independent of the N:P 
ratio. In general, both PbAEs were able to form relatively small siRNA complexes with a positive 
surface charge, a feature known to facilitate cellular binding and uptake.  
 
Table 1. The particle size and zeta potential of the different PbAE:siRNA complexes. As indicated, PbAE:siRNA 
complexes were made at three different nitrogen to phosphate (N:P) ratios. Mean values with corresponding 
standard deviations are shown (n = 5). 
 particle size (nm) zeta potential (mV) 
PbAE1:siRNA   
N:P 10:1 326 ± 14 15 ± 3 
N:P 20:1 315 ± 6 20 ± 2 
N:P 30:1 380 ± 9 31 ± 1 
PbAE2:siRNA   
N:P 10:1 517 ± 29 23 ± 3 
N:P 20:1 457 ± 24 13 ± 3 
N:P 30:1 374 ± 23 18 ± 3 
 
Before performing siRNA transfection experiments, the cytotoxicity of PbAEs (data not 
shown) and PbAE:siRNA complexes (Fig. 3) was assessed by quantifying the intracellular ATP levels 
after transfection. Measuring ATP levels is a sensitive marker of cell viability. Indeed, within minutes 
after a loss of membrane integrity, cells lose the ability to synthesize ATP. Additionally, endogenous 
ATPases destroy any remaining ATP. We found that the free PbAEs and PbAE:siRNA complexes only 
slightly reduced cell viability, with a maximal cytotoxicity of ~20 % in case of PbAE2:siRNA N:P 30:1. 
JetSITM-ENDO:siRNA complexes, which are commonly used for in vitro siRNA delivery and which are 
claimed to lack cytotoxicity, did indeed not decrease cell viability. Furthermore, we also performed 
an MTT-based cell viability test (EZ4U assay), a test that relies on the ability of live but not dead cells 
to reduce MTT into a colorimetric formazan product by active mitochondrial dehydrogenases. In this 
approach none of the free polymers or complexes showed significant cytotoxicity (data not shown) 
which can be explained by the fact that this test only detects severe cytotoxicity effects, in contrast 
to the ATP-based cytotoxicity test. 
CHAPTER 5 – PROLONGED GENE SILENCING AFTER SIRNA DELIVERY WITH BIODEGRADABLE PBAES 
 
 148 
 
Figure 3. Cell viability of HuH-7_eGFPLuc cells incubated with JetSI
TM
-ENDO:siRNA, PbAE1:siRNA and 
PbAE2:siRNA complexes. The siRNA complexes were removed from the cells after 4 hrs and the cell viability of 
the cells was determined after 24 hrs by measuring the intracellular ATP levels. The metabolic activity of non-
treated cells was arbitrarily set at 100 % an all data are shown as mean ± SD (n=3). 
 
Cellular uptake of PbAE:siRNA complexes by primary hepatocytes 
 
To tackle viral hepatitis, the siRNA molecules must be delivered to primary hepatocytes. 
Although numerous mechanical, electrical, and chemical delivery methods have been applied, 
efficient transfer of siRNAs into primary cells is restricted to only a few cell types 42. To study cellular 
uptake, one of the first steps in siRNA delivery, we visualized the cellular entry of the PbAE:siRNA 
complexes in primary hepatocytes via confocal laser scanning microscopy (CLSM). PbAE:siRNA 
complexes containing Alexa-488 labelled siRNA (green colour in Fig. 4) were incubated during 4 hrs 
with primary hepatocytes and the lysosomes were visualized using the Lysotracker Red (red colour 
in Fig. 4). Fig. 4 (A through I) shows the outcome of a typical uptake experiment analysed by CLSM. 
After 4 hrs, all siRNA complexes gave rise to a punctuated green non-homogeneous distribution 
pattern of the siRNA inside the cell, which is indicative of an endocytotic uptake mechanism. This is 
confirmed by co-localization of the green pattern with the red labelled lysosomes. PbAE:siRNA 
complexes are thus clearly taken up by the hepatocytes by endocytosis, but they do not show a clear 
cytoplasmic localization of the siRNA after 4hrs and not even at 24 hrs (data not shown), which is 
needed to evoke a RNAi-mediated inhibitory effect. 
PROLONGED GENE SILENCING AFTER SIRNA DELIVERY WITH BIODEGRADABLE PBAES – CHAPTER 5 
 149 
Gene silencing in primary rat hepatocytes 
 
The ability of PbAE:siRNA complexes to induce gene silencing of viral genes was tested in 
primary rat hepatocytes transduced with replication-deficient adenoviruses expressing firefly 
luciferase. As a control, complexes containing non-specific siRNA, i.e. siRNA with no known target in 
the cells, were added to the cells under identical conditions to ascertain that the reduction in gene 
expression was due to a specific siRNA effect and not to non-specific effects like interferon induction. 
The gene silencing observed 30 hrs after the adenoviral transduction was independent of the N:P 
ratio and equalled ~55% and ~65% for the PbAE1:siRNA and PbAE2:siRNA complexes, respectively 
(Fig. 5). Our lipid-based reference siRNA complexes (JetSITM-ENDO:siRNA complexes) were much less 
efficient and silenced only 30% of the luciferase expression in primary hepatocytes. Additionally, 
both polymers were also used to target the endogenous connexin (Cx) proteins Cx32 and Cx43, the 
building stones of gap junctions controlling direct communication between cells. In both cases a 
strong gene silencing was observed by western blotting (data not shown). 
 
Figure 4. Confocal images of the cellular uptake of jetSI
TM
-ENDO:siRNA (A till C), PbAE1:siRNA (N:P 10:1) (D till 
F) and PbAE2:siRNA (N:P 30 ratio) complexes (G till I) 4 hrs after addition to primary rat hepatocytes. (A), (D) 
and (G) are non-confocal DIC images. Images (B), (E) and (H) display Lysotracker

 Red labelled lysosomes and 
(C), (F) and (I) display Alexa488-labelled siRNA. Microscopical analysis was performed using a confocal laser 
scanning microscope. The white bar equals 10 µm. 
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Figure 5. Relative luciferase levels in primary rat hepatocytes transfected with jetSI
TM
-ENDO:siRNA, 
PbAE1:siRNA and PbAE2:siRNA complexes containing anti-luciferase siRNA. The gene silencing efficiency was 
obtained by comparison with mock siRNA-containing complexes, for which the luciferase level was arbitrarily 
set at 100 % and data are shown as mean ± SD (n=3). The represented control is the average of all mock 
transfected samples. 
 
These results imply that, although not clearly visible by CLSM after 4 hrs (Fig. 4) and not even 
after 24 hrs (data not shown), a portion of the siRNA molecules must be released from the 
endosomes after endocytotic uptake. Because of the recycling of the siRNA after degradation of a 
target mRNA, it can be expected that very low amounts of siRNA in the cytosol can cause an efficient 
gene silencing. Indeed, it has been calculated that ~300 siRNA molecules per cell are sufficient to 
reduce luciferase activity with 50 % 43. Such small amounts of cytosolic siRNA are most likely not 
visible via CLSM. Therefore, the absence of visible siRNA in the cytosol of our cells does not exclude 
that a small fraction is present in the cytosol that is causing the observed gene silencing effect. Since 
no fusogenic function is present in our polymers and based on the physicochemical properties, two 
possible mechanisms may mediate endosomal escape of the siRNA. First, PbAE:siRNA complexes may 
disrupt endosomes via the proton sponge mechanism that is considered to be responsible for the 
high transfection efficiency of PEI-based DNA complexes. The ‘proton sponge’ nature of PEI is 
thought to act as a strong buffer that prevents the pH drop inside endosomes. The endosomes try to 
overcome this high buffer capacity of PEI by pumping in more protons. To maintain charge neutrality, 
the influx of protons is accompanied by an influx of chloride ions. These ion influxes cause a drastic 
increase of the ionic strength inside the endosomes, which leads to an osmotic swelling and finally a 
physical rupture of the endosomes, resulting in the escape of PEI based DNA complexes from the 
endosomes 44. Alternatively, endosomal escape of our siRNA may also occur via an increase of the 
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colloidal osmotic pressure in the endosomes after degradation of the PbAE into low molecular 
weight fragments, as suggested by Murthy et al 45. 
 
Gene silencing in hepatoma cells 
 
In contrast to e.g. viral HCV RNA, the candidate target genes for siRNA therapeutics in 
tumour cells are stably and massively expressed. Therefore, we also tested the gene silencing 
efficiency of the PbAE:siRNA complexes in human hepatoma (HuH-7) cells that stably express the 
eGFP-luciferase fusion protein (HuH-7_eGFPLuc). In several reports, the targeted gene that needs to 
be silenced is introduced in the cells via the same carrier as the siRNA. In such experiments an 
efficient gene silencing is highly expected as the gene and the siRNA are co-delivered to the same 
cells. Furthermore, it was recently questioned whether simultaneous transfection of an exogenous 
gene and the siRNA is suitable to quantify RNA interference 46. Additionally, it is currently unknown 
whether siRNA-mediated knockdown of transiently expressed proteins is an acceptable quantitative 
surrogate for stably expressed proteins 47. In conclusion, targeting a stably expressed gene can be 
considered as a model for oncogene silencing and targeting a transient gene as a model for viral gene 
silencing, if the viral genome is not integrated in the host’s genome. Therefore, the stably transfected 
hepatoma cells used in this work are the most appropriate model for silencing of genes in tumour 
cells. 
 
Figure 6. Relative luciferase levels of HuH-7_eGFPLuc cells transfected with jetSI
TM
-ENDO:siRNA, PbAE1:siRNA 
and PbAE2:siRNA complexes containing anti-luciferase siRNA. The gene silencing efficiency was obtained by 
comparison with mock siRNA-containing complexes, for which the luciferase level was arbitrarily set at 100 % 
and data are shown as mean ± SD (n=3). The represented control is the average of all mock transfected 
samples. 
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As demonstrated in Fig. 6, the extent of gene silencing of the PbAE:siRNA complexes depends 
on the N:P ratio. The gene silencing increased as a function of the N:P ratio and a gene silencing of 
~75 % was obtained at a N:P ratio 30:1. PbAE1:siRNA complexes with a higher N:P ratios were due to 
cytotoxicity concerns not tested. The gene silencing of the PBAE2:siRNA complexes was also higher at 
higher N:P ratios, but at the highest N:P ratios it stagnated at ~60 %. With the jetSITM-ENDO:siRNA 
complexes a gene silencing efficacy of only 20 % could be detected. 
 
Prolonged gene silencing in hepatoma cells 
 
A major disadvantage of the current available non-viral carriers for synthetic siRNA delivery is 
that the period of effective gene silencing is very brief. It has been demonstrated that the rapid 
restoration of gene expression after delivery of synthetic siRNA is mainly due to dilution of the siRNA 
during cell division, and not to a rapid intracellular degradation of siRNA by nucleases 48. This implies 
that prolonged gene silencing after siRNA delivery is of major importance for siRNA delivery to 
especially tumour cells, which exhibit rapid growth with doubling times on the order of only a few 
days. Therefore, carriers that slowly release their siRNA in the cytoplasm could be of interest for 
therapeutic siRNA delivery to tumour cells. The only difference between PbAE1 and PbAE2 is the 4- 
or 6-carbon linkers situated between the esters in the repeat units, which implies variations in both 
charge density and hydrophobicity. It was found that these relatively minor changes in polymer 
structure do play an important role in determining the hydrolysis rate of the polymers when 
incubated in physiologically relevant media. Polyelectrolyte complexes containing PbAE1 and PbAE2 
eroded completely in ~50 hrs and ~6 days, respectively 49. Therefore, we wanted to analyze whether 
this difference in degradation rate could also influence the gene silencing kinetics of both 
PbAE1:siRNA and PbAE2:siRNA complexes. As discussed above, obtaining a sustained gene silencing 
is, due to dilution of the siRNA during cell division, most challenging in dividing cells. Hence, we 
monitored gene silencing up to 5 days after siRNA transfection in the HuH-7 hepatoma cells that 
stably expressed luciferase.  
In Fig. 7, huge differences in the gene silencing kinetics between both PbAE:siRNA complexes 
are shown. After siRNA delivery with PbAE1, we observed a gradual recovery of the gene expression 
(Fig. 7A). The rate of recovery inversely correlated with the N:P ratio of these siRNA complexes. 
Indeed, at an N:P ratio 10:1, the luciferase expression started to recover at day 2 and was completely 
restored at day 5. In contrast, the onset of recovery at N:P ratios 20:1 and 30:1 occurred later and at 
day 5 the luciferase level reached ~90% and ~60%, respectively. An increase in N:P ratio, and thus in 
polymer concentration, probably leads to more tight complexes that release their siRNA more slowly. 
This may explain why PbAE1:siRNA complexes with a higher N:P ratio can suppress gene expression 
PROLONGED GENE SILENCING AFTER SIRNA DELIVERY WITH BIODEGRADABLE PBAES – CHAPTER 5 
 153 
during longer periods. In sharp contrast to the PBAE1:siRNA complexes, the gene silencing was 
almost completely maintained until day 5 when PbAE2:siRNA complexes with a N:P 20 and especially 
30:1 were used. A small recovery in luciferase expression was observed when PbAE2:siRNA 
complexes at a N:P ratio of 10:1 were used. The observation that PbAE2 forms stronger complexes 
with the siRNA (see discussion of Fig. 2 above) is probably not the main reason for the more 
prolonged gene silencing observed with PbAE2. Indeed, at a N:P ratio of 10 PbAE2 also formed, like 
PbAE1, 'weaker' complexes with siRNA that were still able to cause a prolonged gene silencing 
(Fig. 7B). 
 
 
 
Figure 7. Long term gene silencing in HuH-7_eGFPLuc cells transfected with PbAE1:siRNA (A) and PbAE2:siRNA 
complexes (B) containing anti-luciferase siRNA. The gene silencing efficiency was obtained by comparison with 
mock siRNA-containing complexes, for which the luciferase level was arbitrarily set at 100 % and data are 
shown as mean ± SD (n=3). 
 
 
 
B 
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Time-dependent intracellular fate of siRNA delivered via PbAE  
 
To get more insight into the intracellular mechanisms that govern the prolonged gene 
silencing after siRNA delivery via PBAE2, we compared the time-dependent intracellular distribution 
of PbAE1:siRNA (N:P 10) and PbAE2:siRNA (N:P 30) complexes. PbAE1:siRNA (N:P 10) and 
PbAE2:siRNA (N:P 30) complexes containing Alexa-488 labelled siRNA (green colour in Fig. 8) were 
added to cultured HuH-7 cells and the intracellular fluorescence was monitored for 5 days. To 
visualize the lysosomes we again used Lysotracker Red (red colour in Fig. 8). 
 
 
Figure 8. Confocal images of the cellular distribution of siRNA 24 hrs (insert) and 5 days after addition of 
PbAE1:siRNA N:P ratio 10:1 (A-C) and PbAE2:siRNA complexes N:P 30:1 (D-F) to HuH-7 cells. (A) and (D) are 
non-confocal DIC images, (B) and (E) display Lysotracker Red

 labelled lysosomes and (C) and (F) show 
Alexa488-labelled siRNA. 
 
The inserts in Fig. 8 show the intracellular distribution of the labelled siRNA 24 hrs after 
transfection. After 24 hrs, a punctuated pattern, that co-localized with the Lysotracker Red, was 
observed with both PbAE:siRNA complexes. However, 5 days after transfection, a clear difference in 
the intracellular siRNA distribution pattern was visible. The intracellular fluorescence of the siRNA 
after delivery via PbAE1 (N:P 10) became weaker and the dotted fluorescence signal was replaced by 
a more diffuse distribution of the fluorescence. In contrast, the intracellular fluorescence of the 
siRNA after delivery via PbAE2 (N:P 30) showed at day 5 a similar intensity and intracellular 
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localization, i.e. in vesicles, as after 24 hrs. As stated above, a vesicular localization of the siRNA is not 
necessarily expected to result in a good RNAi effect, as the RNAi machinery is present in the cytosol. 
Therefore, the siRNA or the siRNA complexes will have to escape from the endosomes. 
With the slow degrading polymer (PbAE2) the siRNA remained in vesicles up to day 5 (Fig. 8E 
and 8F), while the siRNA signal became more weak and diffuse at day 5 with the fast degrading 
polymer (PbAE1) (Fig. 8B and 8C). If we correlate these observations with the duration of gene 
silencing (Fig. 7), it is tempting to speculate that the endosomal release kinetics of siRNA, and hence 
the duration of the gene silencing, are driven by the degradation kinetics of the PbAEs. This is in line 
with the hypothesis that the endosomal escape of the siRNAs or PbAE:siRNA complexes occurs via 
the above explained colloidal osmotic pressure hypothesis in which the osmotic pressure in the 
endosomes is due to the formation of small PbAE degradation products. The prolonged gene 
silencing with PBAE2 also implies that not all endosomes are ruptured at the same time. Such a 
continuous rupture of endosomes is very likely to occur as the kinetics of the osmotic pressure 
increase in the endosomes will also depend on the amount of PbAE in the endosomes and the latter 
is expected to vary from endosome to endosome. Therefore, the siRNA filled vesicles can be 
considered as a depot from which siRNA is continuously released in the cytoplasm during a time 
period that is mainly determined by the degradation kinetics of the PbAE. 
 
CONCLUSION 
 
Inhibition of highly active genes involved in liver oncogenesis or viral replication via siRNA 
delivery may offer great opportunities for the treatment of several diseases, such as HCC and HCV 
infections. Unfortunately, clinical applications of siRNAs are currently limited because no safe and 
efficient delivery systems are available. In this study we showed for the first time that biodegradable 
polymers (PbAEs) were able to induce efficient siRNA-mediated gene silencing of a viral (transduced) 
gene in primary rat hepatocytes and a stably expressed gene in hepatoma cells without causing 
significant cytotoxicity. However, besides the development of carriers that efficiently deliver the 
siRNA, there is also major clinical interest for siRNA carriers that slowly release the siRNA in the 
cytoplasm and hence induce a prolonged gene silencing effect. We showed that, in contrast to 
PbAE1, PbAE2 was also able to induce a long term gene silencing in the hepatoma cells (up to 5 days). 
Interestingly, the prolonged gene silencing of PbAE2-based siRNA complexes correlated with the 
slower degradation kinetics of PbAE2 and a prolonged vesicular localization of the siRNA. This 
supports the hypothesis that the release of the PBAE:siRNA complexes or siRNA is based on an 
increase in colloidal osmotic pressure in the endosomal vesicles after polymer hydrolysis. In this way, 
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the siRNA filled endosomal vesicles act as a siRNA depot from which siRNA is continuously released in 
the cytoplasm during a time period that is mainly determined by the degradation kinetics of the 
PbAE. We conclude that both PbAEs, and especially PbAE2, open up new perspectives for the 
development of efficient biodegradable siRNA carriers suitable for clinical applications. 
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ABSTRACT 
 
Non-viral gene delivery generally results in low transgene expression, likely due to poor intranuclear 
DNA delivery. In this study, we tried to improve the nuclear import by complexing pDNA with the NLS 
containing HIV-1 Tat peptide. We first showed that the peptide was indeed able to mediate nuclear 
translocation of BSA macromolecules and that the peptide could electrostatically interact with the 
pDNA, resulting in polydisperse particles. However, the formed Tat/pDNA complexes failed to 
significantly increase the transfection efficiency compared to naked pDNA transfection. Moreover, 
transfection efficiency could not significantly be enhanced after addition of the lysosomotropic 
compound chloroquine and cytoplasmic injected Tat/pDNA complexes did not translocate into the 
nucleus. Both observations indicate that the Tat peptide, once complexed with pDNA, was unable to 
interact with the nuclear import machinery, which was confirmed by a negative GST pull down assay. 
Taken together, these data demonstrate that the NLS containing HIV-1 Tat peptide is unable to 
improve nuclear import of pDNA by electrostatic interaction, probably because the NLS of the 
peptide is masked after electrostatic binding to pDNA.  
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Chapter 6 
Electrostatic HIV-1 Tat/pDNA Complexes 
as Non-viral Gene Delivery Vehicles 
 
INTRODUCTION 
 
Despite the several advantages of non-viral gene delivery carriers compared to their viral 
counterparts, low transfection efficiency still limits the usefulness of these vectors for clinical gene 
therapy applications. One important drawback in non-viral DNA delivery is nuclear import, as the 
nuclear membrane forms a closed barrier for DNA molecules. This nuclear import process is 
especially relevant in post-mitotic and quiescent cells, as these cells lack nuclear envelope (NE) 
breakdown. Because many cells that are targeted in gene therapy do not divide or divide very slowly, 
the entry of plasmids into the nucleus becomes a major limiting step in non-viral DNA transfer. 
In non-dividing cells, the only way to pass the NE, is through the nuclear pore complexes 
(NPCs) and this transport can be either passive or active, and both are size restricted. Molecules 
> 20-40 kDa require active transport 
1
, mediated by a nuclear localization signal (NLS), which interacts 
with components of the nuclear transport system, thereby initiating nuclear import 
2,3
. The classical 
NLSs consist of one or two clusters of mostly basic amino acids and the uptake is
 
initiated by binding 
of the NLS to members of the importin family. Most classical NLSs interact first with importin α and 
subsequently bind to the importin β receptor, anchoring the cargo-importin complex to the NPC and 
resulting in
 
transportation into the nucleus via the NPC by an energy-dependent
 
process 
4
. The 
nuclear import of some proteins with classical NLS, e.g. the HIV-1 Tat protein, is mediated by direct 
binding to importin β, without the need of importin α 5. 
Conjugating an NLS peptide to DNA could thus improve nuclear import of exogenous DNA, 
thereby improving transfection efficiency 
6,7
. In 1999 indeed, it was reported that covalent 
attachment of an NLS peptide to linear DNA could result in a 300-fold increase in transfection 
efficiency 
8
. 
The HIV-1 transactivator protein Tat is an 86-amino-acid protein that regulates viral 
transcription by recruiting cellular factors to the HIV promoter, by interaction with protein kinase 
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complexes, acetyltransferases, protein phosphatases and other factors (reviewed by 
9
). The protein 
possesses a high net positive charge at physiological pH, with nine amino acids being either arginine 
or lysine. This short stretch of amino acids highly enriched in basic residues is responsible for the NLS 
activity 
10
. 
Here, we evaluated the capacity of the HIV-1 Tat AA 37-72 (Tat) peptide to (1) transport large 
cargos (FITC-BSA) into the nucleus, (2) condense pDNA into small particles by electrostatic 
interactions, (3) induce nuclear localization of pDNA and (4) increase the pDNA transfection 
efficiency. 
 
MATERIALS & METHODS 
 
Materials 
 
Dulbecco's modified Eagle's medium (DMEM), L-glutamine (L-Gln), heat inactivated fetal 
bovine serum (FBS) and 100 U/ml penicilline-streptomycine (P/S) were supplied by GibcoBRL 
(Merelbeke, Belgium). The HIV-1 Tat peptide AA 37-72 (CFITKALGISYGRKKRRQRRRAPQGS-
QTHQVSLSKQ) was obtained from the EU Programme EVA (European Vaccine Against AIDS) 
Centralised Facility. The secreted alkaline phosphatase (SEAP) expression plasmid (pMet7 hβc SEAP) 
was a kind gift from Prof. Tavernier (Ghent University, Belgium). 
 
Cell culture 
 
Cos-7 cells (African green monkey kidney fibroblast-like cell line; ATCC number CRL-1651) and 
Vero cells (African green monkey kidney epithelial cells; ATCC number CCL-81) were cultured in 
Dulbecco's modified Eagle's medium (DMEM) containing 2 mM L-Gln, 10 % heat inactivated FBS and 
1 % P/S. All cells were grown at 37°C in a humidified atmosphere containing 5 % CO2. 
 
Preparation of FITC-BSA-Tat conjugates 
 
FITC-BSA was covalently coupled to the Tat peptide via a NHS-PEG-MAL linker (Shearwaters, 
Huntsville, AL). In a first step, 3.54 x 10
-8
 mol FITC-BSA was incubated with a 10-fold molar excess of 
NHS-PEG-MAL in 0.1 M NaHCO3 pH 8.3. After 1 hr, the reaction was stopped by adding HONH2.HCl 
and the excess of non-reacted linker was removed using a Microcon
®
 column (MWCO 30 kDa). The 
pH of the FITC-BSA-NHS-PEG-MAL solution was adjusted with 50 mM Hepes buffer pH 6.8, until it 
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reached pH 7. In a second step, the Tat peptide was incubated with a 10-fold excess of TCEP in Hepes 
buffer pH 7, to reduce the disulfide bonds and added to the FITC-BSA-NHS-PEG-MAL solution in a 10-
fold molar excess. The non-reacted Tat peptide was removed using Microcon
®
 column (MWCO 
30 kDa). Finally, the presence of the Tat peptide on the FITC-BSA molecule was confirmed by SDS-
PAGE, followed by Western blotting. 
 
Recombinant protein expression and purification 
 
All GST pull down assays were performed using the purified recombinant S. cerevisiae 
proteins Srp1p (importin α) and Kap95p (importin β). Importin α and the SV40 NLS-GFP (SV40_eGFP) 
were expressed in E. coli and purified by nickel affinity chromatography as described previously
 11
. 
Briefly, both His6 tagged proteins were overexpressed
 
at 30°C in the Escherichia coli strain BL21 
(DE3). The E. coli
 
cells were grown in LB medium containing 30 µg/ml kanamycin, and
 
expression was 
induced at an optical density of 0.6 (600 nm)
 
by addition of 0.2 mM isopropyl-1-thio-β-D-
galactopyranoside for
 
5 hrs. Cells were harvested by centrifugation and resuspended in
 
buffer A 
(20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 1 mM
 
β-mercaptoethanol, 1 mM 
phenylmethylsulfonyl fluoride, and 0.1%
 
igepal). Following French press cell lysis and
 
separation of 
cell debris by high speed centrifugation, the soluble
 
supernatant was loaded onto a Hitrap nickel 
chelator column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), washed with buffer B (50 mM 
Na2HPO4 pH 7.4,
 
0.25 M NaCl), and eluted with a 0.5 M imidazole gradient. GST-importin β was 
expressed in E. coli. A total of 10 ml of saturated overnight cultures of transformed E. coli, was 
diluted 1:100 with Luria–Bertani medium (LB) containing ampicillin (100 µg/ml), and allowed to grow 
overnight at 30°C. After centrifugation at 3800 rpm for 20 min at 4°C, the pellet was resuspended in a 
1/50 culture volume of lysis buffer (50 mM Tris pH 8.0, 200 mM NaCl, 2.5 mM EDTA and 0.1 % 
Tween20). Then 1/50 000 0.1 M phenylmethylsulfonyl fluoride (PMSF) was added and the 
suspension was dissolved by vortexing and disrupted by French press. Cell debris was removed by 
centrifugation for 30 min at 4°C at 15 000 rpm. The crude lysate was added to equilibrated 
Glutathione Sepharose 4B beads (GE Healthcare Bio-Sciences AB) for 2 hrs at 4°C. The beads were 
subsequently washed 5 times for 10 min at 4°C. Once with lysis buffer, once with wash buffer 
(50 mM Tris pH 8.0, 200 mM NaCl), once with high-salt buffer (50 mM Tris pH 8.0, 500 mM NaCl) and 
finally twice with wash buffer. The beads, loaded with GST-importin β, were equilibrated in an 
elution buffer (50 mM Tris–HCl pH 8.0 and 0.1 % Triton X-100) and the fusion protein was eluted by 
the addition of 1 bed volume of ice-cold elution buffer containing 15 mM reduced glutathione, after 
being shaken overnight at 4°C. 
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In all cases, the supernatant was separated from the beads by centrifugation, analyzed by 
10 % SDS-PAGE and visualized by Coomassie
TM 
brilliant blue staining. Subsequently, protein 
concentration was determined by using a bradford protein assay and all
 
proteins were stored at -
80°C at a concentration of 10 mg/ml in
 
PBS containing 10 % glycerol. 
 
GST pull down assay 
 
GST-importin β was incubated with Glutathione Sepharose 4B beads at a concentration of 0.5 
mg/ml. Subsequently, 100 µl GST-importin β bearing beads were incubated with the appropriate 
components (importin α and/or eGFP_SV40 or Tat peptide) in a total volume of 500 µl PBSMT 
(1 x PBS, 5 mM MgCl2, 0.5 % Triton X-100)
 
for 3 hrs at 4°C and then washed three times with PBSMT 
and twice with PBSM. Both unbound and bound
 
fractions
 
were subsequently analyzed on a Precast 
10-20 % gradient SDS-PAGE gel (BioRad) and visualized by Coomassie
TM 
brilliant blue staining. 
 
Preparation of the Tat/pDNA complexes 
 
The pMet7 hβc SEAP plasmid (5 803 bp) has 11 606 negative charges, against 10 positive 
charges of one Tat molecule. The Tat/pDNA complexes were prepared by mixing 2.6 nM pDNA in a 
1:1 volume ratio with the Tat peptide in different plus:minus ratios. The mixtures were prepared in 
20 mM Hepes buffer pH 7.4 and incubated at room temperature for at least 30 min. 
 
Agarose gel electrophoresis assay 
 
For the agarose gel electrophoresis assay, Tat/pDNA complexes were prepared as described 
in the previous section and 5 x loading solution (30 % glycerol, 0.02 % bromophenol blue) was added. 
Subsequently, all samples were loaded on a 1 % agarose gel and run for 45 min at 80 V in 1 x TBE 
buffer (10.8 g/l Tris base, 5.5 g/l boric acid and 0.58 g/l EDTA). Subsequently, the gel was soaked in 
0.5 µl/ml EtBr for 20 min, washed and visualized by UV transillumination. 
 
Microinjection experiments 
 
For microinjection experiments, 2.5 x 10
5 
cells per cm
2 
were seeded onto sterile glass bottom 
culture dishes (MatTek Corporation, MA, USA) and allowed to adhere for 1 day. Microinjection 
experiments were performed using a Femtojet
®
 microinjector and an Injectman
®
 NI 2 
micromanipulator (Eppendorf). All injections were performed in the cytoplasm of the cells. 
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Immediately after injection, CLSM (BioRad MRC 1024; Hemel Hempstadt, UK) was used to visualize 
the fluorescence distibution in the cells.  
 
Confocal laser scanning microscopy (CLSM) 
 
Confocal images were captured with a 60 x water immersion objective and a krypton/argon 
laser (488 nm) for the excitation of the FITC label or YOYO-1
®
 iodide (Molecular Probes). Emission 
light was collected using a 500-530 nm band pass filter and pseudocoloring was performed by using a 
digital imaging system, Confocal Assistant (CAS; BioRad; Hemel Hempstadt, UK). 
 
Size and zeta potential measurement 
 
The average particle size and the zeta potential were measured by dynamic light scattering 
(DLS), using an Autosizer 4700 (Malvern, Worcestershire, UK), and by particle electrophoresis, using a 
Zetasizer 2000 (Malvern, Worcestershire, UK), respectively. Before measurement, the pDNA/Tat 
solutions were diluted 40-fold with 20 mM Hepes buffer pH 7.4. 
 
Cytotoxicity analysis 
 
The cytotoxicity of the Tat/pDNA complexes was determined using the tetrazolium salt based 
colorimetric MTT assay (EZ4U, Biomedica, Vienna, Austria) according to the manufacturer’s 
instructions. Briefly, 2.5 x 10
4
 cells/cm
2
 were seeded in a 24-well plate and allowed to adhere. After 
24 hrs, cells were washed twice with serum free medium and incubated with Tat/pDNA complexes, 
containing 0.18 µg pDNA per cm
2
 in serum free medium. After 2 hrs, the complexes were removed 
and cells were washed with culture medium. Finally, 40 µl EZ4U substrate with 260 µl culture 
medium was added per well and after 4 hrs incubation at 37°C the concentration of reduced 
formazan was measured at 450 nm on a Wallac Victor
2
 absorbance plate reader (Perkin Elmer-Cetus 
Life Sciences,
 
Boston, MA). Additionally, the absorbance was measured at 630 nm to correct for cell 
debris. 
 
Transfection experiments 
 
Cells were seeded into 6-well plates at 2.5 x 10
4
 cells/cm
2
 and allowed to attach overnight. 
The culture medium was removed from the wells and after two wash steps with serum free medium, 
the Tat/pDNA complexes, containing 1.6 µg plasmid DNA, were added to each well. In the 
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chloroquine experiments, the serum free medium was supplemented with 100 µM chloroquine 
12,13
. 
Cells were incubated at 37°C for 2 hrs and then the medium was replaced by 1 ml culture medium. 
SEAP activity was measured after 48 hrs incubation at 37°C. 
 
Reporter gene analysis 
 
To measure SEAP activity, 110 µl of the medium was incubated at 65°C for 30 min with 990 µl 
dilution buffer (0.1 M glycine, 1 mM MgCl2, 0.1 mM ZnCl2, pH 10.4) and 15 µl of 5.1 µg/µl 
4-methylumbelliferyl phosphate substrate (4-MUP, Sigma) in a cuvette. Samples were then incubated 
at room temperature for 30 min and sample fluorescence (λex/λem = 360/449 nm) was measured 
using the SLM-Aminco Bowman spectrofluorimeter (Urbana, IL). 
 
Cy5 pDNA labelling 
 
pDNA was covalently labelled with Cy5 using the LabelIT kit of Mirus Corporation (Madison, 
WI, USA) according to the manufacturer’s recommendations. Briefly, The Cy5 containing LabelIT 
reagent and 100 µg pDNA were mixed in 1 ml Hepes buffer (20 mM Hepes, pH 7.4) at Cy5:pDNA ratio 
(w:w) of 0.5:1 and incubated at 37°C for 1 hr. Subsequently, the labelled pDNA was separated from 
unattached label by precipitation in the presence of ethanol and 0.5 M NaCl and reconstituted in 
Hepes buffer. 
 
YOYO-1
®
 GST pull down assay 
 
Glutathione Sepharose 4B beads (5 µl) were incubated with increasing amounts of pDNA in 
the presence of 1:1000 YOYO-1
®
 iodide and diluted into a total volume of 100 µl with distilled water 
to determine the linear range of the assay. Subsequently, the GST pull down assay was performed as 
described earlier, but this time in the presence of Tat/pDNA complexes (containing 7.5 µg pDNA) and 
5 µl beads was analyzed on the presence of pDNA on a Wallac Victor
2
 fluorescence plate reader (λex = 
485 nm and λem = 530 nm). 
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RESULTS & DISCUSSION 
 
FITC-BSA-Tat and nuclear import 
 
As mentioned in literature, molecules > 20-40 kDa are excluded from the nucleus as they 
cannot pas the NPC channels by passive diffusion 
1
. The used Tat peptide contains a basic amino 
acids stretch that functions as an NLS, resulting in active nuclear transport after interaction with 
importin β. To test the functionality of the Tat peptide, we coupled it to FITC-BSA, a macromolecule 
with a molecular weight of ~68 kDa and consequently unable to passively cross the NE. Both 
molecules, FITC-BSA and FITC-BSA-Tat, were microinjected in the cytoplasm of Vero cells and their 
intracellular distribution was followed during time by CLSM. (Fig. 1). After 30 min, a strong 
fluorescence signal was visible in all nuclei of cells that were microinjected with FITC-BSA-Tat (Fig. 1B 
and 1D). In contrast, no fluorescence was present in the nuclei of cells microinjected with FITC-BSA 
(Fig. 1A and 1C). This experiment clearly shows that the used Tat peptide was indeed able to 
efficiently translocate macromolecules through the nuclear membrane that are normally excluded. 
 
 
Figure 1. CLSM images of the cellular localization of FITC-BSA (A,C) and FITC-BSA-Tat (B,D) 5 min (A,B) and 
30 min (C,D) after cytoplasmic microinjection. The scalebar represents 10 µm. 
 
As nuclear uptake by NLS-containing cargos is mediated by importins, we further confirmed 
Tat functionality by using a GST pull down assay to analyze the ability of the Tat peptide to interact 
with its transporter molecule importin β. Recombinant importine β, containing a GST tag, was 
purified and subsequently incubated with glutathione beads. After incubation, the Tat peptide was 
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added to the importin β bearing beads (with or without the presence of importin α), allowing 
importin β-Tat interaction. After washing, both bound and unbound fraction were analyzed on PAGE, 
together with a control sample, i.e. SV40_eGFP incubated with importin β beads in the presence or 
absence of importin α. As shown in Fig. 2, the Tat-peptide was indeed present in the bound fraction 
of the importin β bound beads, both in the presence and absence of importin α proving the Tat 
peptide-importin β interaction. The control sample, SV40_eGFP NLS, could only be found in the 
bound fraction when both importin α and β were present, which is in agreement with literature. 
 
 
Figure 2. Coomassie
 
brilliant blue staining of a precast 10-20 % gradient SDS-PAGE gel loaded with (1) unbound 
and (2) bound fractions of the control sample (SV40_eGFP) and Tat peptide sample incubated with 
GST-importin β (imp β) bound glutathione beads in the presence or absence of importin α (imp α). 
 
Characterization of Tat/pDNA complexes 
 
As the Tat peptide is strongly positively charged at physiological pH, it should have DNA 
binding ability by interacting with the negatively charged phosphate backbone of nucleic acids. To 
determine this DNA binding ability, increasing amounts of Tat peptide were incubated with a 
constant amount of pDNA, and the resulting effect on DNA mobility was analyzed via agarose gel 
electrophoresis (Fig. 3A). Additionally, the pDNA condensation ability of the Tat peptide was analyzed 
by measuring the fluorescence intensity of PicoGreen
®
 after addition to the Tat/pDNA complexes 
(Fig. 3B). 
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Figure 3. (A) pDNA mobility shift analysis of Tat/pDNA complexes. The pDNA (0.5 µg/ml) was electrophoresed 
alone or after pre-incubation with the Tat peptide in the indicated plus:minus ratio. (B) PicoGreen
® 
fluorescence 
measurement after incubation of pDNA with increasing amounts of Tat. 
 
As shown in Fig. 3A, the pDNA mobility in the agarose gel decreased when increasing 
amounts of Tat were added to the pDNA. At a plus:minus ratio of 2:1, the pDNA was completely 
immobilized. This retardation of pDNA was expected, as binding between Tat peptide and pDNA will 
neutralize the negatively charged pDNA and consequently decrease its mobility during 
electrophoresis. Additionally, if large Tat/pDNA complexes are formed, the DNA will become 
completely immobilized inside the slots of the gel. The data in Fig. 3A clearly show that the Tat 
peptide can indeed bind to the pDNA.  
Furthermore, the complexation degree of the Tat/pDNA complexes was measured with a 
condensation assay (Fig. 3B). An increasing pDNA complexation degree will result in a gradual 
decrease of PicoGreen
®
 fluorescence as this pDNA intercalating molecule cannot penetrate into tight 
complexes. Based on the obtained graph (Fig. 3B), we can conclude that at a plus:minus ratio of 2:1 
all pDNA is complexed into tight complexes, compared to ~60 % and 0 % at a 1:1 and 0:1 plus:minus 
ratio, respectively. 
To know whether the observed condensation is the result of the formation of (homogenous) 
particles, the Tat/pDNA complexes were also analyzed by particle size and zeta potential 
measurements. Particle size measurements via DLS were not possible on Tat/pDNA complexes with 
plus:minus ratios of 0:1 to 3:1. Only at a plus:minus ratio 4:1 we could measure the particle size and 
here we observed particles varying from 100 to 1000 nm. As an alternative, we used CLSM to 
visualize the Tat/pDNA complexes, by using YOYO-1
®
 iodide labeled pDNA. Fig. 4 shows that an 
increasing amount of positive charges leads to an increase in particle size. We also noticed a 
concentration dependency of the particle size. If we used Tat/pDNA mixtures that were 10 times 
more concentrated, particle size was at least ten times higher and showed a higher polydispersity 
(data not shown). 
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Figure 4. CSLM of YOYO-1
®
 labelled Tat/pDNA complexes at different plus:minus ratios. 
 
The zeta potential measurements of the Tat/pDNA complexes are shown in Fig. 5 and can be 
explained by the complex three dimensional structure of the pDNA. If no Tat peptide is added, the 
surface charge is strongly negative. If a small amount of positively charged Tat is added to the 
plasmid DNA, the surface charge almost reaches neutrality, since almost all added Tat peptides 
electrostatically interact with the first encountered, available negative charges of the pDNA at the 
outside of the supercoiled structure. When more Tat peptide is added, according to the zeta 
potential measurements, this suddenly causes a decrease in surface charge. This may be explained by 
a conformational change of the pDNA, leading to a higher exposure of negative groups at the outside 
upon addition of more Tat. Above a 1:1 plus:minus ratio, we observed a continuous increase in zeta 
potential, since the electrostatic Tat/pDNA interactions can’t cause additional conformational 
changes in the pDNA, but only results in more charge neutralization. A plus:minus ratio of 3:1 
eventually results in positively charged particles. 
 
Figure 5. Zeta potential of Tat/pDNA complexes at different plus:minus ratios. If no Tat peptide is added, the 
surface charge is strongly negative. If a small amount of positively charged Tat is added to the plasmid DNA, the 
surface charge almost reaches neutrality. When more Tat peptide is added, this causes again a decrease in 
surface charge and beyond a 1:1 plus:minus ratio, we observed a continuous increase in zeta potential. 
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Cytotoxicity of the Tat/pDNA complexes 
 
One important feature of gene carrier complexes is that they should be non-toxic when 
incubated with cells. The cytotoxicity of Tat/pDNA complexes was analyzed by incubating them with 
Vero cells and measuring the cell viability after 2 hrs using the MTT based EZ4U test. Fig. 6 clearly 
shows that none of the Tat/pDNA complexes exhibited severe cytotoxicity. 
 
Figure 6. Cytotoxicity of Tat/pDNA complexes on Vero cells with different plus:minus ratios. 
 
Transfection efficiency, cellular uptake and nuclear transport of Tat/pDNA complexes 
 
We examined the transfection efficiency of the Tat/pDNA complexes both in Vero and Cos-7 
cells by evaluating the expression of the complexed reporter gene, SEAP. Different plus:minus ratios 
were used. As seen in Fig. 7, the obtained transfection results were disappointing as the increase in 
transfection efficiency was rather limited compared to naked pDNA transfection. 
 
Figure 7. Transfection efficiency of Tat/pDNA complexes with different plus:minus ratios compared to naked 
pDNA in Cos-7 (black) and Vero cells (grey). 
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Measuring the transfection efficiency means measuring the end result of both cellular and 
nuclear transport of the pDNA. As transfection efficiency was barely enhanced, we analyzed both 
processes separately. To study the cellular uptake, Cy5 labelled pDNA was complexed with the Tat 
peptide in a plus:minus ratio of 2:1 and incubated with Vero cells. Subsequently, cellular distribution 
of the Cy5 labelled pDNA was evaluated by CLSM. After 3 hrs incubation, the Tat/pDNA complexes 
formed a punctuated pattern inside the cytoplasm (data not shown), indicating an endosomal uptake 
of the Tat/pDNA complexes. However, the Tat/pDNA complexes were apparently unable to escape 
from the endosomes as no cytoplasmic fluorescence signal was visible. The lysosomotropic 
compound chloroquine is known to mediated endosomal release 
14
, therefore Tat/pDNA transfection 
experiments were performed in the presence of chloroquine, but this had no effect on the 
transfection efficiency (data not shown). As endosomal release couldn’t enhance the efficiency of the 
Tat/pDNA complexes, one of the major limiting factors of the transfection efficiency of these 
complexes is probably the nuclear import. Therefore, we evaluated the effect of Tat on the nuclear 
transport of pDNA by microinjection of free Cy5 labelled pDNA and Tat/Cy5-pDNA complexes 
(plus:minus ratio 2:1). In both experiments, there was no nuclear signal visible, even not after 1 hr 
(data not shown), indicating the absence of nuclear pDNA import. 
 
Relation nuclear import and importin β binding 
 
We confirmed in Fig. 1 that Tat has the ability to translocate the FITC-BSA molecule through 
the nuclear membrane. However, when the peptide is electrostatically mixed with pDNA, no 
enhancement in transfection efficiency could be observed. The absence of nuclear uptake of pDNA 
after cytoplasmic injection of the Tat/pDNA complexes may indicate that (1) pDNA is a too large 
cargo for Tat or (2) Tat loses its NLS capacity after electrostatic binding to pDNA. To elucidate 
whether the latter hypothesis this true, we analyzed if the Tat peptide, complexed with the pDNA, is 
still able to interact with importin β by using the abovementioned pull down assay. Importin β 
bearing beads were mixed with Tat/Cy5-pDNA complexes and subsequently, the presence of 
fluorescent pDNA around the beads was analyzed using a fluorimeter. However, no pDNA could be 
detected around the beads, indicating the inability of the Tat/pDNA complexes to interact with 
importin β. This hypothesis was further confirmed by determining the presence of pDNA in the 
bound fraction using the DNA intercalating agent YOYO-1
®
 iodide. First, the linearity of the test was 
studied in the presence of beads and between 0 and 15 ng pDNA a linear curve was obtained, making 
this approach useful to determine the amount of pDNA. In parallel, also the bound fraction was 
analyzed on the presence of pDNA but again no pDNA could be detected, indicating the inability of 
the Tat/pDNA complexes to interact with the importin β beads. 
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One can speculate about the reasons of the obtained results that are in contrast with 
research published by e.g. Zanta et al. who found that attachment of an NLS peptide to DNA could 
result in a 300-fold increase in transfection efficiency 
8
. However, it should be mentioned that more 
studies were published in which coupling of an NLS peptide to DNA did not result in major increases 
in gene transfection. Attachment of the SV40 NLS to a specific region in the pDNA by using a peptide 
nucleic acid (PNA) molecule, resulted in a limited 5 to 8-fold increase 
15
. Covalent association of NLS 
peptides to the pDNA by photoactivation didn’t result in nuclear translocation after cytoplasmic 
injection 
16
. Covalent linkage of the SV40 NLS to linear DNA did not enhance transfection efficiency of 
cationic polymer based gene delivery systems 
17
. We demonstrated that Tat loses its importin β 
binding capacity when it is electrostatically bound to pDNA. The NLS domain in Tat is probably 
masked after electrostatic binding of Tat to the negatively charged pDNA, resulting in masking of the 
NLS domain. The latter has also been suggested by van der AA et al. 
17
. This hypothesis is supported 
by the finding that introducing a spacer between DNA and peptide can be beneficial for the 
efficiency 
18
. 
 
CONCLUSION 
 
Efficient non-viral gene delivery requires efficient DNA transport into the nucleus. As the 
nuclear membrane forms a tight barrier for molecules larger than 20-40 kDa, such as DNA, nuclear 
import can be considered as one of the major limiting steps, especially in non-dividing cells. One 
strategy to overcome this barrier is the attachment of components of the active nuclear import 
machinery to the pDNA molecules. The positively charged Tat peptide contains a basic amino acids 
stretch exhibiting NLS function. To enhance nuclear uptake of pDNA we prepared non-toxic, 
electrostatic Tat/pDNA complexes with different plus:minus ratios. Cytoplasmic microinjection of 
Tat/pDNA complexes did not result in nuclear import of the labeled pDNA. Similarly, the transfection 
efficiency was barely increased when the pDNA was electrostatically complexed with the Tat peptide. 
In agreement with these results, an in vitro test to evaluate binding of the Tat/pDNA complexes with 
the nuclear import machinery was negative, although the Tat peptide itself was able to interact with 
importin β. So, despite the fact that the Tat peptide was able to mediate nuclear import of BSA 
(~68 kDa), the same peptide was unable to translocate pDNA into the nucleus, probably due to 
masking of the NLS domain after electrostatic interaction between Tat and pDNA. Taken together, 
the results of our study indicate that electrostatically coupling of an NLS to pDNA does not 
necessarily enhance transfection efficiency. 
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ABSTRACT 
 
One of the major obstacles in non-viral gene transfer is the nuclear membrane. Attempts to improve 
the transport of DNA to the nucleus through the use of nuclear localisation signals or importin β have 
achieved limited success. It has been proposed that the nuclear pore complexes (NPCs) through 
which nucleocytoplasmic transport occurs are filled with a hydrophobic phase through which 
hydrophobic importins can dissolve. Therefore, considering the hydrophobic nature of the NPC 
channel, we evaluated whether a non-selective gating of nuclear pores by trans-cyclohexane-1,2-diol 
(TCHD), an amphipathic alcohol that reversibly
 
collapses the permeability barrier of the NPCs, could 
be obtained and used as an alternative method to facilitate nuclear entry of plasmid DNA. Our data 
demonstrate for the first time that TCHD makes the nucleus permeable for both high molecular 
weight dextrans and plasmid DNA (pDNA) at non-toxic concentrations. Furthermore, in line with 
these observations, TCHD enhanced the transfection efficacy of both naked DNA and lipoplexes. In 
conclusion, based on the proposed structure of NPCs we succeeded to temporarily open the NPCs for 
macromolecules as large as pDNAs and demonstrated that this can significantly enhance non-viral 
gene delivery. 
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Chapter 7 
Nuclear Accumulation of Plasmid DNA 
can be Enhanced by Non-selective Gating 
of the Nuclear Pore 
 
INTRODUCTION 
 
Viral vectors are efficient DNA delivery systems as they possess natural mechanisms to enter 
cells, to escape from endosomes and to transport their DNA into the nucleus. However, they also 
display important disadvantages, such as immunogenic response and safety risks when administered 
to patients. Non-viral carriers lack these disadvantages, but poor transfection efficiencies currently 
limit the usefulness of these vectors for gene therapy applications. The low gene transfer capacity of 
non-viral vectors is mainly due to their inability to translocate the therapeutic DNA into the cell 
nucleus. Indeed, it has been shown that microinjection of plasmid DNA (pDNA) in the cytoplasm of 
non-dividing cells resulted in <1 % gene expression, while a massive gene expression occurred when 
the pDNA was injected in the nucleus 
1-3
. In dividing cells the nuclear envelope disassembles on a 
regular base, which offers an opportunity for DNA to enter the nucleus 
4-6
. However, the DNA that is 
waiting in the cytoplasm for the next cell division is sensitive to degradation by nucleases. Therefore, 
methods that can enhance the nuclear uptake of DNA into nuclei of both non-dividing and dividing 
cells are urgently needed in non-viral-based gene therapy.  
Nucleocytoplasmic transport proceeds through the nuclear pore complexes (NPCs) which 
form channels in the nuclear envelope with a diameter of approximately 40 nm 
7,8
. Vertebrate NPCs 
have a mass of ~125 MDa and contain 30-50 different proteins, which are called nucleoporins. Small 
molecules with a molecular weight up to 30 kDa can passively diffuse through the NPC. In contrast, 
the translocation of larger macromolecules into the nucleus occurs via an active mechanism involving 
nuclear transport receptors. The majority of the nuclear transport pathways are mediated by 
receptors of the importin family. Proteins or other cargo molecules that carry a classical nuclear 
localization sequence (NLS) are recognized by importin α, which subsequently forms a complex 
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through its importin β binding domain with importin β 9. NLSs can be highly diverse in nature and 
range from the short bipartite classical NLS to extended protein domains, as is the case for histones 
or ribosomal proteins 
10
. To promote the nuclear import of DNA, NLS peptides, NLS containing 
proteins and even importin β 
11
 have been attached to DNA via several strategies: electrostatic 
12-17
 or 
covalent 
18-22
 binding, via protein-DNA interaction 
23,24
, via PNA clamps 
25-28
 and coupled to 
polymers 
29-31
, lipids 
32-37
 or recombinant lambda phage 
38
. Nevertheless, all these attempts to 
improve the transport of DNA to the nucleus through the use of NLSs or importin β have achieved 
only limited success. 
It has recently been shown that the nuclear uptake of macromolecules can be enhanced 
significantly by addition of the amphipathic molecule trans-cyclohexane-1,2-diol (TCHD) 
39
. The 
mechanism by which TCHD causes nuclear localization of macromolecules can be explained based on 
the inner channel properties of the nuclear pores. It is believed that these nuclear pores are filled 
with a hydrophobic phase through which importins, but not inert hydrophilic substrates, can 
dissolve. The addition of TCHD causes a temporary, non-selective gating of the pore and allows 
passage of molecules which would otherwise be rejected from passage. In other words, a non-
selective gating of the nuclear pore channel by TCHD renders the actual translocation through the 
pore channel independent of nuclear transport receptors. This can be explained by the fact that 
TCHD causes disruption of the hydrophobic interactions between the hydrophobic phenylalanine-
glycine (FG) repeats of the nucleoporines, which consequently causes collapsing of the permeability 
barrier of the NPCs. Importantly, the effect of TCHD is reversible and does not cause damage of the 
nuclear pores 
40
. 
In this paper we studied whether a non-selective gating of nuclear pores by amphipathic 
molecules like TCHD could also be used as an alternative method to facilitate nuclear entry of 
plasmid DNA. Therefore, we examined the effect of TCHD (a) on the nuclear import of 
macromolecules and pDNA and (b) on the transfection efficiency of naked pDNA and non-viral 
nanoparticles, such as poly- and lipoplexes (LPXs). In summary, we found that TCHD was able to 
make the nuclear membrane permeable for both high molecular weight dextrans and pDNA at non-
toxic concentrations. Furthermore, TCHD enhanced the transfection efficiency of both naked pDNA 
and DOTAP:DOPE-based LPXs, but had no effect on the linear PEI-based polyplexes. 
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MATERIALS & METHODS 
 
Materials 
 
Dulbecco's modified Eagle's medium (DMEM), L-glutamine (L-Gln), heat-inactivated fetal 
bovine serum (FBS), Phosphate Buffered Saline (PBS) and penicillin/streptomycin (P/S) were supplied 
by GibcoBRL (Merelbeke, Belgium). The secreted alkaline phosphatase (SEAP) expression plasmid 
was a kind gift from Prof. Dr. Tavernier (Ghent University, Belgium) and 22 kDa linear 
poly(ethyleneimine) (PEI) from Prof. Dr. Wagner (University of Munich, Germany). The pGL3-control 
plasmid and luciferase assay kit were obtained from Promega (Leiden, The Netherlands). 158 kDa 
tetramethylrhodamine isothiocyanate labelled dextran (TRITC-dextran) and TCHD were purchased 
from Sigma Aldrich. 1,2-Dioleoyl-3-Trimethylammonium-Propane Chloride Salt (DOTAP), 1,2-
Dioleoyl-sn-Glycero-3-Phosphoethanolamine (DOPE) and 1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-[Amino(Polyethylene Glycol)2000] (DSPE-PEG2000) were obtained from 
Avanti Polar Lipids (Alabaster, AL, US). 
 
Cell culture 
 
A549 (lung carcinoma cells; ATCC number CCL-185) and Vero (epithelial African green 
monkey kidney cells; ATCC number CCL-81) cells were cultured in DMEM containing 2 mM L-Gln, 
10 % heat-inactivated FBS, 1 % P/S and grown at 37°C in a humidified atmosphere containing 
5 % CO2. 
 
Fluorescent labelling of pDNA 
 
Plasmid DNA was covalently labelled with Cy5 using the LabelIT kit of Mirus Corporation 
(Madison, WI, USA) according to the manufacturer’s recommendations. Briefly, LabelIT reagent, 
containing Cy5, and 100 µg DNA were mixed in 1 ml Hepes buffer (20 mM Hepes, pH 7.4) at Cy5:DNA 
ratio (w:w) of 0.5:1 and incubated at 37°C for 1 hr. Subsequently, the labelled pDNA was separated 
from unattached label by precipitation in the presence of ethanol and 0.5 M NaCl and reconstituted 
in 20 mM Hepes buffer (pH 7.4).  
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Microinjection studies 
 
Microinjection studies were conducted using a Femtojet
®
 microinjector and an Injectman
®
 
NI 2 micromanipulator (Eppendorf, Hamburg, Germany). Vero cells
 
were chosen for these 
microinjection experiments as they have a well defined nucleus and large cytoplasm. Vero cells 
(2.5 x 10
4
 cells/cm
2
) were plated onto sterile glass bottom culture dishes (MatTek Corporation, MA, 
USA) and allowed to adhere for 1 day. The cells
 
were then washed with PBS and transferred into 2 ml 
serum free medium supplemented with 20 mM Hepes (pH 7.4) to improve the buffering capacity of 
the medium during
 
microinjection. 5 µl 158 kDa TRITC-dextran (1 mg/ml) or Cy5 labelled pDNA 
(1 mg/ml) was back-loaded into Femptotip
 
II microinjection needles and cells were injected using an 
injection pressure of 100 psi, a backpressure of
 
 30–50 psi and injection duration of 0.5 sec. Where 
mentioned, the medium was replaced after microinjection by TCHD containing serum free medium, 
supplemented with 20 mM Hepes (pH 7.4). 
To determine the cellular distribution, the fluorescence in the cells was visualized on 
different time points after microinjection using a Nikon C1si confocal laser scanning module attached 
to a motorized Nikon TE2000-E inverted microscope (Nikon Benelux, Brussels, Belgium). with a 60 x 
water immersion objective and the 561 nm and 638 nm laser lines for the excitation of the TRITC and 
Cy5 label, respectively. A non-confocal diascopic DIC (differential interference contrast) image was 
collected simultaneously with the confocal images. 
For the z-scan analysis of the fluorescence after cytoplasmic microinjection of the Cy5 
labelled pDNA (Cy5-pDNA), the confocal volume (~1 femtoliter) of a BioRad MRC 1024  CLSM (Hemel 
Hempstadt, UK) equipped with the ConfoCor 2 fluorescence correlation spectroscopy (FCS) setup 
(LSM510 ConfoCor 2, Zeiss, Göttingen, Germany) was positioned in a randomly selected site in the 
nucleus. The fluorescence, along the z-axis at this selected XY site and perpendicular to the cell 
surface, was recorded with the avalanche photodiodes of the ConfoCor 2 system before and every 
10 min after addition of 1 % (w/v) TCHD dissolved in serum free medium supplemented with 20 mM 
Hepes (pH 7.4). 
 
Preparation of polyplexes and lipoplexes 
 
Polyplexes consisting of 22 kDa linear PEI were prepared as described by Fayazpour et al. 
41
. 
Briefly, polyplexes were prepared in 20 mM Hepes pH 7.4 by adding the PEI all at once to the pDNA 
at a N/P ratio of 10. Subsequently, the mixture was vortexed for 10 sec and the polyplexes were 
allowed to equilibrate for 30 min at room temperature prior to use. The final pDNA concentration in 
the polyplexes was 0.126 µg/µl. 
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Liposomes composed of DOTAP:DOPE:DSPE-PEG2000 (molar ratio 5:5:0.2) were prepared as 
described previously 
42
. Briefly, appropriate amounts of lipids were dissolved in chloroform and 
mixed. The chloroform was subsequently removed by rotary evaporation at 37°C followed by 
flushing the obtained lipid film with nitrogen during 30 min at room temperature. The dried lipids 
were then hydrated by adding Hepes buffer till a final lipid concentration of 10.2 mM. After mixing in 
the presence of glass beads, liposome formation was allowed overnight at 4°C. Thereafter, the 
formed liposomes were extruded 11 times through two stacked 100 nm polycarbonate membrane 
filters (Whatman, Brentfort, UK) at room temperature using an Avanti Mini-Extruder (Avanti Polar 
Lipids). The extruded liposomes were subsequently mixed with pDNA in a +/- charge ratio of 4 and 
incubated at room temperature for 30 min prior to use. The final pDNA concentration in the LPX 
dispersion was 0.126 µg/µl. 
 
Size and zeta potential measurements 
 
The average particle size and zeta potential of the liposomes, LPXs and polyplexes were 
measured by photon correlation spectroscopy (PCS) (Autosizer 4700, Malvern, Worcestershire, UK) 
and particle electrophoresis (Zetasizer 2000, Malvern), respectively. The liposome, lipoplex and 
polyplex dispersions were diluted 40-fold in Hepes buffer before the particle size and zeta potential 
were measured. The average (± standard error) of the liposomes and lipoplexes was 118 ± 1 nm and 
242 ± 6 nm, respectively and their average zeta potential equaled 26 ± 4 mV and 14 ± 1 mV, 
respectively. The diameter and zeta potential of the linear PEI polyplexes were 165 ± 4 nm and 
33 ± 2 mV. 
 
Cell Viability Assay 
 
The influence of TCHD on the cell viability was determined using the CellTiter-Glo

 Assay 
(Promega). according to the manufacturer’s instructions. Briefly, 2.5 x 10
4
 cells/cm
2
 were seeded in a 
96-well plate and allowed to adhere. After 24 hrs, cells were washed with PBS and incubated with 
serum free medium containing increasing amounts of TCHD. After 1 hr, the TCHD was removed and 
replaced by culture medium. After 48 hrs, the plate was incubated at room temperature for 30 min 
and 100 µl CellTiter-Glo

 reagent was added to each well. After shaking the plate for 10 min and 
2 min incubation at room temperature, the luminescence was measured on a GloMax
TM
 96 
luminometer with 1 sec integration time.  
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Transfection experiments 
 
Cells were seeded into 24-well plates at 2.5 x 10
4
 cells/cm
2
 and allowed to attach overnight. 
Subsequently, the culture medium was removed, and after two washing steps with serum free 
medium, 0.4 µg pDNA, polyplexes or lipoplexes (both containing 0.4 µg pDNA) were added to each 
well. After 2 hrs the pDNA or non-viral nanoparticles were removed from the cells and the cells were 
post-incubated for 1 hr with serum-free medium containing increasing amounts of TCHD. 
Subsequently, this medium was replaced by culture medium and the cells were further incubated at 
37°C. After 48 hrs both the SEAP (or luciferase) activity, as well as the total cellular protein 
concentration were measured. 
To determine the SEAP activity, 100 µl of the culture medium above the cells was taken and 
incubated at 65 °C for 30 min. Subsequently, 100 µl dilution buffer (0.1 M glycine, 1 mM MgCl2, 
0.1 mM ZnCl2, pH 10.4) and 15 µl 4-methylumbelliferyl phosphate (4-MUP, 5.1 µg/µl in distilled 
water) was added. The obtained mixtures were then incubated at 37°C and the fluorescence was 
measured on a Wallac Victor
2 
fluorescence plate reader (Perkin Elmer-Cetus Life Sciences,
 
Boston, 
MA) using an excitation and emission wavelength of 360 nm and 449 nm, respectively. 
To determine the luciferase activity of the cells, cells were lysed with 80 µl 1 x CCLR buffer 
(Promega) and luciferase activity was determined with the Promega luciferase assay kit according to 
the manufacturer’s instructions. Briefly, 100 µl substrate was added to 20 µl sample and after a 2 sec 
delay, the luminescence was measured during 10 sec with the GloMax
TM
 96 luminometer. 
To correct for the amount of cells per well, the protein concentration was determined with 
the BCA kit (Pierce, Rockford, IL, USA). 200 µl mastermix, containing 50 parts reagent A to 1 part B, 
was mixed with 20 µl cell lysate and incubated at 37°C for 30 min and the absorbance was measured 
on a Wallac Victor
2
 absorbance plate reader (Perkin Elmer-Cetus Life Sciences) at 590 nm. 
 
Statistics 
 
The experimental data in this report are expressed as mean ± standard deviation (SD). One 
way ANOVA was used to determine whether data groups differed significantly from each other. A p-
value lower than 0.05 was considered statistically significant. 
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RESULTS & DISCUSSION 
 
TCHD facilitates the nuclear accumulation of dextrans and plasmid DNA 
 
It has been demonstrated that TCHD enhances the rate of nuclear entry of the maltose 
binding protein 
43
. However, this protein has a rather low molecular weight (40 kDa) and is 
consequently not totally excluded from the nucleus. Therefore, we studied whether TCHD could 
induce nuclear entry of higher molecular weight compounds like 158 kDa dextrans and especially 
pDNA, since nuclear transport of therapeutic genes forms an important bottle neck in non-viral gene 
delivery. 
 
 
Figure 1. Non-confocal DIC (A, C and inserts in E till G) and confocal images (B and D till G) of Vero cells after 
cytosolic microinjection of 158 kDa TRITC-dextran. Images (A) and (B) represent a microinjected cell 60 min 
after microinjection. Images (C) till (G) represent another microinjected cell after 10 sec (D), 40 sec (E), 5 min 
(F) and 10 min (G) incubation with 1 % (w/v) TCHD. 
 
In a first approach we microinjected 158 kDa TRITC-dextrans in the cytoplasm of Vero cells 
and followed their nuclear influx in the absence and presence of TCHD by confocal laser scanning 
microscopy (CLSM). In the absence of TCHD, no TRITC-dextran could be detected in the nucleus, not 
even after 1 hr of incubation (Fig. 1A and 1B). This is as expected, since it is well known that 
molecules larger than ~70 kDa can not move passively through the NPC network 
44
. When TRITC-
dextran microinjected cells were incubated with 1 % (w/v) TCHD containing medium, a rapid nuclear 
localisation of the TRITC-dextrans was detected (Fig. 1D till 1G). Indeed, as soon as 10 sec after 
addition of TCHD to the cells, TRITC-dextran was already detected in the nucleus. After 10 min the 
TRITC-dextran fluorescence was homogeneously distributed throughout the cell. These data clearly 
demonstrate that TCHD opens the NPCs what results in nuclear passage of macromolecules that 
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otherwise are excluded from the nucleus. We also co-injected TCHD (2 % w/v) and TRITC-dextran 
(158 kDa) in the cytosol, but under these conditions we could not observe nuclear localisation (data 
not shown). One likely explanation is that TCHD, which is an amphiphilic compound and contains a 
polar ethylene glycol moiety and an apolar butylene moiety, can rapidly cross cell membranes and 
thus becomes rapidly diluted in the surrounding medium 
45
. 
 
Figure 2. Effect of TCHD on the nuclear entry of microinjected Cy5-pDNA microinjected in the cytoplasm of 
Vero cells. A schematic overview of the experimental set up is shown in (B). (A) represents a microinjected cell 
with arrow (1) representing the place of cytoplasmic microinjection and arrow (2) the place where the z-scan 
was performed. The black squares (--) in (C) represent the z-scan through the cytosol and nucleus of a 
microinjected Vero at time point zero, so just after microinjection and before addition of TCHD. The grey circles 
(-•-) represent the z-scan 60 min after addition of 1 % (w/v) TCHD. In image (C), the center of the cell nucleus is 
located at z-value -0.048. The time dependent increase of Cy5-pDNA fluorescence in the nucleus after 
cytoplasmic injection of Cy5-pDNA without (--) and with (-•-) TCHD is shown in (D). 
 
Next, we tested whether TCHD can also facilitate the nuclear uptake of pDNA, since pDNAs 
are much larger (2 to 10 MDa) than 158 kDa TRITC-dextran and have dimensions in the range of the 
inner diameter of the channels formed by the NPCs. When Cy5-pDNA was microinjected in the 
cytoplasm of Vero cells, a fluorescent spot was visible at the injection site (Fig. 2A, position 1). After 
1 hr incubation with TCHD, we could not observe accumulation of the pDNA inside the nucleus by 
CLSM (data not shown). Importantly, during that time the fluorescent microinjection spot became 
more diffuse but remained visible, indicating a restricted mobility of pDNAs in the cytoplasm. This is 
in agreement with the observations by Lukacs et al. who showed that the diffusion of pDNA in the 
cytoplasm may be an important rate-limiting barrier in gene delivery utilizing non-viral vectors 
46
. 
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Hence, after 1 hr only a small fraction of the microinjected pDNA will have reached the nuclear 
membrane. Additionally, as stated above the inner diameter of the NPC is in the size range of pDNA. 
Therefore, even in the presence of TCHD the number of pDNA molecules that enter the nucleus is 
probably low and beyond the detection limit of the CLSM. 
To monitor nuclear pDNA influx with higher sensitivity, we used a CLSM equipped with a 
fluorescence correlation spectroscopy (FCS) set up, which can detect as few as ~1 fluorescent 
molecule in a femtoliter range confocal volume 
47
. We performed time dependent z-scans, 
perpendicular to the slide surface and through position 2 (Fig. 2A) before and after microinjection of 
Cy5-pDNA in the cytoplasm at position 1 (Fig. 2A), hereby crossing first a part of the cytoplasm 
beneath the nucleus, then the nucleus and finally the cytoplasm above the nucleus (Fig. 2B). The 
black squares in Fig. 2C show that after cytoplasmic microinjection of the Cy5-pDNA, a fluorescence 
signal could be detected in the cytoplasm, but not in the nucleus. The difference in fluorescence 
intensity detected below and above the nucleus is most likely due to a difference in distance from 
the cytosolic injection site. Subsequently, 1 % (w/v) TCHD was added to the cells and z-scans through 
position 2 were performed every 10 min. The z-scan after 60 min, represented by grey circles in 
Fig. 2C, shows a clear elevated Cy5-pDNA fluorescence signal in the nucleus compared to the 
fluorescence profile before addition of TCHD. Subsequently, we studied the pDNA influx in the 
nucleus in the presence and absence of TCHD. Therefore, the confocal volume of the FCS set up was 
parked in the middle of the nucleus (at z-value -0.048 mm). A gradual increase of Cy5-pDNA was 
observed when TCHD was added to the cells (Fig. 2D; black circles). In contrast, when no TCHD was 
present, no increase in fluorescence could be detected in the nucleus (Fig. 2D; grey squares). This 
demonstrates that the time dependent increase in fluorescence after addition of TCHD is not a result 
of passive diffusion of small degradation products of the Cy5-pDNA into the nucleus. 
 
Cytotoxicity of TCHD 
 
It has been demonstrated that the effect of 7 % (w/v) TCHD on the NPC permeability is 
reversible and that it does not cause denaturation or leakage of nucleoporins out of the NPCs 
48
. 
Nevertheless, the reversible non-selective opening of NPCs may result into an unwanted leakage of 
cellular biomacromolecules from the cytoplasm into the nucleus or vice versa and hence interfere 
with essential cellular processes. Therefore, to ascertain that TCHD does not cause cytotoxic effects, 
we determined the cell viability 48 hrs after exposure to TCHD by the CellTiter-Glo
®
 assay (Promega). 
This assay assesses the cytotoxicity by quantifying the intracellular ATP levels, which is a sensitive 
marker of cell viability as within minutes after a loss of membrane integrity, cells lose the ability to 
synthesize ATP and endogenous ATPases destroy any remaining ATP. Fig. 3 shows that incubation of 
CHAPTER 7 – NUCLEAR ACCUMULATION OF PLASMID DNA CAN BE ENHANCED BY NON-SELECTIVE GATING OF THE NUCLEAR PORE 
 
 190 
Vero and A549 cells during 1 hr with 1 % (w/v) TCHD slightly reduced the viability of these cells. 
These results demonstrate that the TCHD does not cause drastic cytotoxic effects under the 
conditions of the nuclear uptake experiments above, i.e. incubation of the cells with 1 % (w/v) TCHD 
for 1 hr. Furthermore, we noticed a cell dependent TCHD sensitivity. Indeed, TCHD at concentrations 
above 1 % (w/v) significantly decrease the viability of Vero cells whereas almost no cytotoxic effects 
are observed in A549 cells incubated with up to 3 % (w/v) TCHD. 
 
 
Figure 3. Cell viability of Vero (black) and A549 cells (grey) after 1 hr of incubation with TCHD. The asterix (*) 
represents data that significantly differ (p<0.05) from the data point 0 % (w/v) TCHD. 
 
Influence of TCHD on the transfection efficiency of non-viral vectors 
 
Since nuclear uptake of pDNA is considered as one of the major barriers in non-viral gene 
delivery and since we showed that TCHD could cause nuclear uptake of Cy5-pDNA, we wondered 
whether TCHD could enhance the transfection efficiency of naked pDNA, cationic polyplexes and 
lipoplexes. All transfection experiments were performed in two cell types, namely A549 cells (lung 
carcinoma cell line) and Vero cells (kidney epithelial cell line), using different TCHD concentrations. 
The effect of TCHD on the transfection efficiency of naked pDNA was evaluated by incubating 
Vero and A549 cells with naked pDNA for 2 hr. Subsequently, pDNA that was not incorporated into 
the cells was removed by washing, and the cells were exposed to increasing percentages (w/v) of 
TCHD for 1 hr (Fig. 4). The incubation with TCHD clearly increased the gene expression. This increase 
reached a maximal value at a TCHD percentage of 0.5 % and 1.5 % in Vero (Fig. 4A) and A549 cells 
(Fig. 4B), respectively. At these optimal concentrations, a 3- and 66-fold increase in gene expression 
* * 
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was observed in Vero and A549 cells, respectively. At higher percentages no further increase and 
even a drop in gene expression was observed. Most likely this indicates that TCHD at these 
concentrations affects cellular processes that are not detected by the CellTiter-Glo
®
 assay. Indeed, it 
has been shown that the sensitivity of the MTT assay depends on the mechanism causing 
cytotoxicity 
49
. Between 0 and 1.5 % (w/v) TCHD, a gradual increase in gene expression was observed 
in A549 cells (Fig. 4B), which may indicate that the extent of NPC opening by TCHD is concentration 
dependent. Whether at 1.5 % (w/v) TCHD a maximal opening of the NPCs is reached is not certain, 
since above this concentration also cytotoxic effects can play a role. This also explains the lower 
effects of TCHD in Vero cells. Indeed, in these cells the optimal concentration of TCHD to increase 
gene transfer is 0.5 %. Based on the results in A549 cells, we can deduce that at such low TCHD 
concentration the opening of the NPC hasn’t reached its maximum. 
 
 
Figure 4. Transfection efficiency of naked pDNA in Vero (A) and A549 (B) cells post-incubated for 1 hr with 
different TCHD concentrations. The asterix (*) represents data that significantly differ (p<0.05) from the data 
point 0 % (w/v) TCHD. 
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When TCHD was incubated together with the naked pDNA, we also observed an increase in 
transfection efficiency, but the effect was less pronounced compared to the post-incubation 
experiments described above (data not shown). This could be expected as it takes some time for 
pDNA to become internalized by the cells and released from endocytotic vesicles into the cytoplasm. 
Additionally, as cytosolic nucleases degrade pDNA, the optimal moment to add TCHD to the cells is 
immediately after the release of the pDNA in the cytoplasm. 
To exclude that the higher gene expression was due to a perforation of the cell membrane by 
TCHD, which would allow an increased internalization of pDNA through the plasma membrane, we 
tested whether TCHD causes cytoplasmic entry of 158 kDa TRITC-dextrans. Fig. 5 shows that TRITC-
dextrans did not enter the cells in the absence nor in the presence of TCHD (1 % w/v). Consequently, 
we can state that after 1 hr incubation TCHD does not cause membrane perforation. 
 
Figure 5. Transmission and CLSM images of Vero cells after 1 min (A and B) and 1 hr incubation (C and D) with 
158 kDa TRITC-dextran in the presence of 1 % (w/v) TCHD. 
 
In a next step, we analyzed the effect of TCHD on the transfection efficiency of linear PEI-
based polyplexes, a quite efficient non-viral pDNA carrier that induces endosomal release via the 
proton sponge mechanism 
50
. Surprisingly, none of the incubation protocols with TCHD resulted in a 
significant increase in gene expression mediated by linear PEI-based polyplexes even not when the 
Vero and A549 cells were post-incubated with 2 % (w/v) TCHD (Supplementary Fig. 1A and B). 
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Supplementary Figure 1. Transfection efficiency of polyplexes in Vero (A) and A549 (B) cells post-incubated for 
1 hr with different TCHD concentrations. 
 
These data may indicate that, in agreement with Grosse et al., linear PEI based polyplexes are 
mainly released from the endosomes as intact complexes 
51
. Because of the latter and taking into 
account the diameter of the linear PEI based polyplexes (~165 nm), TCHD is not expected to be able 
to enhance the nuclear transport and hence transfection efficacy of such linear PEI-based polyplexes. 
The endosomal escape mechanism of DOTAP:DOPE-based lipoplexes is based on a different 
mechanism and results in the release of uncomplexed pDNA in the cytosol 
52
. This implies that, when 
the free pDNA reaches the nuclear membrane, TCHD should be able to induce its nuclear 
translocation, similar to the naked pDNA transfections. Therefore, we analyzed the effect of TCHD on 
the transfection efficiency of DOTAP:DOPE-based lipoplexes. The same incubation protocols and cells 
were used as in the experiments above. Incubating the cells with TCHD for 1 hr immediately after 
incubation with the lipoplexes, indeed caused an increase in transfection efficiency in both Vero and 
A549 cells (Fig. 6A and 6B). A maximal increase was observed when the Vero and A549 cells were 
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incubated with 0.5 % and 1.5 % (w/v) TCHD, respectively. This increase is lower than observed with 
naked pDNA transfection, which can be attributed to cell division. Compared to naked pDNA 
transfection, transfection with lipoplexes introduces a higher amount of pDNA in the cytoplasm, 
which can translocate to the nucleus with higher probability either by entry through the pores or 
during cell division. Hence, the few extra copies that enter the nucleus after treating the cells with 
TCHD will not tremendously increase gene expression. In contrast, the amount of pDNA that reaches 
the cytoplasm and subsequently the nucleus is extremely low in case of naked pDNA transfection. 
Therefore, if TCHD can cause nuclear translocation of only one pDNA molecule, this effect is much 
more spectacular. 
 
Figure 6. Transfection efficiency of lipoplexes in Vero (A) and A549 (B) cells post-incubated for 1 hr with 
different TCHD concentrations. The asterix (*) represents data that significantly differ (p<0.05) from the data 
point 0 % (w/v) TCHD. 
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CONCLUSION 
 
In conclusion, our study demonstrates for the first time that the amphipathic alcohol TCHD 
can be employed to enhance the nuclear uptake of pDNA by reversibly
 
collapsing the permeability 
barrier of the NPCs at non-toxic concentrations. Furthermore, our transfection data show that TCHD 
has huge potential to enhance especially naked gene transfer. Although less efficient than carrier 
mediated gene delivery, naked gene transfer is currently the most investigated non-viral gene 
delivery strategy in gene therapy clinical trials because of the higher safety profile, the simplicity of 
delivery, the lack of immune responses and nonspecific interactions in the body (with e.g. 
extracellular matrices) 
53
. Naked gene transfer is considered for DNA vaccination, Duchenne muscular 
dystrophy, peripheral limb ischemia, and cardiac ischemia 
54-57
. Therefore, strategies that can 
enhance naked gene transfer by enhancing nuclear uptake of DNA are of huge interest. Additionally, 
we also want to remark that TCHD is a metabolite of the drug candesartan cilexetil 
58
 and of the 
solvent cyclohexanone, a contaminant of intravenous dextrose and parenteral feeding solutions 
59
, 
which possibly makes TCHD a clinical acceptable adjuvant for naked gene transfer. However, 
toxicology and in vivo gene transfer studies are needed to confirm the usefulness of this approach for 
clinical applications. 
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SUMMARY 
 
Genetic-based diseases are mainly caused by the absence of essential or the presence of 
malfunctioning proteins and can consequently be treated by gene therapy. In case of e.g. cystic 
fibrosis, the genetic disorder can be treated by introduction of the corrected Cystic Fibrosis 
Transmembrane Regulato) (CFTR) protein. Cancer and viral infections e.g. can be treated by 
suppression of oncogenic and vital viral proteins, respectively. Introduction of a specific protein can 
be obtained by using plasmid DNA (pDNA) that encodes this protein. Suppression of a specific protein 
can be achieved by introducing short interfering RNA (siRNA) molecules that induce sequence-
specific messenger RNA (mRNA) degradation and subsequent protein expression knock down. To be 
successful, these synthetic nucleic acids should reach the cytoplasm (in case of siRNA) or the nucleus 
(in case of pDNA) of the target cells. Additionally, the nucleic acids should remain intact as their 
integrity is necessary to maintain their biological activity. Consequently, advanced delivery systems, 
either viral or non-viral, are needed and are the main focus of current gene therapy research. 
As summarized in Chapter 1, different nucleic acid delivery systems are available. Although 
the viral systems have shown to be the most effective ones, their clinical use is limited mainly due to 
safety issues. Non-viral delivery systems are a safe(r) alternative but unfortunately they often lack 
high delivery efficiency, caused by the extra- and intracellular hurdles they need to take before 
reaching their intracellular target region. First, they suffer from rapid clearance from the blood after 
intravenous administration and often have difficulties to escape the bloodstream at the right place. 
Additionally, once the target cell is reached, both the extracellular matrix and the plasmamembrane 
limit the cellular uptake of the nucleic acids. Furthermore, even when taken up by the cell, both 
endosomal and cytoplasmic nucleic acid degradation have detrimental effects on the delivery 
efficiency. Once in the cytoplasm, the siRNA has reached its intracellular target region, while pDNA 
has one last, but difficult hurdle to take, namely nuclear import. The primary aim of this thesis was to 
improve the non-viral intracellular nucleic acid delivery by addressing different barriers: cellular 
uptake, endosomal release and nuclear import. 
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When a non-viral nucleic acid containing nanoparticle reaches the cell membrane, it is mostly 
taken up through endocytic processes such as clathrin-dependent or -independent endocytosis or 
macropinocytosis. Upon endocytosis, most particles end-up in vesicles that are processed from early 
to late endosomes with lysosomes as their final destination. The harsh environment of the 
lysosomes, with low pH and destructive enzymes, will cause inactivation and degradation of most 
particles together with their cargo. In this thesis, we tried to solve this problem either by avoiding 
endosomal uptake (Chapter 2 and 3) or by inducing endosomal escape (Chapter 5). 
To circumvent endosomal degradation, it has been proposed to bypass the endosomal 
pathway by using cell penetrating peptides (CPPs), such as the HIV-1 Tat peptide, which rapidly 
translocate cargoes across the cell membrane. The HIV-1 Tat peptide consists of a short stretch of 
basic amino acids responsible for the translocation across
 
cellular membranes called the protein 
transduction domain (PTD). The ability of the Tat peptide to transport cargoes across cell membranes 
could bring significant advantages to the cellular delivery of nucleic acids by non-viral carriers. 
Therefore, in Chapter 2, we attached this peptide to the lipoplex (LPX) surface and subsequently 
analyzed both transfection efficiency and cellular entry mechanism of these Tat-modified LPXs. 
Although the Tat peptide could slightly enhance the gene transfer of 30 mol% DOTAP containing 
LPXs, this was clearly not the case for the 50 mol% DOTAP containing LPXs. In contrast to what we 
aimed for, i.e. non-endocytic internalization of the Tat-LPXs, we found that the uptake mechanism of 
Tat-modified LPXs appeared to be energy dependent. By using endocytosis inhibitors, we 
demonstrated that both Tat-modified and unmodified LPXs were mainly taken up via cholesterol-
dependent clathrin-mediated endocytosis, a pathway previously postulated to be responsible for the 
cellular uptake of cationic LPXs. 
As an alternative approach to avoid endosomal degradation, the use of ultrasound has been 
proposed. It is believed that ultrasound, especially when combined with gas-filled microbubbles, 
induces small transient pores in the cell membrane, allowing entrance of large molecules directly 
into the cell cytoplasm. In Chapter 3 we made use of LPXs supplemented with a poly(ethylene glycol) 
(PEG) containing lipid for the delivery of siRNA molecules to the cytoplasm of target cells. Although 
the PEG group is necessary to avoid rapid clearance from the blood after intravenous administration, 
the presence of PEG has a dramatic adverse effect on the delivery efficiency of the LPXs, probably 
through both reduced cellular uptake and decreased endosomal release. Therefore, we tried to load 
the PEGylated siRNA containing LPXs (PEG-siPlexes) onto the surface of ultrasound responsive 
microbubbles and studied their cellular distribution and gene silencing efficiency after ultrasound 
radiation. First, we showed that exposure of the PEG-siPlex loaded microbubbles to ultrasound 
resulted in a massive release of PEG-siPlexes with similar size, surface charge and complexation 
capacity as before binding to the microbubbles. Moreover, PEG-siPlexes loaded on microbubbles 
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were able to rapidly enter the target cells after exposure to ultrasound and to induce a pronounced 
gene silencing, in contrast to free PEG-siPlexes. Interestingly, in the absence of ultrasound these PEG-
siPlex loaded microbubbles did not cause any gene silencing, allowing both space and time controlled 
gene silencing. Apparently, ultrasound combined with PEG-siPlexes bound to the microbubble 
surface is a promising approach for the in vivo delivery of siRNA. 
As non-viral nucleic acid containing nanoparticles are mainly taken up by endocytic 
processes, several research groups have tried to quantitatively assess the contribution of each 
endocytic pathway in the uptake of non-viral gene delivery vehicles and to correlate these results 
with transfection efficiency. These studies are often performed through the use of endocytosis 
inhibitors, i.e. chemicals that are easy to apply and are presumed to specifically inhibit certain 
endocytic pathways. However, while studying the endocytic process involved in Tat-LPX uptake 
described in Chapter 2, we encountered several problems and decided to have a closer look at these 
inhibitors. In Chapter 4 we clearly showed that unravelling of the uptake pathway of nanoparticles is 
not always as straightforward as one would think based on current literature. First, we clearly 
demonstrated that several of the tested inhibitors exhibit cell type dependent cytotoxic effects. 
Additionally, most inhibitors exhibited only limited inhibitor efficiency and very few inhibitors were 
shown to be specific for a certain endocytic pathway. Finally, we also noticed that most inhibitors 
dramatically change cellular morphology. Therefore, one must be aware of possible side effects 
when using these endocytosis inhibitors, as this can often lead to contradictory results. Moreover, 
one should also realize that different pathways may be operating simultaneously or may take over if 
one pathway is blocked. Subsequently, inhibiting one route, may lead to an increased uptake via an 
alternative route. Additionally, the existence of unknown endocytic processes or even worse, the 
induction of non-natural pathways due to the cellular manipulations, cannot be excluded. Based on 
our results, we can state that performing the correct control experiments to test the efficacy of these 
inhibitors is of extreme importance for obtaining reliable conclusions. And even when all control 
experiments are performed, using a combined approach, e.g. combining inhibition experiments with 
co-localization studies, is in any case the preferred strategy to study the endocytic uptake of delivery 
vehicles. 
As most particles are taken up by endocytic processes, this often leads to endosomal 
degradation of the nucleic acids, unless the carrier is able to induce endosomal release. In Chapter 5 
we made use of non-toxic, biodegradable 1,4-butanediol (PbAE1) or 1,6-hexanediol (PbAE2) 
diacrylate-based polymers, called poly(β-amino esters), to deliver siRNA molecules to the cytoplasm 
of both hepatoma cells and primary hepatocytes. Both polymers were able to induce significant gene 
silencing, although based on confocal images the PbAE:siRNA complexes clearly end up inside the 
endo- and lysosomes. We found that the duration of gene silencing in the hepatoma cells was 
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maintained for at least 5 days after siRNA delivery in case of PbAE2, the polymer with the slowest 
degradation kinetics. In contrast, after 5 days gene expression had completely recovered in case of 
PbAE1. These observations, combined with the time-dependent cellular distribution of PbAE1 and 
PbAE2 complexes, suggest that the slowly degrading PbAE2 causes a sustained endosomal release of 
siRNA during a much longer period than PbAE1. This supports the hypothesis that the endosomal 
release mechanism of PbAE:siRNA complexes is based on an increase of osmotic pressure in the 
endosomal vesicles after polymer hydrolysis, as PbAEs are fully biodegradable through hydrolysis of 
their backbone esters to yield small molecular weight products. 
In case of siRNA the cytoplasm is the final destination, but pDNA should cross a final barrier, 
the nuclear envelope (NE), before arriving at its intracellular target region. Two attempts to improve 
the nuclear transport of pDNA are described in this thesis: complexation of the pDNA with a nuclear 
localization signal (NLS) peptide (Chapter 6) and disruption of the nuclear barrier through 
interference with the hydrophobic interactions inside the nuclear pore complexes (NPCs) 
(Chapter 7). 
The HIV-1 Tat protein contains a short amino acid stretch highly enriched in basic residues 
and responsible for NLS activity. In Chapter 6 we prepared non-toxic, electrostatic Tat/pDNA 
complexes to enhance nuclear uptake of pDNA. In contrast to what we hoped for, cytoplasmic 
microinjection of Tat/pDNA complexes did not result in nuclear import of the labeled pDNA. 
Similarly, the transfection efficiency was barely increased when the pDNA was electrostatically 
complexed with the Tat peptide. In agreement with these results, the Tat/pDNA complexes were not 
able to interact with the nuclear import machinery, although the Tat peptide itself did. Taken 
together, the results of this study indicate that electrostatic coupling of an NLS to pDNA does not 
induce nuclear uptake of pDNA. We demonstrated that the latter is probably due to masking of the 
NLS domain after electrostatic interaction between Tat and pDNA. 
As attempts to improve nuclear transport of pDNA through the use of the Tat peptide did not 
yield the desired result, we focussed on an alternative approach. Considering the hydrophobic nature 
of the NPC channel, we evaluated in Chapter 7 whether non-selective gating of nuclear pores by 
trans-cyclohexane-1,2-diol (TCHD), an amphipathic alcohol that reversibly
 
collapses the permeability 
barrier of the NPCs, could facilitate nuclear entry of plasmid DNA. First, we examined the effect of 
TCHD on nuclear import of cytoplasmic microinjected 158 kDa TRITC-dextran. As soon as 10 sec after 
addition of TCHD to the cells, TRITC-dextran was detected in the nucleus. Additionally, we also 
detected nuclear influx of pDNA in the presence of TCHD, indicating that TCHD indeed could disrupt 
the nuclear barrier, opening up the possibility for pDNA to enter the nucleus. Subsequently, the 
effect of TCHD on the transfection efficiency of naked pDNA and non-viral DNA containing 
nanoparticles, such as polyplexes and LPXs was tested. Although no increase could be detected in 
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case of polyplexes, TCHD incubation clearly increased the gene expression of both naked pDNA and 
LPXs, varying from 2- to 66-fold. In conclusion, we demonstrated that the amphipathic alcohol TCHD 
has huge potential to enhance gene transfer, especially of naked DNA. 
 
GENERAL CONCLUSIONS 
 
In conclusion, the primary aim of this thesis was to improve intracellular nucleic acid delivery 
by addressing different barriers encountered by non-viral delivery systems. Dependent on the 
approach we used, we succeeded in doing so. Avoiding endosomal uptake by attachment of the Tat 
peptide to the LPX surface appeared to be unsuccessful, while we were able to enhance the 
transfection efficiency by coupling our LPXs to a microbubble surface and subsequent ultrasound 
irradiation. We also succeeded in inducing an endosomal release of siRNA in both hepatoma cells 
and primary hepatocytes by using biodegradable poly(β-amino esters) (PbAEs), as these polymers 
were able to induce significant gene silencing. Moreover, PbAEs with slower degradation kinetics 
were able to cause a more prolonged gene silencing. Finally, enhancing nuclear import of pDNA was 
not possible by electrostatic NLS/pDNA complexes, but addition of TCHD proved to be a more 
successful approach. 
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SAMENVATTING 
 
Genetische aandoeningen worden hoofdzakelijk veroorzaakt door de afwezigheid van 
essentiële of aanwezigheid van slecht functionerende eiwitten. Bijgevolg zijn deze aandoeningen het 
ideale doelwit voor gentherapie. Bij taaislijmziekte bijvoorbeeld kan de genetische afwijking 
behandeld worden door toevoeging van het gecorrigeerde ‘cystic fibrosis transmembrane 
conductance regulator’ (CFTR-) eiwit. Sommige kankers en virale infecties daarentegen kunnen 
behandeld worden door specifieke onderdrukking van respectievelijk kankerverwekkende of voor 
het virus levensnoodzakelijke eiwitten. Om het gewenste eiwit toe te voegen kan gebruik gemaakt 
worden van plasmide DNA (pDNA) dat codeert voor dit eiwit. De onderdrukking van de expressie van 
een specifiek eiwit kan verkregen worden door ‘short interfering’ RNA (siRNA-) moleculen aan de 
doelwitcellen toe te dienen. SiRNA-moleculen veroorzaken immers een sequentiespecifieke afbraak 
van boodschapper RNA (mRNA) en bijgevolg ook onderdrukking van de expressie van het 
overeenkomstige eiwit. Beide synthetische nucleïnezuren kunnen maar tot therapeutische successen 
leiden indien ze tot in het cytoplasma (in geval van siRNA) of tot in de kern (in geval van pDNA) van 
de doelwitcellen geraken. Bovendien moeten de nucleïnezuren intact hun doelwit bereiken, 
aangezien dit noodzakelijk is voor het behoud van hun biologische activiteit. Geavanceerde 
afgiftesystemen, viraal of niet-viraal, zijn dan ook noodzakelijk en vormen één van de belangrijkste 
onderzoeksonderwerpen binnen gentherapie. 
Zoals samengevat in Hoofdstuk 1 zijn er verschillende afgiftesystemen voor nucleïnezuren 
beschikbaar. Hoewel de virale dragers overtuigend het meest efficiënt zijn, wordt hun klinische 
toepasbaarheid beperkt door de mogelijke veiligheidsproblemen. Niet-virale dragers vormen een 
veilig(er) alternatief, maar helaas hebben deze dragers vaak slechts een beperkte afgifte efficiëntie 
door de vele hindernissen die ze moeten overwinnen vooraleer ze hun intracellulaire doelwitregio 
kunnen bereiken. Ten eerste worden ze snel verwijderd uit het bloed na intraveneuze toediening en 
zelden verlaten ze de bloedbaan op de juiste plaats. En indien ze er in slagen de doelwitcellen te 
bereiken, beperken zowel de extracellulaire matrix als de plasmamembraan de cellulaire opname van 
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de nucleïnezuren. Eenmaal opgenomen door de doelwitcellen worden ze blootgesteld aan 
endosomale en cytoplasmatische nucleasen die een desastreus effect hebben op de afgifte-
efficiëntie. Het cytoplasma is de intracellulaire doelwitregio voor de siRNA-moleculen, maar pDNA 
moet nog een laatste en moeilijke hindernis nemen, namelijk de nucleaire membraan. Het hoofddoel 
van deze onderzoeksscriptie bestond erin om de efficiëntie van niet-virale intracellulaire 
nucleïnezuurafgifte te verhogen door de volgende hindernissen aan te pakken: cellulaire opname, 
endosomale vrijgave en nucleaire import. 
Wanneer een niet-viraal nucleïnezuurbevattend nanopartikel de celmembraan bereikt, wordt 
het meestal opgenomen via endocytotische processen zoals clathrine-gemedieerde of -
onafhankelijke endocytose of macropinocytose. Na endocytotische opname komen de meeste 
partikels terecht in intracellulaire vesikels die achtereenvolgens evolueren tot vroege en late 
endosomen met lysosomen als eindbestemming. De vernietigende omgeving van de lysosomen, met 
lage pH en afbraakenzymen, zorgt voor inactivatie en afbraak van de meeste partikels samen met 
hun cargo. In deze doctoraatsscriptie werd geprobeerd dit probleem aan te pakken enerzijds door de 
endosomale opname te omzeilen (Hoofdstuk 2 en 3) en anderzijds door de endosomale vrijstelling te 
stimuleren (Hoofdstuk 5). 
Eén mogelijke strategie om endosomale afbraak te voorkomen, is het omzeilen van de 
endosomale opname door gebruik te maken van ‘cell penetrating peptides’ (CPPs) zoals het HIV-1 
Tat-peptide. Het HIV-1 Tat-peptide bestaat uit een korte reeks van basische aminozuren die 
verantwoordelijk is voor de translocatie doorheen cellulaire membranen. Dit domein wordt het 
‘protein transduction domain’ (PTD) genoemd. De mogelijkheid van het Tat-peptide om cargo’s 
integraal doorheen membranen te loodsen zou de afgifte-efficiëntie van niet-virale dragers 
significant kunnen verbeteren. In Hoofdstuk 2 werd dit peptide dan ook aan het lipoplex (LPX) 
oppervlak gekoppeld, waarna zowel de transfectie-efficiëntie als de cellulaire opname van deze Tat-
gemodificeerde LPX’en werden bestudeerd. Hoewel het Tat-peptide zorgde voor een lichte 
verhoging van de gentransfer in het geval van de 30 mol% DOTAP bevattende LPX’en, was dit 
duidelijk niet het geval voor de 50 mol% DOTAP bevattende LPX’en. In tegenstelling tot wat de 
bedoeling was, namelijk een endocytose-onafhankelijke opname, bleek de opname van de Tat-
gemodificeerde LPX’en temperatuursafhankelijk te zijn. Gebruik van endocytose-inhibitoren toonde 
aan dat zowel de Tat-gemodificeerde als niet-gemodificeerde LPX’en hoofdzakelijk opgenomen 
werden via een cholesterol-afhankelijke clathrine-gemedieerde endocytose, een 
opnamemechanisme dat eerder reeds beschreven werd voor de cellulaire opname van kationische 
LPX’en. 
Als alternatieve strategie om endosomale afbraak te vermijden werd in de literatuur het 
gebruik van ultrasone golven reeds voorgesteld. Algemeen wordt aangenomen dat ultrasone golven, 
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zeker in combinatie met microscopische gasbellen, in staat is om tijdelijke poriën in de celmembraan 
te induceren, waardoor grote moleculen in staat zijn om het cytoplasma te bereiken. In Hoofdstuk 3 
werden siRNA-liposoomcomplexen aangemaakt die poly(ethyleen glycol) (PEG-) gemodificeerde 
lipiden bevatten. Deze PEG-groep is noodzakelijk om een snelle verwijdering uit het bloed te 
voorkomen na intraveneuze toediening. De aanwezigheid van deze PEG-groep leidt echter tot een 
verminderde cellulaire opname en endosomale vrijstelling, wat een desastreus effect heeft op de 
transfectie efficiëntie van de LPX’en. Om dit probleem aan te pakken werd geprobeerd om deze 
gePEGyleerde siRNA bevattende LPX’en (PEG-siPlexen) op het oppervlak van microscopische 
gasbellen te binden en vervolgens hun cellulaire lokalisatie en onderdrukkingsefficiëntie te 
bestuderen na behandeling met ultrasone golven. Ten eerste konden we aantonen dat bestraling van 
PEG-siPlex geladen microscopische gasbellen met ultrasone golven resulteerde in een massale 
vrijstelling van PEG-siPlexen met dezelfde grootte, oppervlaktelading en complexatiecapaciteit als 
vóór binding met de microscopische gasbellen. Daarnaast bleken de PEG-siPlexen geladen op het 
oppervlak van microscopische gasbellen snel de doelwitcellen binnen te dringen na bestraling met 
ultrasone golven en, in tegenstelling tot de vrije PEG-siPlexen, een goede onderdrukking van het 
doelwitgen te veroorzaken. Bovendien werd geen onderdrukking van het doelwitgen gedetecteerd in 
de afwezigheid van ultrasone golven, wat zowel een plaats- als tijdsgecontroleerde 
genonderdrukking toelaat. Uit deze resultaten kunnen we concluderen dat ultrasone golven, 
gecombineerd met PEG-siPlex gebonden microscopische gasbellen, een veelbelovende strategie is 
voor de in vivo afgifte van siRNA. 
Aangezien niet-virale nucleïnezuurbevattende nanopartikels hoofdzakelijk opgenomen 
worden via endocytotische processen, proberen verschillende groepen het aandeel van de 
verschillende opnamewegen in de cellulaire opname van een specifieke drager te bepalen en te 
correleren met de uiteindelijke transfectie-efficiëntie. Om dit te bestuderen wordt vaak gebruik 
gemaakt van endocytose-inhibitoren, dit zijn chemische componenten die gemakkelijk zijn in gebruik 
en die specifiek bepaalde endocytotische opnamewegen kunnen inhiberen. Bij het bestuderen van 
de opname van Tat-LPX’en in Hoofdstuk 2 werden echter verschillende problemen vastgesteld 
waardoor beslist werd het gebruik van deze inhibitoren in detail te bekijken. Hoofdstuk 4 toont 
duidelijk aan dat het bestuderen van de opname van nanopartikels niet zo evident is als in de 
literatuur vaak beweerd wordt. Ten eerste stelden we duidelijk vast dan verscheidene van de geteste 
inhibitoren een celafhankelijke cytotoxiciteit vertoonden. Bovendien vertoonden de meeste 
inhibitoren slechts een beperkte efficiëntie en bleken ze vaak niet specifiek te zijn voor één 
opnameweg. Tenslotte werd ook aangetoond dat verschillende inhibitoren naast de inhibitie van 
endocytotische processen ook ernstige neveneffecten hebben op de cellulaire morfologie. Indien 
men dus gebruik wil maken van deze inhibitoren is het belangrijk om hiermee rekening te houden 
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om zodoende tegenstrijdige resultaten te vermijden. Daarnaast moet men ook stilstaan bij het feit 
dat meerdere endocytotische opnamewegen tegelijkertijd een rol kunnen spelen of het zelfs van 
elkaar kunnen overnemen indien een bepaalde opnameweg geblokkeerd wordt. Daardoor kan de 
inhibitie van de ene opnameweg resulteren in een verhoogde opname via een alternatieve 
opnameweg. Daarnaast is het niet uitgesloten dat nog niet alle endocytotische opnamewegen 
gekend zijn of zelfs nog erger, dat de uitgevoerde manipulaties resulteren in het induceren van 
onnatuurlijke opnamewegen. Op basis van onze resultaten kunnen we besluiten dat het extreem 
belangrijk is de correcte controle-experimenten uit te voeren om te bepalen hoe efficiënt en 
specifiek de gebruikte endocytose inhibitoren zijn, zodat betrouwbare resultaten verkregen worden. 
En zelfs indien alle noodzakelijke controle- experimenten uitgevoerd worden, is het absoluut 
raadzaam om voor de studie van de opnameweg van een bepaalde drager, een gecombineerde 
strategie te gebruiken waarbij inhibitorstudies gecombineerd worden met bijvoorbeeld colokalisatie-
experimenten. 
Aangezien de meeste nucleïnezuurbevattende nanopartikels opgenomen worden via 
endocytotische processen leidt dit vaak tot endosomale afbraak van de nucleïnezuren, tenzij de 
drager in staat is om endosomale vrijstelling te induceren. In Hoofdstuk 5 werd gebruik gemaakt van 
niet-toxische, biodegradeerbare poly(β-amino ester) polymeren (1,4-butaandiol (PbAE1) en 1,6-
hexaandiol (PbAE2) diacrylaat-gebaseerd) voor de afgifte van siRNA in het cytoplasma van 
doelwitcellen. Beide polymeren resulteerden in een significante genonderdrukking ondanks het feit 
dat ze volgens confocale beelden uitsluitend in de endo- en lysosomen gelokaliseerd waren. PbAE2, 
het traagst degraderende polymeer, bleek in staat om de eiwit productie gedurende ten minste 5 
dagen te onderdrukken. Bij PbAE1 daarentegen was de eiwitexpressie na deze periode volledig 
hersteld. Deze waarnemingen, gecombineerd met de tijdsafhankelijke cellulaire distributie van beide 
polymeer:siRNA complexen, suggereren dat het traag degraderende PbAE2 polymeer in staat is om 
een meer continue endosomale vrijstelling te bewerkstelligen gedurende een veel langere periode 
dan PbAE1. Dit ondersteunt de hypothese dat het endosomale vrijstellingsmechanisme van de 
PbAE:siRNA complexen gebaseerd is op een toename in osmotische druk binnenin de endosomale 
vesikels na hydrolyse van de PbAEs. Door hydrolyse van de esters in de polymeer ruggengraat 
degraderen deze polymeren immers tot eindproducten met een laag moleculair gewicht. 
In geval van siRNA is het cytoplasma de intracellulaire eindbestemming, maar pDNA moet 
nog een laatste barrière overbruggen voordat het zijn intracellulaire doelwitregio bereikt heeft, 
namelijk de nucleaire membraan. Twee strategieën om het nucleair transport van pDNA te 
verbeteren worden in deze onderzoeksscriptie beschreven: complexatie van het pDNA met een 
nucleair lokalisatiesignaal (NLS-) bevattend peptide (Hoofdstuk 6) en verstoring van de nucleaire 
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barrière door te interferen met de hydrofobe interacties binnenin de nucleaire poriëncomplexen 
(NPC’s) (Hoofdstuk 7). 
Het HIV-1 Tat-eiwit bevat een korte aminozuur reeks met hoofdzakelijk basische residuen en 
verantwoordelijk is voor de NLS-activiteit. Om de nucleaire opname van pDNA te verhogen werden in 
Hoofdstuk 6 niet-toxische, elektrostatische NLS/pDNA-complexen aangemaakt. In tegenstelling tot 
wat verhoopt werd, resulteerde cytoplasmatische micro-injectie van deze complexen niet in nucleair 
import van het pDNA. Ook de transfectie- efficiëntie werd nauwelijks verhoogd na elektrostatische 
complexatie van het pDNA met het Tat-peptide. Het feit dat de Tat/pDNA-complexen, in 
tegenstelling tot het Tat-peptide zelf, niet in staat waren om te binden met de nucleaire 
importmachinerie is hiermee in overeenstemming. Samenvattend kan gesteld worden dat 
elektrostatische koppeling van een NLS met pDNA niet noodzakelijk resulteert in een verhoogde 
nucleaire opname en dat dit hoogstwaarschijnlijk veroorzaakt wordt doordat het functionele NLS-
domein gemaskeerd wordt na elektrostatische interactie met pDNA.  
Aangezien het gebruik van het Tat-peptide niet resulteerde in de verhoopte verhoging van 
nucleair pDNA transport, werd een alternatieve strategie uitgetest. Op basis van de hydrofobe 
eigenschappen van het NPC kanaal werd in Hoofdstuk 7 nagegaan of het niet-selectief openen van 
de nucleaire poriën door middel van trans-cyclohexaan-1,2-diol (TCHD), een amfifiel alcohol dat in 
staat is om reversibel de permeabiliteit van de NPC’s te verstoren, resulteerde in een toename van 
pDNA transport doorheen de NPC’s. Eerst werd het effect van TCHD op de nucleaire import van 
cytoplasmatisch geïnjecteerd 158 kDa TRITC-dextraan nagegaan. Tien seconden na toevoeging van 
TCHD aan deze cellen kon het TRITC-dextraan reeds in de kern gedetecteerd worden. Op een 
gelijkaardige manier kon ook nucleaire influx van pDNA in de aanwezigheid van TCHD gedetecteerd 
worden. Deze data bewijzen dat TCHD inderdaad in staat is de NPC’s te openen en vervolgens 
macromoleculen en pDNA de mogelijkheid biedt om de kern binnen te dringen. Tenslotte werd ook 
het effect van TCHD nagegaan op de transfectie-efficiëntie van naakt pDNA en niet-virale 
nanopartikels zoals polyplexen en LPX’en. Hoewel geen verhoging in transfectie- efficiëntie kon 
bekomen worden bij polyplexen, had TCHD wel een positief effect op zowel naakte pDNA-transfectie 
als bij gebruik van LPX’en, variërend van een 2- tot 66-voudige toename. Hiermee werd aangetoond 
dat het amfifiele alcohol TCHD grote mogelijkheden biedt voor het verhogen van niet-virale 
gentherapie, vooral in het geval van naakte gentransfer. 
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Deze doctoraatsscriptie had tot doel de intracellulaire afgifte van nucleïnezuren te verhogen 
door in te grijpen ter hoogte van de verschillende hindernissen die niet-virale afgiftesystemen 
moeten overwinnen. Afhankelijk van de gekozen strategie zijn we daar in geslaagd. Het omzeilen van 
endosomale afbraak door aanhechting van het Tat-peptide op het LPX oppervlak bleek niet 
succesvol, terwijl koppeling van de LPX’en op het oppervlak van microscopische gasbellen 
gecombineerd met ultrasone golven wel resulteerde in een extreme verhoging van de transfectie-
efficiëntie. We slaagden er ook in om endosomale vrijstelling van siRNA te induceren in zowel 
hepatomacellen als primaire hepatocyten door gebruik te maken van PbAE’s, aangezien in beide 
gevallen significante genonderdrukking verkregen werd. Bovendien resulteerde het traagst 
afbreekbare polymeer in de langstdurende genonderdrukking. Tenslotte kon de nucleaire import van 
pDNA niet verhoogd worden door elektrostatische binding met een NLS-peptide, terwijl toevoeging 
van TCHD wel een succesvolle aanpak bleek te zijn. 
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“Opportunities for digitally encoded microcarriers in pharmacy and cell based assays” – Fayazpour F, 
Lucas B, Huyghebaert N, Braeckmans K, Derveaux S, Vandenbroucke RE, Remon JP, Demeester J, 
Vervaet C and De Smedt SC 
 
RESEARCH VISITS 
 
January 22
nd
 - February 6
th
, 2004 – Corbett Lab, Emory University, Atlanta, Georgia, United States – 
“Importin α and β purification and GST pull down assays” 
 
August 5
th
-7
th
, 2005 – Prof. Pepperkok, EMBL Heidelberg, Germany – “Microinjection experiments 
and CLSM” 
 
